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Abstract 
 
 
The A2A adenosine receptor (A2AAR) functions as a key non-redundant suppressor of 
inflammatory responses in vivo. However, whether it regulates activation of the JAK-
STAT pathway utilised by many pro-inflammatory cytokines is unknown. Using a 
vascular endothelial cell model system, I have demonstrated that adenovirus-mediated 
expression of the human A2AAR conferred an ability of IFNα, leptin and a soluble IL-
6 receptor-α/IL-6 (sIL-6Rα/IL-6) trans-signalling complex to promote a time-
dependent reduction in the levels of STAT proteins that was entirely due to 
proteasomal degradation. In terms of functional consequences, degradation was 
sufficient to attenuate sIL-6Rα/IL-6-stimulated STAT3-dependent up-regulation of 
vascular endothelial growth factor receptor-2 (VEGFR-2) and enhance eNOS 
expression. Degradation required JAK activity since A) it was blocked by 
preincubation with JAK inhibitor. B) STAT1 but not STAT3 was resistant to both 
tyrosine phosphorylation and down-regulation in response to leptin and C) a 
Tyr705→Phe mutated STAT3 was also resistant to cytokine-triggered degradation, 
suggesting that JAK-mediated phosphorylation of this residue is required to produce 
the effect. Consistent with this hypothesis, sIL-6Rα/IL-6 treatment of A2AAR-
expressing cells resulted in the accumulation of polyubiquitylated endogenous and 
epitope-tagged recombinant wild-type but not Tyr705→ Phe-mutated STAT3. In 
addition the results show that inhibition of proteasome function was sufficient to 
block the inhibitory effect of the A2AAR on STAT3 phosphorylation, demonstrating 
that priming of STATs for degradation is the only mechanism responsible for the 
reduced cytokine-stimulated STAT phosphorylation observed in A2AAR-expressing 
cells. To date there is only one E3 ligase known for mediating STAT degradation 
which is SLIM protein. However, our results suggest the involvement of another E3 
ubiquitin ligase in HUVECs, since we have been unable to detect SLIM message or 
protein in HUVECs under conditions in which STAT degradation occurs. In addition, 
while Tyr- phosphorylation is clearly the critical step in targeting STATs for 
degradation in A2AAR-expressing cells, it is unclear as to whether it functions simply 
as a classical phosphodegron, or whether the nuclear translocation that occurs as a 
result of phosphorylation is also important for localising the phosphorylated STAT 
dimer with the relevant E3 ubiquitin ligase. 
 xv 
 
Together, these observations suggest a model whereby expression of the A2AAR in 
endothelial cells primes JAK-phosphorylated STATs for polyubiquitylation and 
subsequent degradation by the proteasome following cytokine treatment, and 
represents a previously unappreciated mechanism by which G-protein-coupled 
receptors can negatively regulate responsiveness to specific JAK-STAT-mobilising 
adipocytokines acting on the vascular endothelium. 
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1.1   JAKs in cytokine signalling  
 
JAKs are intracellular tyrosine kinases with molecular masses of 120-140 KDa. It 
was demonstrated that signalling of IL-6 crucially depends on the presence of JAK1.  
The interaction between gp130 and JAK1 is very tight and long lasting.  JAKs bind to 
the membrane-proximal region of IL-6 receptors containing box1 and box2 motifs. 
The general structure of JAKs is shown in (Figure1.1) (Murakami et al.; 1993; Haan 
et al.; 2006).  
 
Comparison of JAKs sequences reveals seven regions of high homology from JH1 to 
JH7. The C-terminal JH1 tyrosine kinase domain is preceded by a JH2 pseudokinase 
domain, which is devoided of catalytic activity, but regulates the activity of the kinase 
domain (Yamaoka et al.; 2004). Moreover, JAKs contain an SH2 domain.  The N-
terminal region of JAKs comprises a FERM domain, which is important for receptor 
association (Haan et al.; 2006; Haan et al.; 2008) (Figure 1.1). 
  
JAKs are constitutively associated with the proline-rich membrane proximal 
box1/box2 region. Upon ligand stimulation, receptors undergo conformational 
changes that bring JAKs into close proximity to each other, enabling activation by 
trans-phosphorylation (Haan et al.; 2006).  There are four members of the JAK family 
in mammals; JAK1 plays a critical role in mediation of biological responses to 
several major cytokine receptor families, while JAK2 plays a critical role in 
transducting signals for Epo, IL-3, GM-SF, IL-5, Tpo and IFN-γ. JAK3 plays a vital 
role in lymphoid development (Giliani et al.; 2005) while Tyk2 appears to be most 
important in mediating the biological response to IL-12 and LPS.  JAK1, JAK2 and 
Tyk2 are expressed ubiquitously, whereas the expression of JAK3 is restricted to 
cells of the myeloid and lymphoid lineages (Cetkovic-Cvrlje and Uckun; 2004). 
 
The importance of JAKs in mediating signals from a variety of cytokines factors 
underscores their importance in signal transduction in general. However, the 
complexity associated with processing signals from such diverse sources suggests a 
 3 
complicated mechanism of action for the JAK kinases. JAK activation is determined 
by an in vitro kinase assay that measures an increase in tyrosine phosphorylation of 
substrates. JAKs, when expressed in the baculovirus system are enzymatically active 
and are phosphorylated on tyrosine residues (Dezaire and Stark; 2007). Their 
overexpression in mammalian cells also leads to constitutive activation, most 
probably due to dimerisation (Staerk et al.; 2007). On the other hand, a JAK kinase in 
complex with a native un-liganded receptor is in a catalytically inactive latent state. 
Receptor dimerisation/oligomerisation due to ligand binding results in the 
juxtapositioning of the JAKs, which are in the vicinity either through homo- or 
hetero-dimeric interactions. This recruitment of the JAK kinases appears to result in 
either via autophosphorylation and/or cross phosphorylation by other JAK kinases or 
other tyrosine kinase family members. This activation is presumed to result in an 
increased JAK kinase activity. The phosphotyrosine sites on the receptors can then 
serve as docking sites that allow the binding of other SH2-domain containing 
signalling molecules such as STATs, Src-kinases, protein phosphatases and other 
adaptor signalling proteins such as Grb2  (Heinrich et al.; 2003).  
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Figure 1.1 Structure organisations of JAKs, STAT factors, Tyrosine 
Phosphatase (SHP2) and SOCS proteins. 
The JAK kinases are divided into seven JAK homology (JH) domains starting from 
the tyrosine kinase domain located at the C-terminus of JAKs and designated as JH1. 
The tandem kinase domain structure is composed of the tyrosine kinase domain, JH1, 
and a pseudokinase or kinase-like domain, JH2, on the N-terminal side of JH1. Only 
the JH1 domain is catalytically active (Heinrich et al.; 2003). 
 
1.2   The Signal transducer and activator of transcription (STAT) family of   
transcription factors 
 
The mammalian STAT factors are designated as STAT1, 2, 3, 4, 5a, 5b and 6.  
STATs are proteins with a conserved structural organisation (Figure1.1).  They 
consist of 750-850 amino acids and comprise various domains as follows: a tetra-
 5 
merisation domain and a leucine-zipper-like domain at the N-terminus, DNA-binding 
domain in the middle, a Src homology 3 (SH3)-like domain, a SH2/tyrosine 
activation domain, linker domain, and a transactivation domain at the C-terminus. 
The C-terminal transcriptional activation domain is quite divergent between STAT 
members and contributes to signalling specificity (Lim and Cao; 2006).  
 
The N-terminal domain comprising approximately 130 amino acids is conserved 
among the STATs.  Several studies suggest that the N-terminal dimerisation promotes 
cooperativity of binding to tandem GAS elements.  Other studies have suggested that 
the terminal STAT domain promotes interaction with the transcriptional coactivator 
CBP and p300,  PIAS family members, receptor domains, as well as  regulating 
nuclear translocation (Horvath; 2000; Lim and Cao; 2006). 
 
The coiled-coil domain consists of four α-helices.  The crystal structures of STAT1 
and STAT3 reveal that this domain forms a large predominantly hydrophilic surface 
that is available for specific interaction with other helical proteins. Proteins 
interacting with the coiled-coil domain include IFN regulatory factor-9 (IRF-9), the 
transcription factor c-jun, N-myc interactor (Nmi) and STAT3 interacting protein 
(StIP1). In addition the coiled-coil domain is also implicated in receptor binding, 
tyrosine phosphorylation and nuclear export (Kisseleva et al.; 2002; Lim and Cao; 
2006). 
 
Most investigators have found an increase in transcription of target genes after 
cytokine-induced serine phosphorylation of STAT1, STAT3 and STAT5.  Earlier 
studies had already shown serine727 phosphorylation of STAT3 to occur slower than 
the phosphorylation of Tyr705 (Beuvink et al.; 2000). SH2 domains play an important 
role in signalling through their ability to bind to specific phosphotyrosine motifs.  
Activation of STATs requires phosphorylation of the conserved tyrosine residue 
located directly on the C-terminal side of the SH2 domain (Tyr705 in STAT3).  During 
this process, the STATs are recruited to tyrosine phosphorylated cytokine receptors 
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through their SH2 domains, and following phosphorylation of the conserved tyrosine, 
the STATs undergo dimerisation through a reciprocal SH2-phosphotyrosine 
interaction (Greenlund et al.; 1994; Mayya and Loew; 2005).  Only the STAT dimer 
is transcriptionally active, and STAT monomers are unable to bind DNA, and 
importantly, only the dimer translocates to nucleus from the cytoplasm, where the 
STATs are activated.  Furthermore, during activation of STATs, the SH2 domain has 
been found to be required for interaction with and subsequent phosphorylation by 
JAKs (Gupta et al.; 1996).  Mutation of either the conserved phosphotyrosine-binding 
Arg of the SH2 domain or the conserved tyrosine following the SH2 domain 
abrogates STAT activity (Kim et al.; 1998).  Differences in the SH2 domains of 
STATs determine, at least partially, the specificity of STAT binding to various 
cytokine receptors (Heim et al.; 1995; Zhukovskaya et al.; 2004). 
 
Although the sequence of the STAT SH2 domain is quite divergent from other SH2 
domains, its tertiary-structure is well conserved (Gao et al.; 2004).  It consists of an 
anti parallel β-sheet flanked by two α-helices, which form a pocket.  An absolutely 
conserved arginine, which mediates the interaction with phosphate, lies at the base of 
this pocket (Arg-602 for STAT1 and Arg-609 for STAT3). The ability of the SH2 
domain to recognise specific phosphotyrosine motifs play an essential role in three 
STAT signalling events; recruitment to the cytokine receptor through recognition of 
specific phosphotyrosine motifs, association with the activating JAK STAT 
homodimerisation or heterodimerisation, STAT dimerisation depends on the 
interaction between the SH2 domain of one STAT monomer and the tyrosine 
phosphorylated tail segment of the other monomer (T. Kawata; 1997; Mayya and 
Loew; 2005). 
 
STAT dimerisation is a pre-requisite for DNA binding.  The DNA-binding domain of 
STAT proteins is located in the middle of the molecule (amino acid 300-480).  
STATs are activated in the cytoplasm; however they function within the nucleus 
(Matsukawa; 2007).  In general, serine phosphorylation of STAT1, STAT2, STAT3 
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and STAT4 increase their signal potential (Chung et al.; 1997b; Schuringa et al.; 
2000). 
 
STAT dimers need to cross the nuclear envelope to functionally link the cell 
membrane with the promoters of cytokine-responsive genes.  Movement of STATs in 
either compartment is diffusion controlled and not directed along permeant structures.  
Passage through nuclear gateways (nuclear pore complexes NPCs) (Rabut et al.; 
2004). NPCs form channels in the nuclear envelope with a diameter of ~ 40 nm 
(Laskey; 1998; Vasu and Forbes; 2001). Vertebrate NPCs have a mass of ~125 MDa 
and contain 30–50 different proteins, which are called nucleoporins. Small molecules 
of 40 kDa can passively diffuse through the NPC (Caesar et al.; 2006). In contrast, 
the translocation of larger macromolecules into the nucleus occurs via an active 
mechanism involving nuclear transport receptors. The majority of the nuclear 
transport pathways are mediated by receptors of the importin family. Proteins or other 
cargo molecules that carry a classical nuclear localisation sequence (NLS) are 
recognised by importin-α, which subsequently forms a complex through its importin-
β-binding domain with importin-β (Gorlich et al.; 1996; Caesar et al.; 2006). 
Analysis of their nucleo-cytoplasmic translocation has to consider that the STAT 
proteins exist in two different states in terms of signalling:  Before the stimulation of 
cells with cytokines the STAT molecule exists in a nontyrosine phosphorylated state, 
the oligomerisation status of which is still debated (Hurt; 1997; Meyer and 
Vinkemeier; 2004).  
 
 Reporter gene studies have determined that serine phosphorylation enhances 
transcriptional activity of STAT1 and STAT3 (Kovarik et al.; 2001). More 
physiological studies in STAT1-deficient cells reconstituted with STAT1 and 
STAT1S727A demonstrated that serine phosphorylation only enhances the ability of 
STAT1 to drive expression of some, but not all target genes (Kovarik et al.; 2001; Shi 
and Kehrl; 2004). Many studies also indicate that serine phosphorylation enhance 
STAT4 transcriptional activity. Although both STAT5 and STAT6 can become serine 
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phosphorylated, enhanced transcriptional activity has not been convincingly 
demonstrated (Kovarik et al.; 2001). 
 
1.3 Regulation of cytokine signalling by suppressor of cytokine signalling 
(SOCS) family molecules 
 
Cytokine signalling is negatively regulated in part by suppressor of cytokine 
signalling (SOCS), which bind to tyrosine phosphorylated residues of target proteins 
via their SH2 domains (Krebs and Hilton; 2001; Johnston; 2004).  They inhibit JAK 
activity through their N-terminal domains and are thought to induce degradation of 
bound molecules through a conserved SOCS box motif that interacts form part of an 
E3 ubiquitin (Ub) ligase complex (Zhang et al.; 2001).   
 
SOCS proteins are characterised by a relatively divergent N-terminal region followed 
by a SH2 domain and a C-terminal SOCS box region. SOCS proteins inhibit IL-6 
signalling either by suppressing the kinase activity of JAKs or by direct interaction 
with the receptors or by both mechanisms (Yasukawa et al.; 1999; Kurdi and Booz; 
2007). 
 
It is becaming increasingly appreciated that SOCS proteins also act by promoting the 
degradation of specific signalling proteins.  Recent work suggests that SOCS box-
containing proteins act as adapter molecules that recruit activated signalling proteins 
to the proteasome. SOCS proteins interact with elongins B and C through their SOCS 
box. In turn, elongin BC complexes associate with cullin 2 and a ring finger-
containing protein Rbx1 (Roc1) to form part of a putative E3 Ub ligase (Figure1.2). 
The SH2 domains of SOCS bind to tyrosine phosphorylated signalling proteins. They 
can therefore act as adapters to facilitate the polyubiquitination and subsequent 
degradation of associated signalling proteins (Zhang et al.; 1999a; Johnston; 2004).  
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Figure 1.2 SOCS family members might target signalling proteins for 
degradation by the proteasome. 
All SOCS proteins bind the elongin BC complex through their SOCS box. In turn, the 
elongin BC complexes associate with cullin 2 and a ring finger-containing protein 
Rbx1 (Roc1) to form part of a putative E3 Ub ligase. Signalling proteins associated 
with the N-terminal or SH2 domains of SOCS proteins could be ubiquitinated by 
cullin-2 targeting them for degradation by the proteasome. 
  
 
1.3.1 SOCS1 
 
SOCS1 was initially reported as a molecule induced by STATs.  However, SOCS1 
expression is now known to be induced by insulin (Le et al.; 2002; Ueki et al.; 2004), 
LPS (Crespo et al.; 2000; Mostecki et al.; 2005), CpG DNA and other molecules that 
do not use STATs in signal transduction. The SH2 domain of SOCS1 recognises the 
phosphorylated tyrosine residue located in the activation loop of the JAK kinase 
domain (Brysha et al.; 2001; Greenhalgh and Hilton; 2001).  However, inhibition of 
JAK activation requires not only the SH2 domain but also a 30 amino acid kinase 
inhibitory region located upstream of the SH2 domain (Waiboci et al.; 2007).  
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Many studies suggest that SOCS1 inhibits cytokine signalling by associating with 
JAK1, JAK2, JAK3 and TYK2 to inhibit their catalytic activity.  Structure-function 
studies using truncated or chimeric version of SOCS1 have revealed the mechanism 
by which SOCS proteins bind to and inhibit JAKs. Interestingly, although the SOCS1 
SH2 domain is sufficient to mediate the association between SOCS1 and JAKs 
(Yasukawa et al.; 2000), both the SH2 domain and 24 residues immediately N-
terminal to the SH2 domain is necessary for inhibition of JAK2 activity.  Thus, the 
region immediately N-terminal to the SOCS1 SH2 domain appears to have a kinase 
inhibitory function (Waiboci et al.; 2007).  Within this N-terminal region SOCS1 
contains a sequence of 12 residues that resembles the JAK activation loop (Yasukawa 
et al.; 1999). In vivo study of SOCS function has been facilitated by SOCS1 
knockout mice (Alexander et al.; 1999). Phenotypically, SOCS1-/ - mice are stunted 
and die at three weeks of age. These mice have the pathology characterised by severe 
lymphopenia, fatty degeneration of the liver and macrophage infiltration of major 
organs (Starr et al.; 1998).  The complex disease in SOCS1-/- mice was prevented by 
administration of anti-IFN-γ antibodies and did not occur in SOCS1-/- mice also 
lacking the IFN-γ gene (Fenner et al.; 2006). Subsequent studies have established that 
mice lacking SOCS1 show both increased production of and heightened sensitivity to 
IFN-γ which contribute to the perinatal lethality of SOCS1 deletion (Brysha et al.; 
2001). 
 
1.3.2 SOCS3 
 
The structure of SOCS3 is similar to SOCS1, including the position of a kinase 
inhibitory region (KIR). However, these two molecules differ greatly in their 
mechanism of action; SOCS1 can inhibit activation of JAK by directly binding to 
JAK, while SOCS3 inhibit the action of JAK only in the presence of receptors, such 
as gp130. SOCS3 is induced by IL-6 and SHP2 are simultaneously activated 
(Terstegen et al.; 2000; Kisseleva et al.; 2002; Lehmann et al.; 2003) .  
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 It has also been observed that an inhibition of SHP2 activation can lead to an 
enhanced induction of SOCS3 mRNA.  On the other hand the expression of the 
SOCS3 protein decreased the level of tyrosine-phosphorylated SHP2 after IL-6 
stimulation. Furthermore, SOCS3 inhibits IL-6 signalling by inhibiting the 
phosphorylation of gp130. SOCS3 has been found to bind to the phosphotyrosine 
motif 759 of gp130 which is also the binding site for SHP2 (Kisseleva et al.; 2002). 
The affinity of SOCS3 to a phosphotyrosine peptide corresponding to the Tyr759 motif 
of gp130 is much higher than to a phospho-peptide comprising the JAK activation 
loop.  Moreover, the affinity of SOCS3 to bind gp130 is slightly higher than that of 
SHP2.  Thus the involvement of SHP2 and SOCS3 in Tyr759 mediated attenuation has 
been re-examined to determine the individual contribution of both proteins 
(Yasukawa et al.; 1999). Although both SOCS3 and SHP2 are recruited to the same 
site within gp130, there are two largely distinct modes of negative regulation of gp 
130 activity: through the feedback inhibition by SOCS3 or the dephosphorylation of 
phosphorylated JAKs, receptors and STATs by SHP-2 (Lehmann et al.; 2003). The 
proposed mechanisms of action of SOCS 1 and SOCS3 have indicated that the N-
terminal domains of each protein (but not the N-terminal domain of any other SOCS 
protein) are interchangeable.  This suggests that SOCS1 and SOCS3 may inhibit 
JAKs through interaction with their N-terminal domains (Yasukawa et al.; 2000; 
Krebs and Hilton; 2001). It has been shown by several investigators that SOCS1 and 
SOCS3 bind to the kinase domain of activated JAK1 and JAK2 (Marine et al.; 1999; 
Sasaki et al.; 1999; Park et al.; 2003).  A model for JAK inhibition by SOCS1 
suggests that the kinase activation loop of JAK2 interacts with the SH2 domain of 
SOCS1.  This allows SOCS to present its KIR, which is quite homologous to the 
kinase activation loop, to the pocket in the activation site, which in turn might prevent 
the access of substrates or ATP (Alexander and Hilton; 2004). 
 
The physiological function of SOCS3 has been investigated. In vivo expression 
pattern of SOCS3 revealed that although SOCS3 is expressed at low levels in adult 
tissues, it is highly expressed in fetal liver erythroid progenitors (Marine et al.; 1999). 
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Furthermore, SOCS3 expression is specifically induced during a stage of 
erythropoiesis characterised by an explosive Epo-dependent expansion of cells of the 
erythroid lineage, leading to the  hypothesised that SOCS3 plays a role in 
erythropoiesis (Sasaki et al.; 2000). It is interesting to note that neither the SOCS3-/- 
mice nor the transgenic mice that overexpress SOCS3, survived to birth. Strikingly, 
transgenic embryos that constitutively overexpressed SOCS3 exhibited no detectable 
fetal liver erythropoiesis, whereas a proportion of SOCS3-/- embryos died, exhibiting 
pathology characterised by massive erythrocytosis throughout the embryo (Marine et 
al.; 1999) and defects in the placenta (Roberts et al.; 2001). lethality in SOCS3-/-  
mice results from placental insufficiency (Matsumoto et al.; 2003). Taken together, 
these experiments suggest that SOCS3 may play an important role in the regulation of 
fetal liver erythropoiesis  (Roberts et al.; 2001; Wormald and Hilton; 2007). Given 
that Epo signalling is required for erythropoiesis, it is possible that SOCS3 modulates 
this process by attenuating Epo signalling (Sasaki et al.; 2000). 
 
1.4 Cytokines 
 
Cytokines are soluble glycoproteins, which mediate intercellular communication by 
binding to their specific receptors on the surface of target cells and transducing a 
signal to the nucleus to induce transcription of a specific set of genes.  One way to 
classify cytokines is based on their structural and functional properties and the 
receptor molecules they bind to.  Growth factors, such as epidermal growth factor 
(EGF) and platelet-derived growth factor (PDGF), utilise receptors with intrinsic 
tyrosine kinase activity, termed receptor tyrosine kinases (RTKs) (Hubert; 2007). 
Conversely, members of the transforming growth factor-β (TGF-β) superfamily 
utilise receptors with serine/threonine kinase activity (Shimanuki et al.; 2007).  Other 
subsets of cytokines include the TNF family.  Sometimes the term “cytokine” is used 
only for factors whose main targets are the hematopoietic cells, and are thus called 
the hematopoietic cytokines.  The hematopoietic cytokines, together with structurally 
related cytokines acting for example in the neural system, are collectively called class 
I cytokines. This class includes interleukins (IL) -2, -3, -4, -5, -6, -7, -9, -11,-12, -13, 
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15, -21, -23, erythropoietin (EPO), thrombopoietin (TPO), prolactin (PRL), growth 
hormone (GH), thymic stromal lymphopoietin (TSLP), ciliary neurotrophic factor 
(CNTF), oncostatin M (OSM), leukemia inhibitory factor (LIF), cardiotrophin-1 (CT-
1), neurotrophin-1 (NNT-1)/B-cell-stimulating factor-3 (BSF-3), and colony-
stimulating factors for granulocytes (G-CSF) and granulocyte-macrophages (GM-
CSF) (John et al.; 2006).  Interferons (IFN) and IL-10 constitute an additional family 
termed the class II cytokine family. IL-19, -20, -22, and -24 have been recently 
identified as IL-10-related classII cytokines (Sabat et al.; 2007). The class I and class 
II cytokines share an α-helical three-dimensional structure. Class I cytokines typically 
consist of four α-helices, designated from A to D and connected by short loops 
(Huyton et al.; 2007).  The class II cytokines, IFN-γ and IL-10, contain 6 α-helices 
instead of 4. The helical cytokines function usually as monomers, IFN-γ and IL-10 
are dimers (Oliveira Neto et al.; 2008). The receptors utilised by type I and II 
cytokines are structurally related and form the hematopoietic receptor superfamily. 
Importantly, receptors of the hematopoietic receptor superfamily share common 
mechanisms for signal transduction (Nishimoto and Kishimoto; 2008).   
 
1.4.1 IL-6  
 
IL-6 plays an active role in immunity, bone metabolism, reproduction, arthritis, and 
in the development of neoplasia. Dysregulation of IL-6-type cytokine signalling 
contributes to the onset and maintenance of several diseases such as multiple 
myeloma, inflammatory bowel disease and rheumatoid arthritis (Nishimoto and 
Kishimoto; 2006).  Moreover, IL-6 plays a significant role in the acute phase 
inflammatory response.  IL-6 stimulates the acute phase reaction that enhances the 
innate immune system and protects against tissue damage. It results in the release of 
certain proteins, called "acute phase proteins", into the plasma by liver cells and 
induces a decrease in the rate of synthesis of other proteins.  Specifically, IL-6 
increases the synthesis of the two major acute phase proteins, C-reactive protein 
(CRP), which increase the rate of phagocytosis of bacteria, and serum amyloid (SAA) 
by regulating the rate of gene transcription (Dziedzic; 2008). 
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IL-6 also increases the synthesis of fibrinogen, an important clotting agent albumin 
and transferrin levels are also decreased in the presence of IL-6 (Ohta et al.; 2004; 
Marquardt et al.; 2005). Not surprisingly,  knockout of the IL-6 gene has severe 
effects on the immune system, including a major decrease in the acute phase immune 
reaction and production of IgA antibodies (Benihoud et al.; 2000).  On the other 
hand, overexpression of the IL-6 gene can lead to the substantial polyclonal 
proliferation of plasma cells.  Lack of gene regulation can lead to autoimmune 
disease and many lymphoid malignancies, including multiple myeloma. An 
uncontrolled or defective production of this protein most often leads to disease and is 
involved in the pathogenesis of many disease and autoimmune disorder such as liver 
autoimmune disease.  Furthermore, IL-6 is important for the development of specific 
immunological responses and also plays an important role in bone metabolism 
through the initiation of osteoclastogenesis and increasing osteoclast activity (Liu et 
al.; 2006). 
 
1.4.1.1  IL-6 structure 
 
The average molecular weight of human IL-6 ranges between 21 to 28 KDa, 
depending on the post-translational processing, such as glycosylation. The full length 
IL-6 peptide comprises 212 amino acids (aa) from which a 28 aa hydrophobic signal 
peptide is cleaved off from the N-terminus resulting in a mature protein of 184 aa.  
IL-6 contains four conserved cysteine residues within a highly conserved central 
region.  Additionally, the C-terminus appears to be critical for IL-6 activity, since 
deletion of four aa from the C-terminus abolishes IL-6 activity. In contrast, deletion 
of 28 aa from the N-terminus does not affect IL-6 activity (Maggio et al.; 2006). 
 
1.4.1.2   IL-6 Receptors 
 
IL-6 receptors can be subdivided into non-signalling α-chain and signal transducing 
subunits such as gp130.  IL-6 first binds specifically to its respective α-receptor 
subunits.  The ectodomain of the receptors involved in IL-6 signalling comprise an 
array of FNII-like and Ig-like domains (Heinrich et al.; 2003) ( Figure 1.3).  
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Mutagenesis studies have identified distinct areas on the surface of the cytokine, 
which specifically interact with the respective receptors.  Common to all IL-6-family 
members is the site II that interacts with the cytokine binding module (CBM) of 
gp130 (Nishimoto and Kishimoto; 2008).  
 
 
Figure 1.3 Receptor complexes of IL-6-type cytokines. For gp130 the box1 and box2 
regions, as well as the dileucine motif (LL, Leu786-Leu787), are highlighted 
(Heinrich et al.; 2003). 
 
Cytokine receptors are single trans-membrane glycoproteins that have a conserved 
extracellular domain and three short conserved motifs in the intracellular regions.  
The intracellular region of cytokine receptors do not have intrinsic catalytic activity, 
but are linked via ligand binding to activation of signal transduction by associating 
with a number of signalling proteins (Heinrich et al.; 2003).  The cytokine receptors 
have box1 and box2 motifs (Haan et al.; 2006).  Box1 is located within the first 20 
amino acids of the cytoplasmic domain. Box2 motif is characterised by a stretch of 
hydrophobic amino acids, which are followed by several charged amino acids (Haan 
et al.; 2002; Heinrich et al.; 2003).  
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The membrane-distal region of cytokine receptors also mediate essential signalling 
functions of receptors and contain tyrosine residues that become phosphorylated upon 
cytokine stimulation. These serve as docking sites for Src homology2 (SH2) domain-
containing signalling proteins.  IL-6 receptors are membrane proteins that belong to 
the cytokine receptor class I family.  This receptor family is defined by the presence 
of at least one cytokine binding module (CBM) consisting of two fibronectin-type-
III-like domains of which the N-terminal domain contains a set of four conserved 
cysteine residues (Aasland et al.; 2003) and the C-terminal domain a WSXWS motif 
(Heinrich et al.; 2003) (Figure 1.3).   
 
Moreover, IL-6R has an IgG-like domain located at the N-terminus and three 
additional membranes proximal fibronectin typeIII like domain. In addition to the 
membrane-bound receptor, a soluble form of the IL-6R (sIL-6R) has been purified 
from human serum and urine.  This soluble receptor binds IL-6 with an affinity 
similar to that of the cognate receptor and prolongs its plasma half-life 
(Michalopoulou et al.; 2004). More importantly the sIL-6R/IL-6 complex is capable 
of activating cells via interaction with membrane-bound gp130.  This is in contrast to 
the function of most soluble cytokine receptors that bind their ligand to antagonise 
cellular signalling by preventing the interaction of the cytokine with their respective 
plasma membrane-bound receptor (Jones et al.; 2005). Soluble IL-6 receptors present 
on hematopoietic progenitor cells, Kaposi’s sarcoma cell lines and synovial 
fibroblasts can form a ligand receptor complex with IL-6 which stimulates a variety 
of cellular responses including proliferation, differentiation and activation of 
inflammatory processes (Peake et al.; 2006; John et al.; 2007).  Moreover, gp130 is 
used not only by the IL-6 receptor but also by the receptors for other members of IL-6 
family LIF and OSM (Nishimoto and Kishimoto; 2008). 
 
 
SIL-6R performs an important role in the regulation of IL-6 responses and 
consequently disease progression.  Although changes in sIL-6R concentration have 
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been determined in numerous clinical disorders, high IL-6 concentrations hve been 
documented in the serum and synovial fluid of rheumatoid arthritis and juvenile 
rheumhatoid arthritis patients (Pignatti et al.; 2003; Peake et al.; 2006). Through a 
series of in vitro approaches, sIL-6R has been implicated in a variety of cellular 
conditions typically associated with arthritis, such as the severe destruction of 
cartilage and bone (Pignatti et al.; 2003). 
  
Examination of both IL-6 and sIL-6R concentrations in synovial fluid from arthritic 
patients showed that the extent of joint destruction correlated with the increased 
concentration of these mediators.  Furthermore, synovial fluids from rheumatoid 
arthritic patients containing high levels of IL-6 and sIL-6R promoted osteoclast like 
cell formation when added to cocultures of osteoblastic cells and bone marrow cells 
(Peake et al.; 2006). 
 
1.4.1.3  Signalling of IL-6-type cytokines 
 
 
IL-6 utilises tyrosine kinases of the JAK family and transcription factors of the STAT 
family as mediators of signal transduction.  gp130 is constitutively associated with 
Tyr kinases JAK1, JAK2 and TYK2.  Several phosphotyrosine residues of gp130 are 
docking sites for STATs with matching SH2 domains, particularly, STAT1 which 
bind to phospho Tyr701 in gp130 and STAT3 binds to phospho Tyr705 (Klein et al.; 
2005). STATs then become Tyr-phosphorylated, form dimers and translocate to the 
nucleus, where they regulate transcription of target genes (Lim and Cao; 2006) 
(Figure 1.4). 
 
Moreover, the tyrosine phosphatase SHP2 also binds to phosphotyrosine 759 motif of 
activated gp130 and counteracts receptor and STAT activation (Lehmann et al.; 
2003).  Also, Suppressor of cytokine signalling (SOCS) 3 is a potent IL-6-induced 
feedback inhibitor terminating IL-6 signal transduction is bind to the same site in 
gp130 and inhibits JAK activity  (Fischer et al.; 2004). 
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Figure 1.4 Schematic presentation of gp130 mediated activation of JAK/STAT 
pathway and MAPK / ERK cascade by IL-6 signalling (Heinrich et al.; 2003). 
 
1.4.2 IFN alpha  
 
The interferons (IFNs) represent proteins with anti-viral activity that is secreted from 
cells in response to avariety of stimuli. There are at least five classes of IFN alpha, 
beta, gamma, tau and omega. The interferons are divided into two groups designated 
type I and type II interferons. IFNγ is the only type II interferon, whereas the type I 
interferons consist of four major classes: IFN-α, IFN-β, IFN-W, IFN-I, and IFN-K 
(Caraglia et al.; 2005). 
 
Type I IFNs have pleiotropic effects in both the innate and the adaptive immune 
responses. Recently, it has become clear that one of the key cells in the IFN-α 
physiological response is the natural IFN-producing cell (NIPC), also known as the 
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immature plasmacytoid dendritic cell PDC or precursors of type 2 DC (pDC2). PDCs 
differentiate into mature antigen-presenting DCs, which have a crucial role in T and 
B cell activation. NIPCs/PDCs were shown to be the major IFN-α producer in 
response to a wide range of agents, including bacteria and immune stimuli 
(Fitzgerald-Bocarsly and Feng; 2007). The pivotal role of IFN-α and NIPC/pDC in 
autoimmune disorders has also been demonstrated (Gottenberg and Chiocchia; 2007). 
Although IFN-γ production was thought to be restricted to T and NK cells, recent 
findings demonstrate that other cell populations of the DC lineage involved in 
antitumour defense produce IFN-γ, which mediates cancer cell apoptosis via tumor 
necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) induction (Taieb et 
al.; 2006) Type I and type II IFNs play a central role in host defenses not only against 
viruses but also against intracellular bacteria and parasites (Casanova and Abel; 
2004). It has been clearly demonstrated that the lack of IFN receptors or defects in 
signalling pathways are responsible for inherited immunodeficiencies against 
mycobacteria (Jouanguy et al.; 1996; Newport et al.; 1996). Human primary 
immunodeficiencies of type I IFNs have been recently discovered (Casrouge et al.; 
2006). They appear to be due to defects in either type I IFN production or in type I 
IFN responses.  
 
Type I and II IFNs are secreted cytokines that regulate numerous biological activities 
associated with host defence and homeostasis. The JAK-STAT pathway is the 
primary signalling pathway for the transcriptional regulation of many IFN-stimulated 
genes (ISGs).  Following high-affinity binding to their specific cognate receptor 
complexes, type I and type II IFNs transduce signals through activation of receptor-
associated JAKs.  Binding of the type I IFNs (IFN-α, IFN-β, IFN-W, IFN-I, and IFN-
K) to their cognate receptor complex induces association of the two receptor chains, 
IFNAR-1 and IFNAR2-c (Domanski et al.; 1997; Brierley and Fish; 2002), which 
leads to the phosphorylation of tyrosine residues located in the intracellular domain of 
each receptor chain. These tyrosine phosphorylation events are thought to be carried 
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out by  TYK2 and JAK1, which are themselves activated by tyrosine phosphorylation 
(Uze et al.; 2007) .  
 
Similarly, the type II receptor complex comprises two receptor chains, IFNGR-1 and 
IFNGR-2.  Binding of the type II IFN for example, IFN-γ to its receptor complex 
leads to the phosphorylation and activation of JAK1 and JAK2.  Upon activation, the 
JAKs phosphorylate specific tyrosine residues within the intracellular domains of the 
receptor subunits (Caraglia et al.; 2005). These phosphorylated residues serve as 
docking sites for STATs (Uze et al.; 2007). Once recruited to the receptor complex, 
the activated JAKs phosphorylate a single tyrosine residue within the C-terminus of 
the STAT proteins as described previously. The phosphorylated and activated STATs 
form both homodimeric and heterodimeric complexes that translocate to the nucleus 
and bind specific DNA sequences within the promoter regions of ISGs to initiate 
transcription (Wesoly et al.; 2007).  
 
1.4.2.1    IFN-inducible STAT complexes 
 
Type I IFN binding to its receptor induces the dimerisation of IFNAR-1 and IFNAR-
2c receptor chains and the subsequent activation of the receptor-associated JAKs 
(Figure 1.5).  The IFNAR-1 chain associates with Tyk2, and the IFNAR-2c chain 
associates with JAK1. Once activated, Tyk2 phosphorylates tyr466 on IFNAR-1, 
generating a docking site for STAT2 by means of its SH2 domain (Yan et al.; 1996; 
Campbell; 2005).  Tyk2 then phosphorylates STAT2 on Tyr690, which serves as a 
docking site for STAT1 (Wesoly et al.; 2007). Subsequently, STAT1 itself is 
phosphorylated on Tyr701.  This activated STAT1 and STAT2 heterodimer dissociates 
from the receptor complex and localises to the nucleus.  Only the intracellular domain 
of the IFNAR-2c chain is necessary for mediating the docking and phosphorylation of 
STAT protein as well as the formation of STAT complexes (Colamonici et al.; 1995; 
Kotenko et al.; 1999).   
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Figure 1. 5 Primary JAK/STAT pathways involved in cellular signalling by type 
I and type II IFNs. 
Binding of either class of IFN to its receptor leads to activation of receptor-associated 
JAK proteins that phosphorylate tyrosine residues on the intracellular domains of the 
receptor. This is followed by the docking of STAT molecules to the receptor that are 
in turn phosphorylated at tyrosine residues by the JAKs. The activated STATs 
dissociate from the receptor chain and form dimers that translocate to the nucleus and 
bind to specific DNA recognition elements to modulate gene transcriptional activity. 
For the type I IFNs, both STAT1 and STAT2 are activated to form a heterodimer that 
associates in the nucleus with a third molecule, IRF-9. This trimolecular complex 
(also called ISGF3) binds to the interferon-stimulated response element (ISRE) 
(Campbell; 2005). 
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Within the IFNAR-2c intracellular domain, only a single tyrosine residue at either 
position 337 or 512 is required for a full IFN response (Velichko et al.; 2002).  
STAT2 associates with the IFNAR-2c subunit, whereas STAT1 binds only the 
IFNAR-2c-STAT2 complex, suggesting that STAT2 provides a recruitment site for 
the SH2 domain of STAT1, linking it to the receptor complex (Nadeau et al.; 1999; 
Campbell; 2005).  This IFNAR-2c-STAT2 association does not depend on the 
tyrosine phosphorylation of the receptor or the STAT protein. Type I IFN induces the 
activation of all members of the STAT family, namely, STAT1, STAT2, STAT3, 
STAT4, STAT5a, STAT5b, and STAT6 (Wesoly et al.; 2007). Although numerous 
different types of STAT-containing complexes are formed, STAT2 is an essential 
component of type I IFN signalling (Paulson et al.; 1999). Notably, IFNs-α/β induce 
the formation of the ISGF3 complex, comprising STAT1, STAT2, and a DNA-
binding adapter protein of the IFN regulatory factor (IRF) family, IRF-9 (p48 or 
ISGF3γ) (Genin et al.; 2003).   
 
Upon nuclear import, STAT1 and IRF-9 of this ISGF3 complex bind the IFN-
stimulated response element (ISRE), AGTTTN3TTTC, to initiate gene transcription.  
Within this complex, STAT2 does not contribute to DNA binding but provides a 
potent transactivation domain (TAD)  (Paulson et al.; 1999). Type I IFNs also induce 
the formation of other STAT-containing complexes: STAT1, STAT3, and STAT5 
homodimers as well as STAT1 and STAT3 hetrodimers (Wesoly et al.; 2007). These 
homodimers and heterodimers bind palindromic so-called ‘‘GAS’’ sequences, 
TTCN3GAA, designated GAS, located in the promoters of a different subset of ISGs.  
Type II IFN signalling primarily activates the STAT1 transcription factor (Figure1.5).  
The two chains of the type II IFN receptor, IFNGR-1 and IFNGR-2, associate prior to 
ligand binding. The biologically active form of IFN-γ is a noncovalent homodimer 
that binds its receptor complex in a 2:2 ratio (Walter et al.; 1995; Campbell; 2005).   
 
In the case of IFN-γ binding, the intracellular domains of the receptor complex 
undergo a conformational change upon IFN-γ binds that induces the 
 23 
autophosphorylation and activation of JAK2 and subsequent JAK1 
transphosphorylation by JAK2 (Chang et al.; 2004). Activation of JAK1 
phosphorylates tyrosine residue 440 within the intracellular domain of the two 
IFNGR-1 chains.  STAT1 proteins associate with the IFNGR-1 chains by means of 
SH2-phosphotyrosyl interactions and are subsequently phosphorylated on Tyr701 
(Hashemite et al.; 2004).  The activated STAT1 proteins dissociate from the receptor 
complex and form STAT1 homodimers. Once in the nucleus, these STAT1 dimers 
bind GAS elements and induce gene transcription. These IFN-inducible STAT 
proteins thus permit direct transmission of signals from the cell surface to the 
nucleus, resulting in the generation of IFN-mediated biological responses (Campbell; 
2005; Wesoly et al.; 2007). 
 
1.4.3 Leptin Biology 
 
Leptin is a multifunctional cytokine that plays a key role in the regulation of food 
intake and energy expenditure. The discovery of leptin at the end of 1994 (Zhang et 
al.; 1994) opened up a whole new perspective to study the role of adipocyte-derived 
factors in energy balance and homoeostasis (Fruhbeck et al.; 2001).  The 16 kDa non-
glycosylated polypeptide product of the ob gene is mainly produced and secreted by 
fat cells in proportion to fat mass to signal the repletion of body energy stores to the 
hypothalamus (Banks; 2004). Leptin exhibits striking structural similarities to 
members of the class I cytokine family, including LIF, CNTF, OSM and CT-1, as 
well as IL-6, IL-11 and IL-12 (Fruhbeck et al.; 1998; John et al.; 2006).  Both the 
crystal structure and NMR studies of leptin have revealed that the protein adopts a 
cytokine fold similar to that exhibited by the short-helix subfamily of cytokine folds 
(Zhang et al.; 1997).  The three-dimensional structure of the 167-amino-acid leptin 
molecule is based on four antiparallel α-helices, connected by two long crossover 
links and one short loop arranged in a left-handed helical bundle, which forms a two-
layer packing. A disulphide bond between two cysteine residues (Cys96 and Cys146) 
of the C-terminus of leptin and the beginning of one of the loops has been shown to 
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be important for folding and receptor binding, as mutation of either of the cysteine 
residues renders the protein biologically inactive (Prolo et al.; 1998).   
 
Circulating leptin concentrations have been reported to correlate closely with 
indvidual BMI (body mass index) and the total amount of body fat (Fruhbeck et al.; 
1998; Strocchio et al.; 2007).  Although leptin is mainly produced and secreted into 
the bloodstream by white adipocytes, this is not the only source of the hormone.  
Placenta (Valuniene et al.; 2007), gastric mucosa (Francois et al.; 2008), bone 
marrow (Isaia et al.; 2005), mammary epithelium (Motta et al.; 2007), skeletal 
muscle, pituitary (Tipsmark et al.; 2008), hypothalamus and bone have also been 
shown to be able to produce small amounts of leptin in certain circumstances 
(Masuzaki et al.; 1997; Bado et al.; 1998; Morash et al.; 1999).  Based on an almost 
ubiquitous distribution of receptors, leptin has been reported to play a role in a 
diverse range of physiological functions both in the central nervous system and at the 
periphery (Fruhbeck; 2001; Fruhbeck; 2002; Bjorbaek and Kahn; 2004). Its functions 
encompass metabolism, reproduction, immunity, cardiovascular pathophysiology, 
respiratory function, wound healing, as well as in growth and development 
(Gainsford et al.; 1996; Holness et al.; 1999).   
 
1.4.3.1   Leptin receptor 
 
The hormone leptin is encoded by Ob gene. Leptin acts through its receptor (db 
gene), which has six isoforms (from ObRa to ObRf ) (Malendowicz et al.; 2006).  
Only one of them the leptin receptor b (ObRb), has full signalling capabilities and is 
able to activate the JAK/STAT pathway.  Like all other class I cytokines receptors, 
ObRb lacks any intrinsic kinase activity, and uses cytoplasmic-associated JAKs to 
signal downstream. Leptin binding results in formation of a dimmer receptor complex 
leading to trans-phosphorylation and activation of the JAKs (Kloek et al.; 2002). 
These then phosphorylate tyrosine residues (Tyr974, Tyr985, Tyr1138 and Tyr1077) in the 
cytosolic domain of the receptor, which provide binding sites for signalling molecules 
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including SHP-2 and members of the STAT family, which are also subject to JAK-
mediated phosphorylation activation (Baumann et al.; 1996; Bjorbaek and Kahn; 
2004).  
 
 The full-length ObRb receptor contains several cytoplasmic sequence elements that 
are required for subsequent signalling events. ObRb binds JAK2 constitutively 
(Ghilardi and Skoda; 1997; Bjorbaek and Kahn; 2004) and, like other cytokine 
receptors, it contains a highly conserved, proline-rich box1 between intracellular 
a.a.’s 6-17  and two putative less conserved box2 motifs between intracellular a.a.’s 
49-60 and 202-213 (Ghilardi and Skoda; 1997). While  Box1 and box2 motifs are 
thought to recruit and bind JAKs (Haan et al.; 2006), it has been demonstrated that 
only box1 and the immediate surrounding amino acids are essential for JAK 
activation.  Although an intact box2 motif is not required to activate JAK activity 
(Bahrenberg et al.; 2002), the pivotal STAT signalling pathway cannot be induced 
without box2. Forming homodimers and showing signalling capabilities with mutated 
box2 motfs, ObR can be classiflied as a member of the growth hormone receptor 
(GHR) subfamily (Fruhbeck; 2006). For downstream signalling events, tyrosine 
residues at positions 985 and 1138 are needed to provide docking sites for subsequent 
signalling molecules with SH2 domains such as STATs and SHP2 (Banks et al.; 
2000; Heshka and Jones; 2001).  
 
1.5 Adenosine receptors  
 
Adenosine receptors belong to the G protein-coupled 7 transmembrane superfamily of 
cell surface receptors and include A1, A2A, A2B, and A3 subtypes. The interest in The 
realisation that the psychostimulatory effects of caffeine are largely due to 
antagonism of brain-tissue adenosine receptor signalling (Fredholm; 1995) further 
stimulated interest in adenosine receptors system. A better understanding of the 
purinergic receptors and their intracellular signalling pathways lead to the 
classification of adenosine receptors according to the rank order of potencies of 
agonists with respect to the intracellular production of cAMP.  ARs transduce their 
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signal by heterotrimeric G-proteins that can either stimulate (Gs) or inhibit (Gi) 
adenylyl cyclase, the enzyme that catalyses the formation of cAMP (Sitkovsky et al.; 
2004).  The cloning of four AR subtypes (A1, A2A, A2B, A3) (Olah and Stiles; 1995; 
Palmer and Stiles; 1997) helped to prove that high-affinity A2A and low-affinity 
A2BAR activate adenylyl cyclase, whereas high-affinity A1 and high-affinity A3ARs 
inhibit it. Accordingly, when immune cells acquire the expression of multiple 
adenosine receptors, they will be recruited in a stepwise manner with Gi-coupled 
A1AR activation initially at very low adenosine levels, followed by the stimulation of 
Gs-coupled A2A and A2BARs, and finally by Gi-coupled A3AR (Fredholm et al.; 2001; 
Sitkovsky et al.; 2004). 
 
1.5.1 A2AAR  
 
The A2AAR is highly expressed within most cells of the immune system, platelets, 
heart, lung and endothelium (Fredholm et al.; 2001). Classically, the A2AAR signals 
via the Gs family of G proteins leading to an activation of adenylyl cyclase and the 
generation of cAMP. However, it has been shown that there may be cell type-specific 
patterns of A2AAR-activated signalling. A2AARs have been cloned from several 
species, including dog (Libert et al.; 1990), rat (Fink et al.; 1992) and man (Furlong 
et al.; 1992) and show 84% sequence identity between rat and human forms. 
 
Adenosine-induced vasodilatation is thought to involve both A2AAR and A2BARs 
(Ralevic and Burnstock; 1998; Sitkovsky et al.; 2004; Fredholm; 2007). The A2AAR 
is expressed in ECs and its activation may lead to activation of nitric oxide synthase 
(Lin et al.; 2007). A direct effect of adenosine on arterial smooth muscle cells has 
also been proposed to contribute to vasodilatation (Kleppisch and Nelson; 1995; 
Tamajusuku et al.; 2006). In addition to increasing local blood flow, the extracellular 
accumulation of adenosine triggers signalling cascades that enable oxygen-deprived 
tissues to cope with both the short-term (Fredholm; 1997; Picano and Abbracchio; 
1998) and the long-term effects of oxygen deprivation (Sexl et al.; 1995; Sexl et al.; 
1997). ECs proliferation is a consequence of the activation of ERK via A2AAR. This 
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is also evoked by activation of β2-adrenergic receptors. It is surprising that 
stimulatory receptors linked to cAMP formation activate ERK since cAMP inhibits 
proliferation in many cells. Indeed, signalling to ERK in endothelial cells is 
independent of cAMP, but through an unidentified pathway that involves the small 
G-protein Ras (Barthomeuf et al.; 2004). In immortalised cell lines, A2AAR activation 
leads to ERK phosphorylation (Seidel et al.; 1999; Schulte and Fredholm; 2000). 
However, the signal cascade that links the A2AAR to ERK differs between cell types. 
In CHO cells, cAMP formed by stimulating A2AAR activates Rap1 through a cAMP-
dependent exchange factor (EPAC). Rap1 then associates with B-raf, but this is 
insufficient for ERK activation in CHO cells. Alternative intermediary candidates are 
protein kinase A (PKA) and members of the Src nonreceptor tyrosine kinase family 
because A2AAR-dependent ERK activation can be blocked by appropriate inhibitors 
(Seidel et al.; 1999).  
 
The coupling of the A2AAR to its cognate G protein Gs displays two unusual features.  
Firstly, adenylyl cyclase activation rates are incompatible with the collision coupling 
model that adequately describes the kinetics of normal receptor/Gs interaction; 
nevertheless, in reconstitution experiments, the receptor can actually be shown to use 
Gs as a substrate (Nanoff et al.; 1994; Fredholm; 2007).  Secondly, in membranes, 
addition of guanine nucleotides fails to induce dissociation of the ternary HR 
complex of agonist (H), receptor (R) and G protein (G), such that the agonist remains 
trapped in the high-affinity state. Brief incubation of the membranes with trypsin 
results in proteolytic cleavage of the receptor and restores guanine nucleotide 
regulation of agonist binding (Nanoff et al.; 1991). Proteolysis reduces the apparent 
molecular mass of the receptor by some 8 kDa; this is most likely accounted for by 
cleavage of the extended C-terminus because of the small size of the N-terminus. 
Taken together, these data suggest a role for the C-terminus in regulating the coupling 
properties of the A2AAR. Since the majority of the C-terminal tail itself is dispensable 
for a productive interaction with the G protein, this domain may represent the anchor 
for a modulatory component (Grieco et al.; 2003) .   
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The A2AAR displays a considerable degree of constitutive activity and this is 
independent of the cell line and the receptor expression level (Ledent et al.; 1992; 
Nanoff and Stiles; 1993; Yang et al.; 2005). Although both properties seem to reflect 
a preference of the receptor to remain in the active, G protein-coupled conformation, 
constitutive activity and guanine nucleotide refractoriness can be dissociated. The 
extended C-terminal domain of the receptor is primarily responsible for constitutive 
activity. This is shown in truncated receptors which lose constitutive activity and in 
chimeric receptor constructs where cytoplasmic loop 3 and the C-tail of the A2AARs 
have then introduced into the A1AR and which become spontaneously active (Tucker 
et al.; 2000). However, the inability of guanine nucleotides to convert the receptor to 
the low-affinity conformation is preserved in the C-terminally truncated receptor. It 
seems  that the guanine nucleotide refractoriness of the membrane-bound receptor is 
solely due to coupling to Gs, the Gs selectivity being specified by cytoplasmic loop 3 
(Olah; 1997; Tucker et al.; 2000).  
 
Given the apparent link of constitutive activity with an intact C-terminus, this domain 
deserves closer examination. The C-terminus is rich in serine/threonine residues (12 
of 122 residues) and, in cell experiments, is rapidly phosphorylated following 
activation of PKC. However, mutations that remove the consensus sites for PKC-
dependent phosphorylation do not affect the ability of the receptor to serve as a 
substrate for phosphorylation. It is therefore likely that PKC isoforms do not directly 
phosphorylate the receptor but that they activate an intermediary kinases (Palmer and 
Stiles; 1999). In addition, it is worth noting that the C-terminus of the A2AAR is 
enriched with proline residues: 22 prolines are present in the human A2AAR, 11 of 
which are interspersed in the first 311 amino acids.  The remaining 11 prolines are 
found in the last 100 amino acids with a cluster of four occurring in an acidic stretch 
at positions −10 to −18 removed from the C-terminus and a second cluster of five 
prolines between positions 341 and 357. A sequence comparison of the A2AAR shows 
a high degree of conservation in man, dog and guinea pig.  However, the C-terminus 
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of the rat receptor diverges substantially. Regardless of this discrepancy between 
phylogenetic relation and species orthologues of the receptor, the proline-rich 
stretches are obviously indicative of a potential interaction with SH3 domains.  In 
other instances, SH3 domain-containing proteins have indeed been found to bind to G 
protein-coupled receptors (Oldenhof et al.; 1998).  A recent study has provided a 
functional link between the A2AAR and the actin cytoskeleton. Direct interaction 
between α-actinin and A2AAR was observed suggesting that agoinst-mediated 
clustering and internalisation of the A2AAR regulated by its C-terminus is dependent 
on an intact α-actinin/actin network (Burgueno et al.; 2003). 
 
1.5.1.1  The A2AAR as anti-inflammatory GPCR 
 
Multiple in vivo and in vitro studies suggest a potent anti-inflammatory role of the 
A2AAR. Early reports indicated that A2AAR activation could inhibit superoxide 
release from guinea pig and human eosinophils stimulated with opsonised zymosan 
(Yukawa et al.; 1989). Furthermore,  the A2AAR agonist NECA inhibits Fc-γ R-
mediated phagocytosis and superoxide generation in polymorphonuclear leukocytes 
(PMN) which inhibited by the AR antagonist 8-ρ-sulphenyltheophylline (Salmon and 
Cronstein; 1990). It has been reported that adenosine or NECA concentrations 
sufficient to inhibit the generation of ROS decreases adhesion of fMLP-induced 
PMNs to endothelial cells (Cronstein et al.; 1992). This reduction was found to be 
due to the inhibition of αMβ2 integrin expression (Wollner et al.; 1993). 
 
The potent anti-inflammatory effect of the folate drug methotrexate (MTX) is also 
adenosine-dependent (Chan and Cronstein; 2002). Low concentrations of MTX 
reduce leukocyte accumulation in carrageenan-inflamed air pouches (Cronstein; 
1994). This effect was completely reversed by an A2AAR antagonist DMPX, 
suggesting that adenosine acting at an A2AAR subtype mediated the protective effect.  
The same study also demonstrated that inhibition of adenosine kinase reduced 
leukocyte accumulation, an effect that was completely reversed by co-injection of 
adenosine deaminase (Cronstein et al.; 1994). 
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A2AAR gene-deficient mice have proved to be an important tool in studying the anti-
inflammatory effects of the A2AAR and in establishing the critical role of these 
receptors in several models of immune-mediated tissue damage (Ledent et al.; 1997; 
Ohta and Sitkovsky; 2001). The absence of A2AAR on immune cells causes the 
cessation of cAMP production in activated immune cells, allowing uninterrupted 
tissue damage  (Sitkovsky et al.; 2004).  It has been reported that the A2AAR has a 
role in wound healing as mice lacking the A2AAR form less dense granular tissue and 
fewer blood vessels during wound repair and accumulate fewer leukocytes in 
response to inflammatory stimuli (Montesinos et al.; 2002).  
 
The anti-inflammatory role of A2AAR has driven the development of selective 
agonists to exploit its therapeutic potential (Lappas et al.; 2005). Most A2AAR-
selective agonists are 2-substitution of the non-selective AR agonist NECA, such as 
CGS21680, HENECA (Cristalli et al.; 1992; Rebola et al.; 2003), ATL-146e (Chang 
et al.; 2007) and MRE-0470 (Glover et al.; 2001).  Selective activation of the A2AAR 
has been shown to have significant protiective effects in several models of 
inflammation, including a decrease in neutrophil transmigration into the cerebrospinal 
fluid in patients with endotoxin-stimulated meningitis, attenuation of the 
inflammation-induced increase in the blood-brain barrier permeability (Sullivan et 
al.; 1999), inhibition of oxygen radical production (Thiel et al.; 2003)  and inhibition 
of  the production of cytokines such as TNFα (Majumdar and Aggarwal; 2003). In 
addition, ATL-146e reduced joint destruction caused by septic arthrosis and CGS-
21680 can regulate HIV-1 transactivation regulating protein (Tat)-induced 
inflammatory responses (Cohen et al.; 2004; Fotheringham et al.; 2004).  
 
In mouse models of ischaemia/resperfusion injury, co-reperfusion of the A2AAR-
selective agonist ATL-146e decreased liver injury by 90%. Co-administration of the 
A2AAR-selective antagonist ZM241385 attenuated this effect indicating the receptor 
specificity of the response (Day et al.; 2004).  In addition, the A2AAR was shown to 
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protect from concanavilin A-induced liver injury in vivo (Ohta and Sitkovsky; 2001). 
In vitro studies suggests the anti-inflammatory response is due to a reduction in the 
expression of cytokine and chemokines from cells expressing the A2AAR (Bshesh et 
al.; 2002). THP-1 cells treated with LPS increased the expression of A2AAR and 
adenosine. Further treatment of the cells with an A2AAR-selective agonist CGS21680, 
decreased LPS-stimulated TNFα production in a time and dose-dependent manner.  
This inhibitory pathway involves A2AAR-mediated activation of PKA and 
phosphorylation of cAMP response element binding protein (Bshesh et al.; 2002) . 
 
One of the most well-defined protective effects of AR activation is inhibition of pro-
inflammatory responses. While numerous studies have shown that activation of 
A2AARs on neutrophils represents a critical mechanism by which adhesion is 
blocked, selective activation of A2AAR in ECs from multiple origins also inhibits 
leukocyte-EC interaction. For example, Bouma et al. (1996) demonstrated that pre-
treatment with either adenosine or the non-selective AR agonist 2-chloroadenosine 
inhibited the release of IL-6 and IL-8 from IL-1β and LPS-activated HUVECs. AR 
activation also reduced the potency with which TNF-α could induce the cell surface 
expression of E-selectin and VCAM-1 with no effect on ICAM-1 induction (Bouma 
et al.; 1996). Analysis of these anti-inflammatory effects suggests the involvement of 
one or both of the A2AAR subtypes. Recent work employing more selective drugs has 
revealed that A2AAR activation is sufficient to inhibit E-selectin induction both in 
vivo (McPherson et al.; 2001) and in vitro (Sands et al.; 2004). Interestingly, while 
A2AAR stimulation is capable of inhibiting induction of VCAM-1 in vitro, this effect 
cannot be mimicked simply by elevation of intracellular cAMP levels (Bouma et al.; 
1996), suggesting that the receptor must activate at least one additional signalling 
pathway in ECs to mediate this effect. A2AARs on ECs are potentially useful targets 
for drugs aimed at alleviating endothelial dysfunction. Administration of agonists 
should enhance the protective effects of receptor activation and reverse the excessive 
inflammation associated with disease progression. Several observations support the 
potential utility of the A2AAR in this regard. First, administration of the selective 
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agonist ATL-146e reverses the accumulation of VCAM-1, P-selectin and ICAM-1 
observed in a carotid ligation model of vascular injury (McPherson et al.; 2001), 
although the ability of A2AAR activation to inhibit leukocyte and platelet activation 
may also indirectly inhibit EC activation by attenuating leukocyte-EC and platelet-EC 
interaction. Second, it has been demonstrated that potentiation of A2AAR-activated 
signalling pathways in vascular ECs by adenovirus-mediated human A2AAR gene 
transfer is sufficient to block E-selectin induction and monocyte adhesion to TNFα-
stimulated HUVECs even in the absence of an A2AAR-selective agonist (Sands et al.; 
2004). This is an important observation as it suggests that increasing flux through 
A2AAR-activated signalling pathways in ECs can dramatically suppress the pro-
inflammatory events associated with diseases, such as atherosclerosis and sepsis 
(Montesinos et al.; 2002) and rheumatoid arthritis (Montesinos et al.; 2000). 
 
Blocking the effects of endogenous extracellular adenosine in wild type mice using 
selective A2AR antagonists addressed possible caveats for interpreting experiments 
using genetically engineered mice. These experiments confirmed the conclusions 
derived from the studies of A2AAR gene-deficient mice. Injection of A2AAR 
antagonists exacerbates tissue damage by sub-threshold doses of inflammatory 
stimuli. In addition, control experiments confirmed that although extracellular 
adenosine-triggered cAMP accumulation was severely inhibited in A2AAR-deficient 
mice, agonists at other Gs-protein-coupled receptors were still capable of inducing 
similar degrees of elevation of cAMP in wild-type and A2AAR-deficient mice 
(Lukashev et al.; 2003). Other studies confirmed that A2A adenosine receptor-
deficient mice did not have unanticipated spontaneous mutations in the cAMP-
signalling, inflammation-inhibiting pathway downstream of the A2AAR (Ohta and 
Sitkovsky; 2001).  
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1.6 Ubiquitination 
 
Ubiquitination/ubiquitylation refers to the post-translational modification of a protein 
by the covalent attachment (via an ε-amino isopeptide bond) of one or more Ub 
mnomers. Ub is a highly conserved small (8 kDa) regulatory protein that is 
ubiquitous in eukaryoyes (Hershko and Ciechanover; 1998; Hochrainer and Lipp; 
2007). The most well characterised function of Ub is labeling proteins for 
proteasomal degradation (Hochrainer and Lipp; 2007). Ubiquitination also controls 
the stability, function and intracellular localisation of a wide variety of proteins. Ubs 
covalently attach via an isopeptide bond to the ε-amino group of Lys residues on 
target proteins. This occurs through a three-step process involving Ub-activation 
(E1), Ub-conjugation (E2) and Ub-ligation (E3) enzymes (Hershko and Ciechanover; 
1998; Gao and Karin; 2005). The types of Ub modifications that can form are diverse. 
In the simplest form, a single Ub molecule is attached, which is defined as 
monoubiquitylation (Hicke and Dunn; 2003).  Alternatively, several Lys residues can 
be tagged with single Ub molecules, giving rise to multiple monoubiquitylation, also 
referred to as multiubiquitylation (Haglund et al.; 2003).  Since Ub contains seven 
Lys residues (Lys6, Lys11, Lys27, Lys29, Lys33, Lys48 and Lys63), Ub molecules 
can form different types of chains in an iterative process known as polyubiquitylation 
(Pickart and Fushman; 2004).  All seven Lys residues are possibly involved in chain 
formation in vivo, and Ub chains linked via Lys48 or 63 are the best characterised so 
far (Hicke et al.; 2005).  It is clear that Lys48-linked poly-Ub chains represent a 
signal for proteasomal degradation of modified substrates.  This discovery merited 
the award of a Nobel Prize in Chemistry 2004 and has been extensively reviewed 
(Hershko and Ciechanover; 1998). However, other types of Ub conjugates are 
involved in the regulation of different cellular processes independently of proteolytic 
degradation (Haglund et al.; 2003; Hicke and Dunn; 2003; Krappmann and 
Scheidereit; 2005). 
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1.6.1 Ub as an inducible and reversible signal 
 
It is well established that protein ubiquitylation is induced by a vast variety of stimuli 
and upstream signalling events in cells.  For example, various cell surface receptors 
become ubiquitylated upon stimulation with extracellular ligands (Hicke and Dunn; 
2003).  In addition, many cytoplasmic and nuclear proteins become ubiquitylated 
following their phosphorylation (Fiore et al.; 2003; Muratani and Tansey; 2003).  
Moreover, the functions of Ub ligases are tightly regulated by signal-induced 
mechanisms such as compartmentalisation, degradation, oligomerisation and post-
translational modifications (Hershko and Ciechanover; 1998; Thien and Langdon; 
2001; Dikic and Giordano; 2003).  Regulation at this level is particularly important, 
since Ub ligases play a central role in substrate recognition and specificity.  A second 
key feature of the ubiquitylation system is that Ub can be rapidly removed by 
deubiquitylating enzymes (DUBs), which serve to switch off the Ub signal or to shift 
between different modifications of the same Lys residue (Hershko and Ciechanover; 
1998; Amerik et al.; 2006). Notably, ubiquitylation shares the two above-mentioned 
similarities with protein phosphorylation. In addition, both modifications are 
recognised by specific protein domains, providing a mechanism for translation of the 
Ub or phospho-specific signal to downstream effectors (Pawson et al.; 2001; Hicke et 
al.; 2005). Intriguingly, although it might not be universally required, 
phosphorylation is a signal that often precedes ubiquitylation of proteins either at the 
level of the E3 Ub ligase (e.g. Cbl) or the substrate protein (e.g. Eps15, Hrs and IқB). 
This shows that the two modifications are in tight cooperation in cells.  A major 
difference between the two systems is that Ub is a chemically more complex 
molecule than phosphate, since it has a larger surface to interact with other proteins.  
The fact that Ub can form chains increases the complexity even further.  In fact, the 
Lys63 and Lys48 chains have different conformations, with Lys63 chains being much 
more extended than those linked via Lys48, indicating that they likely have distinct 
targets and functions in the cell (Pickart and Fushman; 2004). All these features allow 
the ubiquitylation system to integrate and synchronise protein networks all the way 
from the cellular membrane to the nucleus. 
 35 
1.6.2 Proteasomal degradation 
 
Ub-mediated protein degradation provides a major mechanism for controlled 
proteolysis of targeted proteins. Ub conjugation to a substrate involves a cascade of at 
least three different enzymatic reactions (Figure1. 6).  First, Ub is activated by E1, the 
Ub-activating enzyme, to form a high-energy thioester linkage between its C-terminal 
glycine residue and an active cysteine on the E1. Next, the thiol-linked Ub is 
transiently transferred to the next enzyme in the cascade E2, the Ub conjugating 
enzyme.  Finally, an E3 ubiquitin ligase either transfers the activated Ub molecule 
from the E2 to a lysine residue on the substrate or facilitates the transfer of Ub from 
the E2 directly to the substrate (Hershko and Ciechanover; 1998; Gao and Karin; 
2005).   
 
 The substrates marked with a Lys48-linked polyubiquitin chain are selectively 
targeted for 26S proteasome-mediated degradation (Wilkinson et al.; 2001). The 
consequences of Ub attachment depend upon how many Ub moieties are attached and 
the chain-linkage involved. Recognition for degradation by the proteasome involves 
polyubiquitin chains of at least four molecules in length (Thrower et al.; 2000) in 
which each Ub is linked via an isopeptide bound from the carboxy-terminus of one 
Ub to K48 on the adjacent Ub (Petroski and Deshaies; 2005). A proteomics screen of 
Ub conjugates in Saccharomyces cerevisiae found Ub modified at all seven lysine 
residues (Peng et al.; 2003).  The 26S proteasome consists of the 20S core complex, 
composed of four stacked rings of seven subunits that contain the proteolytic sites in 
the central cavity (Groll et al.; 1997). and a multisubunit 19S regulatory particle that 
caps both ends of the 20S particle.  The 19S particle, comprising a lid, a linker and a 
base, mediates the recognition of polyubiquitinated targeted proteins and promotes 
their unfolding in an ATP-dependent reaction. The base contains eight subunits (six 
ATPases of the AAA family and two large subunits, S2/Rpn1 and S1/Rpn2) and is 
connected to the lid by the S5a/Rpn10 protein (Ferrell et al.; 2000).  
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Figure 1. 6 Overview of the Ub Conjugation Pathway 
Ub is first activated by a Ub-activating enzyme E1; activated Ub is then transferred to 
a Ub-conjugating enzyme E2; a Ub ligase E3 facilitates the transfer of Ub from E2 to 
the protein substrate. There are two major classes of E3 Ub ligases: proteins with a 
HECT catalytic domain and proteins with a RING finger adaptor domain. Additional 
E3s, such as those containing a U box, were recently described. Substrates marked 
with a Lys48-linked polyubiquitin chain are selectively targeted to 26S proteasome-
mediated degradation, whereas certain substrates conjugated with mono- or 
multiubiquitins or Lys63-linked polyubiquitin chains are targeted for endocytosis or 
are enabled to engage in new protein-protein interactions. The polyubiquitin chain 
can be removed from the substrate by a  DUBs (Gao and Karin; 2005). 
 
1.7 E3 ligase and STAT degradation 
 
Ubiquitination is implicated in the regulation of STATs. The ubiquitination of 
STAT1 has been reported (Kim and Maniatis; 1996), but the underlying molecular 
mechanisms remained unknown. Proteasome inhibitors were also shown to stabilise 
the tyrosine-phosphorylated forms of STAT4, STAT5, and STAT6 (Wang et al.; 
2000). Recent findings have clarified the role of ubiquitination in the regulation of 
STATs and provided insights into the specificity of this modification. 
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Paramyxoviruses efficiently use the Ub pathway as a mechanism to escape the 
antiviral activities of IFNs (Horvath; 2004b). Paramyxoviruses are RNA viruses and 
include the human pathogens mumps, measles, and Nipah viruses (Nishio et al.; 
2002). Their host evasion mechanisms are largely attributed to the V proteins. At 
least three V proteins function as E3 ligases with high specificity for STAT1, STAT2, 
or STAT3. The V proteins form a multisubunit E3 enzyme complex that shows 
homology to the SOCS-E3 complex. The current model of the E3 ligase suggests a 
complex that contains the V protein and the cellular V-interaction proteins (VIPs), as 
well as additional proteins, including DDB1 (an ultraviolet- damaged DNA binding 
protein) and members of the Cullin family, especially Cullin 4A (Cul4A). The E3 
complex is termed VDC (for V/DDB1/CUL4A or V-dependent degradation complex) 
(Figure 1.7). VDC mediates STAT degradation using a combination of virus-encoded 
and cell-derived factors, where VIPs are the core degradation complex and the other 
cellular cofactors are responsible for the variations in V-protein target specificities 
(Ulane and Horvath; 2002). 
 
Recently, SLIM, an Ub E3 ligase for Tyr-phosphorylated STATs, was identified, 
promoting the ubiquitination and degradation of STAT1 and STAT4.  This is 
supported by the enhanced protein levels of STAT1 and STAT4 observed in SLIM-
deficient mice (Tanaka et al.; 2005). SLIM also inhibited the Tyr phosphorylation of 
STATs, which is independent of its role in proteasomal degradation. There are two 
plausible interpretations. First, SLIM could act as an adaptor molecule to recruit 
phosphatase to dephosphorylate STAT. Second, ubiquitination may induce 
conformational change that would enable the association with phosphatase (Figure 
1.7). Whether SLIM can also ubiquitinate other STATs remain to be investigated. 
 
A growing body of evidence suggests that ubiquitin-mediated proteosomal 
degradation plays an important role in the regulation of cytokine signalling, such as 
JAK-STAT pathway (Figure 1.7). 
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Figure 1.7 Schematic model of JAK/STAT regulation through the ubiquitin- 
proteasome pathway. 
Ligand binding induces receptor tyrosine phosphorylation by tyrosine kinases of the 
JAK family, producing a docking site for the STAT family of transcription factors. 
Phosphorylated STAT dimers translocate to the nucleus to initiate the transcription of 
target genes. At the receptor complex, activated JAKs interact with SOCS proteins 
and become polyubiquitinated and degraded in a SOCS box–dependent manner 
mediated by the elongin B/C (EloB and EloC)–Cul2–Rbx1 E3 ligase complex. 
Rubulaviruses can target STATs for ubiquitin-mediated proteasomal degradation 
using a VDC E3 ligase complex that requires the participation of V protein, VIPs, 
DDB1, and Cul4A. In the nucleus, STAT interaction with SLIM E3 ligase can result 
in STAT ubiquitination and degradation or dephosphorylation (Ungureanu and 
Silvennoinen; 2005). 
 
1.8 Aims and objectives of research 
Immune cell trafficking between tissues compartments is regulated in part by ECs 
surface ARs.  Endothelial cells have multiple roles in inflammation and innate 
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immunity.  Indeed, the first events recognised as inflammation are mediated solely or 
largely by endothelial cells.  In response to inflammatory mediators, endothelial cells 
express adhesion molecules, which are responsible for the recruitment of leukocytes 
to inflamed sites.  Endothelial cells synthesise and release mediators, such as platelet 
activating factor, IL-8 and IL-6, which have a direct role in the inflammatory process 
by conducting the movement of leukocytes between tissue compartments. Functional  
expression of A2A and A2BARs on various types of vascular ECs is well documented 
(Fredholm et al.; 2001), whereas there is little evidence for the functional expression 
of A1 and A3ARs (Montesinos et al.; 1997). 
 Moreover, it is becoming increasingly apparent that pro-inflammatory signalling 
pathways are subject to regulate by non-cytokine stimuli, providing an alternative 
control mechanism.  For example, the chemokine IL-8 and bacterial-derived 
chemoattractant fMetLeuPhe promote the accumulation of SOCS-1 in myeloid cells 
and neutrophils, following activation of their cognate G-protein-coupled receptors, 
resulting in an inhibition of STAT3 phosphorylation in response to granulocyte 
colony-stimulating factor (Stevenson et al.; 2004).  The G-protein-coupled A2AAR 
has emerged as an important suppressor of inflammatory responses in vivo (Ohta and 
Sitkovsky; 2001; Sitkovsky et al.; 2004), but the mechanisms responsible for this 
effect remain to be fully defined.  Studies in several labs and elsewhere have 
demonstrated that an important aspect of the A2AAR’s effects is its ability to inhibit 
NF-κB activation by multiple cell type-specific mechanisms (Majumdar and 
Aggarwal; 2003; Sands et al.; 2004). However, given its potent anti-inflammatory 
effects in vivo, this is unlikely to be the only cytokine-activated pathway affected. 
Following on from these findings, I am goind to focus during my study on A2AAR as 
a potent inhibitor of inflammatory processes. It has emerged as an important 
suppressor of inflammatory responses in vivo (Ohta and Sitkovsky; 2001; Sitkovsky 
et al.; 2004), but the mechanisms responsible for this effect remain to be fully 
defined. To study the effects of potentiating A2AAR signalling on inhibiting 
inflammatory responses, we have generated a recombinant adenovirus (AV) encoding 
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the human A2AAR gene for expression in a human umbilical vein endothelial cell 
(HUVEC). This facilitates highly efficient delivery of A2AAR to endothelial cells in 
vitro to examine the effects of an increase in receptor signalling upon cellular 
response to inflammatory stimuli. The consistent anti-inflammatory role for A2AAR 
signalling in a variety of different models of inflammation indicates a possible 
common mechanism of action. A considerable number of studies suggest that this 
inhibition may occur at the level of transcription. The aim of this project is to study 
the effect of A2AAR-overexpression on activation of the JAK-STAT pathway in 
vascular ECs. Specifically, I aimed to test the effect of the A2AAR-overexpression on 
STAT phosphorylation and expression in response to multiple cytokines (i.e sIL-
6/IL-6, IFNα and leptin). The dissection of the pathways involved may ultimately 
lead to designing more specific and potentially useful drugs for the treatment of pro-
inflammatory diseases. 
 
At the end I would like to summarise the hypothesis of my work in two questions, 
which are; 
Does A2AAR gene transfer to HUVECs suppress sIL-6/IL-6, IFNα and leptin 
signalling? 
Is SOCS3 induction an important mechanism or are other processes involved? 
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Chapter 2 
Materials and Methods 
 
 
 
 
 
 42 
2.1   Chemicals and Suppliers 
All reagents were of the highest grade commercially available and obtained from the 
 
 
Abcam Ltd., Cambridge 
Rabbit polyclonal antibody to STAT4 (cat# ab7967), Mouse mAb to anti-
glyceraldehyde-3-phosphate dehydrogenase GAPDH (cat# ab8245) 
 
Amersham Biosciences AB, Uppsala, Sweden 
Glutathione-Sepharose beadsTM 4B, 
 
Affinity Bioreagents, Golden, Co, USA 
 Anti-A2AAR-specific antibody 
 
BioRad Laboratories Ltd, Hemel Hempstead UK 
 Protein assay dye reagent concentration (Bradford's Reagent) 
 
BDH Laboratories Supplies, Pooles UK 
 Ammonium persulphate (APS), acetic acid, isopropylalcohol, methanol, potassium 
chloride, potassium hydroxide, sodium chloride. 
 
Cambrex BioScience Wokingham Ltd. Wokingham, Berkshire 
Endothelial Basal Media-2TM (EBM-2) and the following supplements (foetal bovine 
serum (FBS), hydrocortisone, fibroblast growth factor-B (hFGF-B), vascular 
endothelial growth factor (VEGF), insulin-like growth factor-l (IGF-l), ascorbic acid, 
epidermal growth factor (hEG-F), gentamicin sulphate and amphotericin-B (GA-
l000) and heparin). 
 Human umbilical vein endothelial cells (HUVECs), SeaPlaque ® agarose, Dulbeco’s 
modified Eagle’s medium (DMAM), cell culture grade phosphate-buffered saline 
(PBS) 
 
    following suppliers:- 
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Calbiochem-Novabiochem (UK) Ltd., Nottingham 
MG132, JAK inhibitor I 
 
Cell Signalling Technology Inc., Beverly, MA USA 
Anti-phospho STAT3 (Tyr705) (cat# 9138), Anti-phospho STAT1 (Tyr701) (cat# 
9171), Anti-STAT3 (cat# 9132), Anti-STAT1 (cat# 9172), Anti-VEGFR2 (cat# 2479) 
 
Duchefa Biochemie, Haarlem, Netherlands 
Yeast extract, tryptone, microagar 
 
Astra-Zeneca Pharmaceuticals Alderley Park 
ZM241385 
 
 
N-(2-Hydroxyethyl)-piperazine-N’-(2-ethanesulfonic acid) (HEPES), sodium dodecyl 
sulphate (SDS), ethylenediaminotetra-acetic acid (EDTA), dimethyl sulphoxide 
(DMSO), ethidium bromide solution, glacial acetic acid, absolute ethanol, 
concentrated hydrochloric acid (HCL), glycine, sodium hydroxide, Tris(hydromethyl-
amino)ethane (TRIS) base, sodium carbonate, sodium hydrogen carbonate, sodium 
dihydrogen ortho-phosphate, di-sodium hydrogen ortho-phosphate, boric acid, 
chloroform, sucrose. 
 
GIBCO BRL Life Technologies, Paisley UK 
Isopropanol, OptiMEM. 
 
Interactiva- Thermo Hybaid, Thermo Biosciences GmbH, UIm, Germany  
HPLC-purified custom synthesised oligonucleotides 
 
Inverclyde Biologicals, Strathclyde Business Park, Bellshill, UK  
Schleicher and Schuell protran nitrocellulose membrane (0.2µm pore size) 
Fisher Scientific, Loughborough, Leicestershire UK 
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Melford laboratories, Chelsworth, Ipswich, UK 
Dithiothreitol (DTT), isopropyl-β-D-thiogalactopyranoside (IPTG) 
 
New England Biolabs Inc., Beverley, MA USA 
Pre-stained protein molecular weight markers (ranging from 6.5-175kDa). 
 
Perkin-Elmer Life and Analytical Sciencesa, Monza, Italy 
Enhanced chemiluminescence (ECL) reagents 
 
Pierce, Rockford, IL, U.S.A. 
 Western Blot Stripping Solution, Slider-A-Lyzer ® Dialysis Cassette (0.5-3 ml 
capacity) 
 
Promega, Southhampton UK 
T4 DNA Ligase, PromegaTM Wizard plus SV DNA mini-prep kit, restriction 
enzymes, deoxynucleotides triphosphates (dNTPs), Ableson Maloney leukaemia 
virus (AMV reverse transcriptase), ribonuclease inhibitor, Taq DNA polymerase, 
DNA molecular size markers (ranging from 100bp-1kbp). 
 
Qiagen, Crawley, West Sussex UK 
 DNA plasmid maxi-prep kit 
 
Reidel-de Haen, Seezle, Germany 
Glycerol, calcium chloride 
 
Research Biochemicals International, Natick, MA, USA 
CGS 21680 
 
Roche Applied Science USA 
FuGENE6 transfection reagent 
 
Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA 
Anti-ubiquitin Antibody (PD41) (cat# D1206), Anti-STAT3 (cat# H3104) 
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Sigma-Aldrich Company Ltd., Poole, UK 
Triton X-100, soybean trypsin inhibitor, benzamidine, IgG-free bovine serum 
albumin (BSA), protein A-Sepharose, sodium periodate, 30% (w/v) acrylamide/0.8% 
(w/v) bisacrylamide solution, horseradish peroxidase (HRP)-conjugated rabbit anti-
mouse IgG, HRP-conjugated  goat anti-rabbit IgG, HRP-conjugated rabbit anti-goat 
IgG,  thimerosal, bromophenol blue, sodium azide,  agarose, deoxycholic acid sodium 
salt, polyethylenimine, ampicillin,  paraformaldehyde, N,N,N’,N’-
tetramethylethylenediamine (TEMED), phenylmethylsulphonyl fluoride (PMSF), 
foetal bovine serum (FBS), cell culture grade trypsin EDTA, endothelial grade 
trypsin EDTA, penicillin, L-glutamine, bicinchonic acid salt ( BCA), 3,3’5,5’ -
tetramethylbenzidine (TMB), human  recombinant interferon-α (IFN-α), anti-FLAG® 
M2 monoclonal antibody F-3165, sodium fluoride,  sodium potassium tartrate, 
deoxycholic acid (sodium salt),  Trizol reagent, lysosyme, sodium orthovanadate, 
phenol:chloroform:isoamyl alchol (25:24:1 (v/v/v)), ethylene glycol-bis (2-
aminoethylether)-N,N,N’,N’-tetracetic acid (EGTA), mouse anti-eNOS antibody 
(cat# AF400594).   
 
Whatman International Ltd., Maidstone, Kent UK  
 
 Filter paper protran 300 mm x 3m (Conv.No# FM0535-1). 
 
 
Adenoviruses (AVs) encoding Flag epitope-tagged wild-type (WT) and Tyr705        
Phe-mutated murine STAT3 were generously donated by Prof. Brian Foxwell 
(Kennedy institute of Rheumatology, U.K.) and Prof. Keilko Yamauchi-Takihara 
(Osaka University Health Care Centre, Japan) and described in (Kunisada et al.; 
1998; Williams et al.; 2004) 
 
A pGEX-KG bacterial expression construct encoding a glutathione-S-transferase 
(GST) fusion protein containing the ubiquitin-associated (UBA) domain from 
Saccharomyces cerevisiae Dsk2p (Funakoshi et al.; 2002)  was generously donated 
by Prof. Hideki Kobayashi ( Kyushu University, Japan).  
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2.2   Cell Culture & Transfection Methods 
 
2.2.1 Cell maintenance 
 
All cell types were grown at 37°C in a humidified atmosphere containing 5% (v/v) 
CO2. HUVECs were maintained in endothelial basal medium supplemented with 2% 
(v/v) foetal bovine serum, 0.04% (v/v) hydrocortisone, 0.4% (v/v) human fibroblast 
growth factor-B (hFGF-B), 0.1 % (v/v) vascular endothelial growth factor (VEGF), 
0.1% (v/v) insulin-like growth factor-l (IGF-l), 0.1% (v/v) ascorbic acid, 0.1% (v/v) 
human epidermal growth factor (hEGF), 0.1% (v/v) gentamicin sulphate and 
amphotericin-B (GA-1000) and 0.1% (v/v) heparin. Since HUVECs rapidly adapt in 
culture conditions, they were not used after passage 5 (Muller et al., 2002). For 
passaging, confluent cells were washed in 5 ml of PBS and then treated briefly with 3 
ml endothelial grade trypsin in order to detach the cells. The trypsin was then 
neutralised with 10 ml of spent medium and the contents transferred to a 50 ml 
centrifuge tube. Cells were centrifuged for 5 min at 1000g and the supernatant was 
discarded. The cell pellet was gently resuspended in medium at a dilution factor 
suitable to establish a cell density that could be reliably counted within a standard 
haemocytometer, typically 1:10 dilution. Wells were then seeded at an appropriate 
level according to the analysis performed as indicated in the figure legends. Typically 
a 6-well plate would be seeded with 1 x 105 cells/well, ready for infection the 
following day with adenovirus. A minimum of 1x104 cells was used to maintain the 
cell line in a fresh 150 cm2 tissue culture flask to which 11 ml of fresh medium was 
added. 
 
Human embryonic kidney 293 cells (HEK 293) were maintained in DMEM 
supplemented with 10% (v/v) FBS, 1 mM L-glutamine, 100 units/ml penicillin and 
100 µg/ml streptomycin. Confluent monolayers were washed once in 5 ml of sterile 
PBS and then treated with 1 ml trypsin EDTA. Cells were then returned to the 
incubator for a few minutes before the flask was disrupted to dislodge the cells. Cells 
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were then typically diluted 1:8, 7 ml of which was used in experimental analysis and 
1 ml was used to maintain the cells to which 9 ml of fresh DMEM was added.  
 
 
2.2.2 Transfection with Fugene 
 
In a sterile microfuge tube 2 µg of plasmid DNA was incubated with 200 µl of serum 
free medium per well of a 6 well dish and vortexed briefly. 10 µl of Fugene was 
added mixed gently and incubated for 15 min at room temperature. The DNA-Fugene 
mix was then added to each well containing 2 ml of fresh medium and left to incubate 
overnight. The next day, the medium was replaced with fresh growth medium. For 
experiments, cells were analysed 48 hr after transfection. 
 
2.2.3  Infection of HUVECs with AVs 
 
1x105 HUVECs were seeded in a 6 well plate and grown to 70% confluence.  The 
cells were then infected for 24 hr at a m.o.i. of 25 pfu/cell with recombinant AVs. 
The next day, the medium was replaced with fresh growth medium. The following 
day, confluent HUVECs in six-well plates were treated as described in the figures 
prior to washing in ice cold PBS and solubilised by  50 µl/well detergent lysis buffer ( 
Section 2.5.1). 
 
2.3    Molecular Biology 
 
2.3.1  Preparation of antibiotic agar plates 
 
LB agar (1 % (w/v) bactotryptone, 0.5% (w/v) yeast extract, 1 % (w/v) sodium 
chloride, 7% (w/v) agar) was prepared, autoclaved and allowed to cool before 
addition of ampicillin at the final concentrations 50 µg/ml. The liquid LB agar was 
then poured into 90 mm-diameter Petri dishes, allowed to solidify and then allowed to 
sweat overnight at room temperature to get rid of excess moisture. Plates were then 
stored at 4°c until required for a maximum period of 2 weeks. 
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2.3.2 Preparation of competent BL21 E.coli 
 
An overnight culture of BL21 E. coli was grown in 3 ml of LB broth containing 50 
µg/ml tetracycline. The following day, this was used to inoculate 250 ml of LB broth, 
which was then grown with aeration in a 37°C shaking incubator at 200 rpm, until the 
growth rate reached log phase as determined by the culture reaching an optical 
density at 600 nm of 0.35-0.375. Bacteria were transferred to two chilled 250 ml 
sterile centrifuge tubes and left for one hour on ice. Bacteria were then sedimented by 
centrifugation at 3,500 g for 20 min at 4°C and the supernatant discarded. The 
bacterial pellet was then washed and resuspended in 62.5 ml of ice-cold 0.1M 
magnesium chloride. Following another 20 min centrifugation at 3,500g, the bacteria 
were resuspended in 62.5ml of ice-cold 15% (v/v) glycerol with 0.1M calcium 
chloride. 250 µl of bacteria were aliquoted into sterile microfuge tubes in a  
ice/methanol bath to induce rapid freezing, and stored at -80 oC until required. 
 
2.3.3  Transformation of competent BL21 E.coli 
 
Approximately 30-50 ng of plasmid DNA was added to a plastic 13 ml Falcon round-
bottom tube on ice. Once thawed 80 µl/tube of competent E.coli was immediately 
added and the mix incubated on ice for 30 min. The tubes were incubated for 2 min at 
42°C before tube placed on ice and 1 ml of LB per tube was then added. Tubes were 
then shaken at 37°C for 30 min.  The transformation mix was then plated out onto LB 
agar plates containing the appropriate selection antibiotic and incubated overnight at 
37°C. 
 
2.3.4  Preparation of plasmid DNA 
 
Transformed colonies picked from agar plates using sterile pipette tips, were used to 
inoculate 10 ml of LB ( 1% (w/v) bactrotryptone, 0.5 % (w/v) yeast extract, 1% (w/v) 
sodium chloride broth supplemented with the appropriate selection antibiotic 
(50µg/ml ampicillin), and placed in the shaking incubator at 37°C overnight. Plasmid 
DNA was then isolated using the Promega TM Wizard plus SV miniprep purification 
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system as per the manufacturer’s instructions. For larger quantities of plasmid DNA, 
the initial 10 ml culture was then used to inoculate a 500 ml culture containing the 
appropriate antibiotic and grown overnight at 37oC with shaking. Plasmid DNA was 
isolated using the Qiagen Maxi Kit system as directed by the manufacturer’s 
instructions. The concentration of double stranded DNA obtained was calculated 
based on the assumption that 1 absorbance unit (A260) is equivalent to 50 µg/ml of 
double stranded DNA. An absorbance ratio (A260/A280) greater than or equal to 1.6 
indicated good quality DNA. 
 
2.3.5 Digestion of plasmid DNA 
 
1-2 µg of purified plasmid DNA was digested in a sterile microfuge tube containing 
the appropriate enzyme buffer and 2-4 units of enzyme as per the manufacturer's 
instructions. In certain cases it was necessary, due to incompatible buffers, to purify 
the linearised plasmid DNA from the first digestion, before digestion with the second 
enzyme and buffer. This was achieved by phenol extraction and ethanol precipitation. 
Briefly 1/10 volume of 3M sodium acetate and 3 volumes of ice-cold absolute 
ethanol were added to the sample. Following 30 min incubation on ice, samples were 
centrifuged at 4°C for 30 min at 13,000g and the supernatant removed. The DNA 
pellet was washed 3x in 50 µl of 70% (v/v) ethanol, centrifuged at 4°C for 5 min at 
13,000g and allowed to air-dry. It was then resuspended in 15 µl of the second 
enzyme buffer before the addition of 2-4 units of the second enzyme as per the 
manufacturer instructions. Restriction fragments were typically resolved on a 1 % 
(w/v) agarose gel containing 2.5 µg/ml ethidium bromide run at 75 mV for 20-30 min 
in TAE buffer (40 mM Tris-acetate, 1 mM EDTA, and 0.1 % (v/v) glacial acetic 
acid).  
 
2.3.6 Preparation of RNA 
 
A 6-well plate was seeded with HUVECs at density of 1x105 and was treated as 
described in the figure legend. Total RNA from HUVECs was isolated using Tri-
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Reagent (sigma-Aldrich, Irvine, U.K.). Briefly, cells were washed 3 times in ice cold 
PBS and solubilised by scraping into 0.5 ml of Tri- reagent. 0.2 ml of chloroform was 
added and the samples were thoroughly mixed and incubated at room temperature for 
5 min. Samples were then centrifuged at 13000g in a bench centrifuge for 5 min. The 
upper colourless layer which contains the RNA was transferred to a new RNASe 
tube, to which 1 ml of absolute ethanol was added. After spinning the samples at 4 oC 
for 30 min at full speed.  The supernatant was discarded and the pellet was washed 
once in 1 ml of 70% (v/v) ethanol, then centrifuged for 5 min and the supernatant was 
discarded.   The pellet was air-dried by putting it on a heater at 37 oC.  Once dry, the 
pellet was resuspended in 15 µl of RNAase free water. The concentration of RNA 
obtained was calculated based on the assumption that 1 absorbance unit (A260) is 
equivalent to 40 µg/ml of RNA. 
 
2.3.7  Reverse transcription-PCR (RT-PCR) 
 
For making cDNA from RNA (Section 2.3.6) 1 µg RNA was mixed with 90 ng of 
Random hexanucletide primers in total volume of 15 µl. Samples were heated at 70 
oC for 3 minutes and then immediately placed on ice to cool.  A mixture of 5x reverse 
transcriptase buffer ( supplied with kit) and dNTPs was made and added to each 
reaction to give final concentrations of 50 mM Tris-HCl (pH 8.3 at 25 oC), 40 mM 
KCl,  8.75 mM MgCl2, 10 mM DTT, 0.1 mg/ml acetylated BSA and 1mM of each 
dNTP. 20U of the Ribonuclease inhibitor and 5U AMV reverse transcriptase were 
then added, the samples mixed by pipetting and incubated at 42 oC for 3 hrs. The 
cDNA generated was stored at -20 oC until PCR analysis was performed. 
 
2.3.8  PCR of prepared cDNA 
 
 PCR was carried out using GoTaq® Flexi DNA polymerase kit.  Prior to this, PCR 
conditions were optimised to ensure that primers caused amplification of only one 
product of correct size (human SLIM/Mystique amplicon size of 900bp and human 
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GAPDH amplicon size of 150 bp). The kit provides 5x Green or Colorless GoTaq® 
Flexi Buffer,  25 mM MgCl2 and . GoTaq® Flexi DNA polymerase  
 
PCR was performed in a sterile nuclease-free microcentrifuge tube, by combine, the 
following components on ice, 17.5 µl Green Flexi Buffer,7 µl MgCl2 solution (1mM 
for SLIM and 10 µl of 1.5 mM for GAPDH), PCR nucleotide Mix 2.8 mM each 
dNTP, primers for SLIM are reverse (5´-CTCAGGCCCGAGAG-3`) and forward (5´-
GTATGGCGTTGACG-3`)  while  GAPDH are reverse GAPDH1 (5´- 
GAAGATGGTGATGGGATTTC-3`) and forward GAPDH2 (5´-
GAAGATGGTGATGGGATTTC-3`) for GAPDH. GoTaq DNA polymerase 1.24µl 
and 1µl of template DNA were mixed in a final reaction volume of 25µl. 
 
The thermal cycling conditions for the SLIM/Mystique PCR amplification were: 
initial denaturation at 95 oC for 2 min, followed by 30 cycles of denaturation at 95 oC 
for 1 min , and annealing at  58 oC for 1min followed by an extension at 72 oC for 1 
min/kbp. A final extension at 72 oC has perform for 5 min.   
 
The conditions for GAPDH were: initial denaturation at 94 for 2 min, followed by 26 
cycles of denaturation at 95 oC for 1 min, and annealing at 52 oC 1min, followed by 
extension at 72 oC for 1 min/kbp. A final extension at 72 oC has performed for 5 min. 
After that products were then separated by agarose gel electrophoresis and visualized 
with ethidium bromide staining. 
 
2.3.9 Purification of adenoviral vectors 
 
 The generation and purification of plaque-purified adenoviruses (AV) encoding myc 
epitope-tagged human A2AAR and GFP made by (Sands et al.; 2004). The presence 
of the gene encoding GFP in a separate open reading frame allowed us to monitor 
viral expression by fluorescence microscopy. 8 days post-infection low passage 
HEK293, cells were scraped and collected in a sterile centrifuge tube and pelleted by 
a 5 min centrifugation step at 400g at room temperature. The supernatant was 
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discarded and the pellet was washed in 1 ml sterile PBS. Cells were then disrupted by 
four freeze/thaw cycles in a dry ice/methanol bath and the pellet resuspended in 10 ml 
of sterile PBS. This was then used to infect two T-150 flasks of 50-60% confluent 
HEK 293 cells, grown in medium containing 2% (v/v) FBS. Virus particles from 
these cells were then prepared 3 days later, and used to infect a larger scale culture of 
20 x T-150 flasks of HEK 293 cells. From this large scale preparation, virus was 
isolated as per the method of (Nicklin et al.; 2001). Briefly, dislodged cells were 
pooled and pelleted by a brief centrifugation at 250g for 10 min at room temp. The 
supernatant was then discarded and the pellet resuspended in 10 ml of sterile PBS. 
The pellet was then washed four times with 1 ml of sterile PBS and the supernatant 
discarded. This was then subjected to four freeze/thaw cycles in order to lyse the cells 
and release the virus particles. The preparation was then added to a discontinuous 
caesium chloride gradient set up in a 13ml sterile ultracentrifuge tube, and was 
subjected to centrifugation at 100,000g for 90 min at 8°C with zero deceleration. The 
opaque adenovirus band was then isolated by syringe extraction and added into a 
Slide-A-Lyser that allowed efficient overnight dialysis at 4°C in lL of dialysis buffer 
(15 mM sodium chloride, 51.2 µM Tris (pH 7.5), 10 µM EDTA) which was changed 
3 times. Virus samples were removed from the Slide-A-Lyser and diluted in a 1:1 
(v/v) ratio with sterile virus storage buffer (10 mM Tris-HC1, pH 8, 100 mM sodium 
chloride, 0.1 % (w/v) BSA, 10% (v/v) glycerol) and stored at -80°C in 30 µl aliquots. 
 
Once isolated, the virus was subject to titration by the end-point dilution method 
(Nicklin and Baker, 2001) using GFP as a marker for positive colonies. 1 x 104 HEK 
293 cells/well was subcultured into 8x10 wells of a 96-well plate in order to reach 
approximately 50-60% confluency after 24 hr growth. 0.1 ml of virus was then used 
to infect the wells over a range of serial dilutions (10-2-10-11). This was incubated for 
18 hr before the virus was removed and the medium replaced. The medium was 
replaced every 3 days up to 10 days post-infection until the well showed evidence of 
viral infection as assessed by GFP expression. After 10 days the number of virus 
positive wells was counted for each concentration of virus and the virus titre was.  
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2.3.10   Preparation of GST-UBA Sepharose beads 
 
10 ml of LB broth supplemented with 50 µg/ml ampicillin was inoculated from a 
glycerol stock of BL21 E.coli transformed with Dsk2pUBA was then grown 
overnight, shaking at 37 oC.  This starter culture was then used to inoculate  400ml 
LB containing 50µg/ml ampicillin was grown shaking at 200 rpm for 5 hours  (or 
until OD600 = 0.3 or greater) at 37 oC.  Fusion protein expression was then induced by 
addition of IPTG to a final concentration of 1mM, and then grown for 4 hours at 37 
oC with shaking at 200 rpm.  The bacteria were then harvested by centrifugation at 
6700g for 15 min, and the supernatant discarded. The cells were resuspended in 20ml 
lysis buffer (50mM sodium HEPES, pH 7.4, 150 mM NaCl, 5 mM EDTA and 1% 
(v/v) Triton-X-100) and incubated at room temperature for 30 min.  The samples 
were then probe sonicated on ice 3 times for 30 second to ensure efficient cell lysis 
and then centrifuged at 27000g for 30 mins to pellet insoluble material.  The cleared 
lysate was then added to 0.6 ml 50 % (v/v) glutathione-Sepharose bead suspension 
and placed on a rotating wheel at 4 oC for 1 hour to allow the fusion protein to bind.  
The beads were then washed three times with 10 ml PBS and, following the final 
wash, resuspended in 50% (v/v) glycerol in PBS supplemented with protease 
inhibitors (0.1 mM PMSF, 10 µg/µl soybean trypsin inhibitor and 10 µg/µl 
benzamidine) for storage at -20 oC.  The same procedure was utilised for the 
preparation of GST-immobilised Sepharose beads which were used as a negative 
control.  
 
2.3.11   SPAGE assays for quantitation of immobilised GST fusion proteins. 
 
20 µl of prepared bead suspension was centrifuged at 5000g for 20 sec at 4 oC and the 
supernatant was removed with a 1 ml syringe. The protein was eluted from the beads 
by addition of 20 µl of 2% (w/v) SDS sample buffer and incubated at 37 oC for 30 
min. The sample was briefly centrifuged at room temperature and the protein 
containing supernatant was removed via a Hamilton syringe into a fresh microfuge 
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tube. Known amounts of BSA ranging from 0.2-2 µg and 5µl and 10µl of eluted 
proteins were analysed by SDS PAGE using a 10% (w/v) resolving gel.  The gel was 
then stained for 1 hr at RT with Coomassie Brilliant Blue (3mM Coomassie Brilliant 
Blue G, 45% (v/v) methanol, 10% (v/v) acetic acid).  Following destaining overnight, 
the gel was then scanned and the density of the BSA bands were used to generate a 
standard curve from which the concentration of protein immobilised on the GST-
Sepharose beads could be determined (Figure 2.1). The same method used for GST 
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Figure 2.1 SDS-PAGE protein assay for immobilised GST fusion proteins on 
beads 
Known amounts of BSA ranging from 0.2-2 µg and 5µl and 10µl of eluted proteins 
were analysed by SDS PAGE. The gel was stained for 1 hr at RT with Coomassie 
Brilliant Blue (3mM Coomassie Brilliant Blue G, 45% (v/v) methanol, 10% (v/v) 
acetic acid). The gel was destained overnight, scanned and the density of BSA bands 
was used to generate a standard curve. The BSA standard curve was then used to 
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estimate the concentration of protein immobilised on the beads. The same method 
was used for GST. 
 
2.4   Laboratory techniques 
 
2.4.1 Cell lysis 
 
Confluent HUVECs in six-well plates were treated as described in the figures prior to 
washing in ice cold PBS and solubilised by  50 µl/well detergent lysis buffer (50mM 
sodium HEPES, pH 7.5, 150 mM sodium chloride, 5 mM EDTA, 10 mM sodium 
fluoride, 10 mM sodium phosphate , 1% (v/v) Triton X-100, 0.5% (w/v) sodium 
deoxycholate, 0.1% (w/v) SDS, 0.1 mM phenylmethylsulphonyl fluoride, 10 µg/ml 
soybean trypsin inhibitor, 10 µg/ml benzamidine and EDTA-free complete protease 
inhibitor mix). Samples were then scraped pipeting to microfuge tube and followed 
by brief vortexing, insoluble material was removed by microcentrifugation at 5000g 
for 5 min at 4 oC  and the supernatant assayed for protein concentration using a  
bicinchonnic acid assay described in (Section 2.5.2). 
 
2.4.2  Discontinuous SDS-PAGE and Immunoblotting 
 
Samples were equalised for protein amounts (typically 10-20 µg/sample) and 
following the addition of an equal of samples buffers were fractionated by 
discontinuous SDS-PAGE using a 6 cm 10% (w/v) polyacrylamide resolving gel 
(10% (w/v) acrylamide, 0.3% (w/v) bisacrylamide, 0.4 M Tris (pH 8.8), 0.1 % (w/v) 
SDS, 3% (v/v) glycerol, 0.01% (w/v) ammonium persulphate and 0.001% (v/v) 
TEMED) and a 2 cm 3% (w/v) stacking gel (3% (v/v) acrylamide, 0.1% (v/v) 
bisacrylamide, 0.1M Tris (pH 6.8), 0.1% (w/v) SDS, 0.01% (w/v) ammonium 
persulphate and 0.001 % (v/v) TEMED). Pre-stained protein markers (Invitrogen 
Rainbow Markers, range 6.5-175kDa) in sample buffer (50 mM Tris (pH 6.8), 10% 
(v/v) glycerol, 12% (w/v) SDS, 0.0001 % (w/v) of bromophenol blue, 1 mM DTT) 
were also used in order to determine protein molecular mass. Electrophoresis was 
carried out using Biorad Mini-Protean II or III gel electrophoresis systems in running 
buffer (27.4 mM Tris, 0.19M glycine, 0.1 % (w/v) SDS) at 150 V until the 
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bromophenol blue dye front reached the bottom of the gel. Proteins were then 
transferred electrophoretically onto a nitrocellulose membrane at 400 mA for 45 min 
in transfer buffer (24.7 mM Tris, 0.19 M glycine in 20% (v/v) methanol). Following 
transfer to nitrocellulose, membranes were blocked for one hour at room temperature 
in blocking solution (5% (w/v) skimmed milk in Tris-buffered saline (TBS) 
containing 0.1 % (v/v) Tween-20 (TBST) or 5% (w/v) skimmed milk in phosphate-
buffered saline (PBS), 0.2% (v/v) Triton X-100 in PBS. Antibody, diluted in Blotto 
as indicated in the Figure Legends. This was incubated in the cold room overnight on 
a rotating platform. The membranes were rinsed briefly in PBS before being washed 
three times in Blotto for 10 min. Membranes were then washed again briefly in PBS 
before being transferred to a bag containing 2 ml of the appropriate secondary 
antibody conjugated to HRP in High-Detergent Blotto (10% (v/v) Blotto in PBS 
supplemented with 1.02% (v/v) Triton X-100 and 0.1 % (w/v) SDS). This was then 
placed on a rotating platform at room temperature and incubated for 1 hr. The 
membrane was then washed three times for 10 min in Blotto and then washed a 
further twice for 10 minutes in PBS. Membranes were then exposed to an enhanced 
chemiluminescent procedure in which HRP-specific oxidative degeneration of 
luminal causes emission of light at 428 nm which is detected by Kodak XOMAT 
Blue X-ray film (see Table 2.1). 
 
2.4.3  Protein concentration determination using the bicinchonic acid (BCA) 
protein assay 
 
Duplicate 10µl samples of known BSA standards in the range 0-2 mg/ml and 
unknown protein samples were added to a 96-well plate. 0.2 ml BCA solution (1 % 
(w/v) 4,4 dicarboxy-2,2 biquinoline disodium salt, 2% (w/v) sodium carbonate, 
0.16% (w/v) sodium potassium tartrate, 0.4% (w/v) sodium hydroxide, 0.95% (w/v) 
sodium bicarbonate pH 11.25, 0.08% (w/v) copper (II) sulphate) was then added to 
each well. Protein concentration-specific reduction of Cu2+ to Cu1+ allows the 
bicinchoninic acid sodium salt to bind the Cu1+ ion forming an intense purple colour 
allowing measurement of the absorbance at 492 nm using a plate reader. Colour was  
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There fore allowed to develop at room temperature for 30 min and the absorbance of 
the standards was used to determine a straight line from which unknown protein 
concentrations could be calculated (Smith et al, 1985). 
 
 
 
 
Table 2.1 Antibody Incubation Conditions 
 
 
INCUBATION 
CONDITIONS 
 
BLOTTO 
 PROTEIN 
1ºAB 2ºAB 1ºAB 
 
2ºAB 
 
 
P-STAT1 
 
P-STAT1 
1:1000 
Overnight, 
cold room 
Anti-Rabbit 
HRP 
1:1000 
1hr, room 
temp 
 
5% (W/V) 
BSA 
TBST 
5% (W/V)  
BSA 
TBST 
 
STAT1 
 
STAT1 
1:1000 
Overnight, 
cold room 
Anti-Rabbit 
HRP 
1:1000 
1hr, room 
temp 
 
 
5% (W/V) 
skimmed milk 
PBS TWEEN 
5% (W/V) 
skimmed milk 
PBS TWEEN 
P-STAT3 
 
 
P-STAT3 
1:1000 
Overnight, 
cold room 
 
Anti-mouse 
HRP 
1:1000 
1hr, room 
temp 
 
5% (W/V)  
BSA 
TBST 
5% (W/V)  
BSA 
TBST 
 
STAT3 
 
STAT3 
1:1000 
Overnight, 
cold room 
Anti-Rabbit 
HRP 
1:1000 
1hr, room 
temp 
 
5% (W/V)  
skimmed milk 
PBS TWEEN 
5% (W/V)  
skimmed milk 
PBS TWEEN 
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P-STAT4 
P-STAT4 
1:1000 
Overnight, 
cold room 
Anti-mouse 
HRP 
1:1000 
1hr, room 
temp 
 
 
5% (W/V)  
BSA 
TBST 
5% (W/V)  
BSA 
TBST 
 
Ub 
 
 
Ub 
1:1000 
Overnight, 
cold room 
Anti-mouse 
HRP 
1:1000 
1hr, room 
temp 
 
 
5% (W/V)  
skimmed milk 
PBS TWEEN 
5% (W/V) 
skimmed milk 
PBS TWEEN 
 
GAPDH 
 
GAPDH 
1:20000 
1hr, room temp 
 
Anti-mouse 
HRP 
1:5000 
1hr, room         
temp 
 
5% (W/V) 
skimmed milk 
PBS TWEEN 
5% (W/V) 
skimmed milk 
PBS TWEEN 
 
 
VEGFR2 
 
VEGFR2 
1:1000 
Overnight, 
cold room 
Anti-Rabbit 
HRP 
1:1000 
1hr, room 
temp 
 
5% (W/V)  
BSA 
TBST 
5% (W/V)  
BSA 
TBST 
 
 
eNOS 
 
eNOS 
1:1000 
Overnight, 
cold room 
 
Anti-Rabbit 
HRP 
1:2000 
1hr, room 
temp 
 
 
5% (W/V)  
BSA 
        TBST 
 
5% (W/V)  
BSA 
       TBST 
 
 
SLIM 
 
 
 
SLIM 
1:1000 
Overnight, 
cold room 
Anti-Rabbit 
HRP 
1:1000 
1hr, room 
temp 
 
 
5% (W/V) 
BSA 
TBST 
 
5% (W/V)  
BSA 
TBST 
 
 
Flag 
 
Flag 
1:1000 
Overnight, 
cold room 
Anti-mouse 
HRP 
1:1000       
1hr, room 
temp 
5%(W/V) 
skimmed 
milkPBS 
TWEEN 
5%(W/V) 
skimmed 
milkPBS 
TWEEN 
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P-JAK1 
 
P-JAK1 
1:1000 
Overnight, 
cold room 
 
Anti-Rabbit 
HRP 
1:1000 
1hr, room 
temp 
 
 
5% (W/V)  
BSA 
TBST 
 
5% (W/V)  
BSA 
TBST 
 
 
 
P-JAK2 
 
P-JAK2 
1:1000 
Overnight, 
cold room 
 
Anti-Rabbit 
HRP 
1:1000 
1hr, room 
temp 
 
 
5% (W/V)  
BSA 
TBST 
 
5% (W/V)  
BSA 
TBST 
 
 
 
JAK1 
 
JAK1 
1:1000 
Overnight, 
cold room 
 
Anti-Rabbit 
HRP 
1:1000 
1hr, room 
temp 
 
 
5% (W/V)  
skimmed milk 
PBS TWEEN 
 
5% (W/V)  
skimmed milk 
PBS TWEEN 
 
 
 
JAK2 
 
JAK2 
1:1000 
Overnight, 
cold room 
 
Anti-Rabbit 
HRP 
1:1000 
1hr, room 
temp 
 
 
5% (W/V)  
skimmed milk 
PBS TWEEN 
 
5% (W/V)  
skimmed milk 
PBS TWEEN 
 
 
 
GFP 
 
 
GFP 
1:10000 
Overnight, 
cold room 
 
Anti-Goat or 
Anti-Sheep 
1:30000 
1hr, room 
temp 
 
 
5% (W/V)  
skimmed milk 
TBS TWEEN 
 
5% (W/V)  
skimmed milk 
TBS TWEEN 
 
 
 
2.4.4  GST-Dsk2pUBA pull-down assays 
 
Recombinant GST and GST-Dsk2pUBA were purified from transformed E. coli 
BL21 (DE3) cultures using glutathione-Sepharose beads following induction of 
fusion protein expression with IPTG as described in (Section 2.3.10). For pull-down 
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assay, confluent HUVECs in six-well dishes were treated as described in the results 
prior to termination of the reactions by addition of ice cold PBS.  All subsequent 
procedures were performed at 4oC unless indicated otherwise. Cells were solubilised 
by scraping into 0.25 ml/well pull-down lysis buffer (50mm sodium HEPES, pH 7.5, 
150 mM sodium chloride, 5mM EDTA, 1mM sodium vanadate, 6 µM MG132, 1 mM 
N-ethylmaleimide, 1% (v/v) Triton X-100, 0.1 mM PMSF, 10 µg/ml soybean trypsin 
inhibitor, 10 µg/ml benzamidine and EDTA-free complete protease inhibitor mix) and 
incubated on ice for 30 min. Following centrifugation at 5000g for 5 min at 4 oC to 
pellet insoluble material, samples were equalised for volume and protein content 
(typically 50 µg in 0.2 ml) prior to the addition of either  GST or   GST-Dsk2pUBA 
(5µg/sample) immobilised to glutathione-Sepharose beads and incubated with 
rotation for 1 hr. Beads were recovered by brief centrifugation and washed five times 
with 1 ml lysis buffer prior to the elution of bound protein by the addition of 50µl 
electrophoresis sample buffer containing 12% (w/v) SDS and incubation at 60 oC for 
15 min. Sample were then fractionated by SDS-PAGE and transferred to 
nitrocellulose for immunoblotting.  
 
To remove polyubiquitin chains from captured proteins prior to SDS-PAGE, beads 
were washed twice with 1ml deconjugation buffer (50 mM sodium HEPES, pH7.5, 
1mM dithiothretol) after the lysis buffer wash steps and then resuspended in 50µl 
deconjugation buffer supplemented with 0.2 µM recombinant human isopeptidease 
T/UBP5 and incubated at 37 oC for 1 hr. Reactions were terminated by brief 
centrifugation and the supernatant containing deconjugated proteins was removed for 
analysis by SDS-PAGE and immunoblotting following the addition of electrophoresis 
sample buffer. 
 
2.4.5 Immunoprecipitation  
 
Confluent HUVECs in six well dishes were pre-incubated with 6 µM MG132 for 30 
min prior to treatment with or without sIL-6Rα/IL-6 as described in the figure 
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legends prior to termination of the incubation by placing dishes on ice and washing 
cell monolayers three times with ice-cold PBS. Cells were solubilised by scraping 
into 0.1 ml denaturing lysis buffer (50 mM sodium HEPES, pH 7.5, 100 mM sodium 
chloride, 1 mM N-ethylmaleimide, 2% (w/v) SDS, 0.1 mM phenylmethylsulphonyl 
fluoride, 10 µg/ml soybean trypsin inhibitor, 10 µg /ml benzamidine and EDTA-free 
complete protease inhibitor mix). The samples were then incubated at 95 oC for 5 min 
followed by probe sonication on ice 3 times for 30 second. After the addition of 0.9 
ml lysis buffer containing sufficient Triton X-100 and sodium deoxycholate to give 
final concentrations of 1% (w/v) and 0.5% (w/v) respectively, insoluble material was 
removed by centrifugation at 5000g for 5 min at 4 oC and soluble fractions equalised 
for protein content volume prior to incubation for 1 hr at 4 oC with rotation with 25 µl 
packed volume of protein A-Sepharose beads in the presence of 0.2% (w/v) IgG-free 
BSA. Anti-STAT3 antibody (2µg/sample) was then added and the incubation 
continued for a further 1 hr.  Immune complexes were isolated by brief centrifugation 
at 5000g for 5 min at 4 oC and washed three times with 1 ml detergent lysis buffer 
prior to elution of precipitated proteins by the addition of 40 µl electrophoresis 
sample buffer containing 12% (w/v) SDS and incubation at 60 oC for 15 min. 
Samples were then fractionated by SDS-PAGE using 7.5% (w/v) polyacrylamide 
resolving gels and transferred to nitrocellulose for immunoblotting. 
 
Confluent HUVECs in six well dishes were pre-incubated with 6 µM MG132 for 30 
min prior to treatment with or without sIL-6Rα/IL-6 as described in the figure 
legends prior to termination of the incubation by placing dishes on ice and washing 
cell monolayers three times with ice-cold PBS. Cells were solubilised by scraping 
into 0.1 ml denaturing lysis buffer (50 mM sodium HEPES, pH 7.5, 100 mM sodium 
chloride, 1 mM N-ethylmaleimide, 2% (w/v) SDS, 0.1 mM phenylmethylsulphonyl 
fluoride, 10 µg/ml soybean trypsin inhibitor, 10 µg /ml benzamidine and EDTA-free 
complete protease inhibitor mix). The samples were then incubated at 95 oC for 5 min 
followed by probe sonication on ice 3 times for 30 second. After the addition of 0.9 
ml lysis buffer containing sufficient Triton X-100 and sodium deoxycholate to give 
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final concentrations of 1% (w/v) and 0.5% (w/v) respectively, insoluble material was 
removed by centrifugation at 5000g for 5 min at 4 oC and soluble fractions equalised 
for protein content volume prior to incubation for 1 hr at 4 oC with rotation with 
Recombinant Flag-tagged STAT3 was immunoprecipitated by the addition of 20 µl 
packed volume of anti-Flag M2-Sepharose beads and incubation with rotation for 1 hr 
at 4 oC. Immune complexes were isolated by brief centrifugation at 5000 xg for 5 min 
at 4 oC and washed three times with 1 ml detergent lysis buffer prior to elution of 
precipitated proteins by the addition of 40 µl electrophoresis sample buffer containing 
12% (w/v) SDS and incubation at 60 oC for 15 min. Samples were then fractionated 
by SDS-PAGE using 7.5% (w/v) polyacrylamide resolving gels and transferred to 
nitrocellulose for immunoblotting. 
 
 
2.4.6 3-(4,5-dimethylthiazol-2yl)-2,5-diphenyl 2H-tetrazolium bromide (MTT) 
assay of cell viability 
 
HUVECs were seeded in a 24 well plate and grown to 70% confluence.  The cells 
were then infected for 48 hr with recombinant AVs. On the next day, the medium was 
replaced with fresh growth medium. The following day, cells were treated with sIL-
6Rα/IL-6 for 3hr or 0.1 (w/v) sodium azide for 16 hr.  Then 20 µl of 12 µM MTT (3-
[4,5-dimethylthioazol-2-yl] was added to each well for 2 hrs. After that the medium 
in use was discarded and 200 µl of dimethyl sulfoxide (DMSO) was used to 
solubilize samples. 150 µl from each well was then added to 96 well plates and the 
formazan product was determined by 
  
measuring the absorbance at 550 nm.  
 
2.4.7  Statistical Analysis 
 
Statistical analysis was carried out using the Student t-test using GraphPad Instat 3 as 
indicated in the Figure Legends. Significance was assessed as p<0.05. 
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Chapter3 
Effect of A2AAR Expression on Cytokine Activation of the 
JAK-STAT pathway in vascular ECs 
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3.1  Introduction 
 
Endothelial cells were once viewed as relatively inert cells lining the vasculature. 
They are now recognized as active and responsive regulators of coagulation, platelet 
adhesion, fluid homeostasis, wound healing, leukocyte extravasation and vascular 
tone. Endothelial cells play a key role in the host response to infectious agents by 
regulating leukocyte trafficking, producing inflammatory cytokines and presenting 
antigen in association with major histocompatibility class II (MHC II) molecules (Cid 
et al.; 1998) . A number of infectious induce pathology by interacting with 
endothelial cells. Infection of endothelial cells can promote thrombosis, vascular 
leakage, and increased adherence and emigration of leukocytes. Furthermore, 
activation of a systemic inflammatory response, in the absence of direct endothelial 
cell infection, can also lead to endothelial cell dysfunction. The endothelial 
dysfunction occurs under activation conditions, with the acquisation of many new 
functional, inflammatory and immune properties. A consequence of this is to display 
many different transcription profiles. In addition, endothelial cells selectively control 
vascular permeability, which is important in many pathophysiological processes 
(Mader; 1996). 
 
Endogenous adenosine is a potent regulator of inflammation. It has been reported that 
adenosine accumulation underlines the anti-inflammatory action of anti-rheumatic 
drugs such as methotrexate (Montesinos et al.; 2000). Monocytes and macrophages 
synthesise and release into their environment a variety of cytokines and other proteins 
that play a central role in the development of acute and chronic inflammation. There 
is evidence suggesting a regulatory connection between adenosine and its receptors 
and inflammatory cytokines. In human and murine monocytes/macrophages, the 
activation of adenosine receptors, particularly A2AAR, by adenosine or it analogues, 
modulates the production of inflammatory cytokines including TNF-α, IL-10, and IL-
12 (Hasko et al.; 2000). IL-12, a pro-inflammatory cytokine and a central inducer of 
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Th1 responses and cell-mediated immunity, is suppressed by adenosine and its 
analogues (Hasko et al.; 2000; Link et al.; 2000) . 
 
In human peripheral blood mononuclear cells, treatment with cAMP-elevating agents, 
such as the PDE4 inhibitor rolipram, causes complete inhibition of TNF-α production 
and an increase in IL-10 synthesis (Eisenhut et al.; 1993). In the same way, cAMP 
agonists inhibit endotoxin-induced IL-6 expression in monocytes or macrophages 
differentiated in cell culture (Eigler et al.; 1998). Identification of A2AAR as natural 
brakes of inflammation has provided a useful framework for understanding how 
tissues regulate inflammation. Thus, targeting the endogenous inflammatory 
pathways such as JAK-STAT signalling pathway by the A2AAR might be a useful 
strategy in the clinical management of inflammation. The aim of this chapter was to 
determine what effect adenoviral gene transfer of the myc-His-tagged human A2AAR 
would have on the inflammatory response in HUVECs, and what A2AAR-stimulated 
molecular mechanism were involved. 
 
A2AARs have a non-redundant role in the attenuation of inflammation and tissue 
damage in vivo. Sub-threshold doses of an inflammatory stimulus as ((Tiegs; 1997; 
Kaneko et al.; 2000) showed cause minimal tissue damage in wild-type mice were 
found to cause extensive tissue damage, more prolonged and higher levels of pro-
inflammatory cytokines, and death of male animals deficient in the A2AAR. Similar 
observations were made in studies of three different models of inflammation and liver 
damage as well as during bacterial endotoxin-induced septic shock.  Previous studies 
suggest that A2AAR plays a critical role in the physiological negative feedback 
mechanism for limiting and terminating both tissue-specific and systemic 
inflammatory responses.  Accumulation of extracellular adenosine in inflamed and 
damaged tissues (Rudolphi et al.; 1992) and the immunosuppressive properties of 
cAMP-elevating adenosine receptors (Cronstein; 1994; Huang et al.; 1997; Sullivan 
et al.; 2000) indicate that A2AAR signalling in immune cells is a possible natural 
mechanism of inhibition and/or termination of inflammation.  
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3.2  Results  
 
HUVECS are a commonly used endothelial cell  in studies of inflammation (Ahn et 
al.; 2003; Carman et al.; 2003), as they grow more easily in cell culture compared to 
other human endothelial cell type. It is widely accepted that a heterogeneity of 
endothelial function (Yang et al.; 1991) and phenotype exists depending on the 
vascular bed of origin (Page et al.; 1992). One of the major documented differences 
between endothelial cells, as far as inflammatory processes are concerned, relates to 
responses to cytokines. HUVEC respond to cytokines such as sIL-6Rα/IL-6 and IFNα 
by changinly their targe gene expression as well as allowing mononuclear cell 
transmigration.  However, a disadvantage of using primary endothelial cells is the 
difficulty with which new cDNAs can be introduced. This was important as any 
inhibitory effect of the A2AAR activation in transfected cells would be undetected if 
transfection efficiencies were poor. Generally standard transfection methods yield 
poor transfection efficiencies (2-10%) in endothelial cells (Teifel et al.; 1997). 
Therefore, in order to bypass this problem, a replication-deficient recombinant 
adenovirus encoding a myc-His-tagged human A2AAR, was used to obtain higher 
level of A2AAR infection.This facilitates highly efficient delivery of A2AAR to 
endothelial cells in vitro to examine the effects of an increase in receptor signalling 
upon cellular responses to class I cytokines. Several experiments have been designed 
to investigate the effect of overexpression of A2AAR in HUVECs to the same level as 
endogenous A2AAR level during the inflammation such as in hypoxia and its ligands 
on the function of IL-6, IFNα and Leptin in HUVECs. Specifically, experiments 
tested the effects of IL-6 and IFNα on the activity of downstream signal transduction 
proteins (JAK-STAT pathway).  Previous work undertaken in our lab has shown that 
A2AAR-mediated inhibition of nuclear factor кB (NFкB) activation is a critical aspect 
of its anti-inflammatory signalling properities and that the molecular basis of this 
inhibition is cell type-specific (Sands et al.; 2004). Thus, experiments initially tested 
the effect of simply overexpressing the A2AAR (Figure 3.1A) on cytokine stimulation 
of the JAK-STAT pathway in these cells. It was necessary to ensure adequate A2AAR 
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overexpression levels were achieved via adenoviral gene transfer before utilising this 
binding to examine the effect of the A2AAR on JAK-STAT pathway. Adenoviral gene 
transfer was necessary due to the passage-dependant loss of endogenous A2AAR 
expression observed in HUVECs. Confluent monolayers of HUVECs were infected 
with 25pfu/cell of either AdA2AAR or control virus AdGFP, which was required to 
achive consistent A2AAR-expression. Infected cells were identified under 
fluorescence by the presence of green fluorescent protein GFP). (Figure 3.1B) shows 
A2AAR gene transfer in HUVECs under phase and fluorescence light with the 
infected efficiency was determined to be ¬75%. GFP gene transfer was found to have 
an infection efficiency of ¬75% (Figure 3.1B). Moreover, immunoblot probe with 
anti-GFP antibody shows there is no different in GFP-expression between GFP-
overexpressing cells and A2AAR-overexpressing cells (Figure 3.1C). 
 
 In control GFP-overexpressing cells, treatment with a sIL-6Rα/IL-6 trans-signalling 
complex produced a transient increase in the phosphorylation of STAT1 on Tyr701 
and STAT3 on Tyr705. Overexpression of the A2AAR significantly reduced STAT 
phosphorylation at each time point after 15 min (Figure 3.2 and 3.3).   Interestingly, 
while total levels of STAT1 and STAT3 were unaltered by sIL-6Rα/IL-6 treatment of 
GFP-overexpressing cells, a marked decreased in the amount of total STAT1 and 
STAT3 in A2AAR-overexpressing HUVECs was detectable from as early as 30 min 
(Figure 3.2 and 3.3). To determine whether this effect was restricted to sIL-6Rα/IL-6, 
the effect of A2AAR overexpression on IFNα-mediated activation of the JAK-STAT 
pathway was also tested. In GFP-overexpressing cells, IFNα treatment produced a 
more transient increase in the Tyr-phosphorylation of STAT1 and STAT3 as sIL-
6Rα/IL-6. Nevertheless, A2AAR overexpression inhibited phosphorylation at each 
time point (Figure 3.4 and 3.5). In addition, levels of total STAT1 and STAT3 were 
markedly reduced as early as 15 min following IFNα exposure (Figure 3.4 and 3.5). 
More extensive characterisation of the effect of sIL-6Rα/IL-6 and IFNα on STAT 
levels over time revealed that for sIL-6Rα/IL-6, STAT1 and STAT3 were reduced to 
almost undetectable levels after 3hrs in A2AAR-overexpressing HUVECs (Figure 3.6 
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and 3.7) whereas, for IFNα,  STAT1 and STAT3 were reduced to almost undetectable 
levels after 2hrs (Figure 3.8 and 3.9). In contrast, cytokine exposure of GFP-
overexpressing HUVECs under the same conditions produced no detectable change 
in total levels of STAT1 or STAT3 in response to either cytokine, demonstrating that 
the down-regulation effect is specific for overexpression of the A2AAR (Figure 3.2-
3.9). Finally, the effect of the (A2AAR-selective agonist) CGS21680 and the (A2AAR 
antagonist) ZM241385 on cytokine stimulation of the JAK-STAT pathway in these 
cells was investigated. Thus, to assess the functional consequences of cAMP 
elevation on sIL-6Rα/IL-6. The effect of A2AAR overexpression on STAT1 and 
STAT3 phosphorylation and down regulation could be rescued by co-incubation of 
sIL-6Rα/IL-6 with the A2AAR-selective antagonist ZM241385 (3.10, 3.11). 
Conversely, co-incubation with the selective agonist CGS21680 did not further 
potentiate the effect of receptor expression to down regulate STAT in A2AAR-
overexpressing cells (Figure 3.10, 3.11).  
 
Importantly, the cytokine-stimulated decrease in STAT phosphorylation did not 
simply reflect reduced HUVECs viability following A2AAR overexpression. For that 
the  3-(4,5-dimethylthiazol-2yl)-2,5-diphenyl 2H-tetrazolium bromide (MTT assay) 
used to demonstrate that GFP- and A2AAR-overexpressing HUVECs had similar 
viabilities that were not affected by sIL-6Rα/IL-6 exposure at a 3 hr time point at 
which STAT degradation was detectable only in A2AAR-overexpressing cells (Figure 
3.12). 
 
The ubiquitin-proteasome pathway plays a central role in the targeted destruction of 
cellular proteins, including cell cycle regulatory proteins. Because these pathways are 
critical for the inflammation, proliferation and survival of all cells, proteasome 
inhibition is a potentially attractive therapeutic target in eukaryotic cells (Section 1.6). 
Regulated degradation is a commonly utilised mechanism by which cellular levels of 
transcription factors, such as p53 (Watson and Irwin; 2006), are controlled. To 
determine whether STATs are targeted for degradation by the proteasome, 
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experiments were performed to investigate the effect of proteasome inhibition on the 
ability of the A2AAR overexpression to prime STATs for cytokine-mediated down-
regulation. Pre-incubation with the proteasome inhibitor MG132 was sufficient to 
abolish the effect of the A2AAR overexpression on priming both STAT1 and STAT3 
for down-regulation in response to sIL-6Rα/IL-6 (Figure 3.13 and 3.14). In addition, 
Mg132 was sufficient to abolish the effect of the A2AAR overexpression on priming 
both STAT1 and STAT3 for down-regulation in respone to IFNα (Figure 3.15 and 
3.16). Blocking of proteasomal degradation with MG132 abolished A2AAR inhibition 
of both sIL-6Rα/IL-6 and IFNα-mediated phosphorylation of STAT1 and STAT3, 
suggesting that STAT degradation is the only mechanism responsible for this effect 
(Figure 3.17-3.20). 
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Figure 3.1  A2AAR gene transfer to HUVECs 
 
Panel A: HUVECs were infected with the indicated AVs at an MOI of 25 pfu /cell as 
indicated in the Materials and Methods prior to preparation of soluble cell extracts for 
SDS-PAGE and immunoblotting with anti-myc Ab 9E10 to identify recombinant 
A2AARs.  
 
Panel B: 48hrs post-infection, HUVECS were examined for GFP via fluorescent 
microscopy. 
 
Panel C: HUVECs were infected with the indicated AVs at an MOI of 25 pfu /cell as 
indicated in the Materials and Methods prior to preparation of soluble cell extracts for 
SDS-PAGE and immunoblotting with anti-GFP Ab to identify the GFP-expression 
between GFP-overexpressing cells and A2AAR-overexpressing cells. 
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Figure 3.2 Effect of A2AAR gene transfer on STAT1 phosphorylation and 
expression in response to sIL6Rα/IL-6 
1x105 HUVECs / well were seeded into 6 well plates. 24 hrs after seeding, cells were 
infected with the indicated AVs prior to treatment with or without 25ng/ml sIL-6 
Rα/5ng/ml IL-6 for the indicated times. Soluble cell extracts equalised for protein 
content were then fractionated by SDS-PAGE for immunoblotting with the indicated 
antibodies. Quantitative analysis of phospho-STAT1 and total STAT1 levels from 
three experiments is presented (***p<0.001 and *P<0.05 versus the response 
observed in AV.GFP-infected cells). Basal set at 100. 
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Figure 3.3 Effect of A2AAR gene transfer on STAT3 phosphorylation and 
expression in response to sIL6Rα/IL-6 
1x105 HUVECs / well were seeded into 6 well plates. 24 hrs after seeding, cells were 
infected with the indicated AVs prior to treatment with or without 25ng/ml sIL-6 
Rα/5ng/ml IL-6 for the indicated times. Soluble cell extracts equalised for protein 
content were then fractionated by SDS-PAGE for immunoblotting with the indicated 
antibodies. Quantitative analysis of phospho-STAT3 and total STAT3 levels from 
three experiments is presented (***p<0.001 and *P<0.05 versus the response 
observed in AV.GFP-infected cells). Basal set at 100. 
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Figure 3.4 Effect of A2AAR gene transfer on STAT1 phosphorylation and 
expression in response to IFNα 
1x105 HUVECs / well were seeded into 6 well plates. 24 hrs after seeding, cells were 
infected with the indicated AVs prior to treatment with or without 500 unit/ml IFNα 
for the indicated times. Soluble cell extracts equalised for protein content were then 
fractionated by SDS-PAGE for immunoblotting with the indicated antibodies. 
Quantitative analysis of phospho-STAT1 and total STAT1 levels from three 
experiments is presented (***p<0.001 and *p<0.05 versus the response observed in 
AV.GFP-infected cells). Basal set at 100. 
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Figure 3.5 Effect of A2AAR gene transfer on STAT3 phosphorylation and 
expression in response to IFNα 
1x105 HUVECs / well were seeded into 6 well plates. 24 hrs after seeding, cells were 
infected with the indicated AVs prior to treatment with or without 500 unit/ml IFNα 
for the indicated times. Soluble cell extracts equalised for protein content were then 
fractionated by SDS-PAGE for immunoblotting with the indicated antibodies. 
Quantitative analysis of phospho-STAT3 and total STAT3 levels from three 
experiments is presented (***p<0.001 and *p<0.05 versus the response observed in 
AV.GFP-infected cells). Basal set at 100. 
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Figure 3.6 Effect of A2AAR gene transfer on STAT1 expression in response to 
prolonged exposures to IL-6Rα/IL-6 
1x105 HUVECs / well were seeded into 6 well plates. 24 hrs after seeding, cells were 
infected with the indicated AVs prior to treatment with or without 25ng/ml sIL-6 
Rα/5ng/ml IL-6 for the indicated times. Soluble cell extracts equalised for protein 
content were then fractionated by SDS-PAGE for immunoblotting with the indicated 
antibodies. Quantitative analysis of total STAT1 levels from three experiments with 
each cytokine is presented (***p<0.001 versus the levels in AV.GFP-infected cells at 
the given time point). Basal set at 100. 
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Figure 3.7 Effect of A2AAR gene transfer on STAT3 expression in response to 
prolonged exposure to sIL-6Rα/IL-6 
1x105 HUVECs / well were seeded into 6 well plates. 24 hrs after seeding, cells were 
infected with the indicated AVs prior to treatment with or without 25ng/ml sIL-6 
Rα/5ng/ml IL-6 for the indicated times. Soluble cell extracts equalised for protein 
content were then fractionated by SDS-PAGE for immunoblotting with the indicated 
antibodies. Quantitative analysis of total STAT3 levels from three experiments with 
each cytokine is presented (***p<0.001 versus the levels in AV.GFP-infected cells at 
the given time point). Basal set at 100. 
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Figure 3.8   Effect of A2AAR gene transfer on STAT1 expression in response to 
prolonged exposure to IFNα 
1x105 HUVECs / well were seeded into 6 well plates. 24 hrs after seeding, cells were 
infected with the indicated AVs prior to treatment with or without 500 unit/ml IFNα 
for the indicated times. Soluble cell extracts equalised for protein content were then 
fractionated by SDS-PAGE for immunoblotting with the indicated antibodies. 
Quantitative analysis of total STAT1 levels from three experiments with each 
cytokine is presented (***p<0.001 versus the levels in AV.GFP-infected cells at the 
given time point). Basal set at 100. 
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Figure 3.9  Effect of A2AAR gene transfer on STAT3 expression in response to 
prolonged exposure to IFNα 
1x105 HUVECs / well were seeded into 6 well plates. 24 hrs after seeding, cells were 
infected with the indicated AVs prior to treatment with or without 500 unit/ml IFNα 
for the indicated times. Soluble cell extracts equalised for protein content were then 
fractionated by SDS-PAGE for immunoblotting with the indicated antibodies. 
Quantitative analysis of total STAT3 levels from three experiments with each 
cytokine is presented (***p<0.001 versus the levels in AV.GFP-infected cells at the 
given time point). Basal set at 100. 
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Figure 3.10 Effect of A2AAR on STAT1 phosphorylation and expression in 
response to sIL-6 Rα/ IL-6 
1x105 HUVECs / well were seeded into 6 well plates. 24 hrs after seeding cells were 
infected with the indicated AVs prior to pre-treatment with or without 6µM 
CGS21680 or 1µM ZM241485 for 1hr and treatment with 25ng/ml sIL-6 Rα/5ng/ml 
IL-6 for 1hr as indicated. The final concentration of vehicle (DMSO) in all wells was 
0.1% (V/V). Soluble cell extracts equalised for protein content were then fractionated 
by SDS-PAGE for immunoblotting with the indicated antibodies. Quantitative 
analysis of phospho-STAT1 and total STAT1 levels from four experiments is 
presented (***p<0.001 and **p<0.01 versus the levels in untreated AV.mycA2AAR-
infected cells). Basal set at 100. 
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Figure 3.11 Effect of A2AAR on STAT3 phosphorylation and expression in 
response to sIL-6 Rα/ IL-6 
1x105 HUVECs / well were seeded into 6 well plates. 24 hrs after seeding cells were 
infected with the indicated AVs prior to pre-treatment with or without 6µM 
CGS21680 or 1µM ZM241485 for 1hr and treatment with 25ng/ml sIL-6 Rα/5ng/ml 
IL-6 for 1hr as indicated. The final concentration of vehicle (DMSO) in all wells was 
0.1% (V/V). Soluble cell extracts equalised for protein content were then fractionated 
by SDS-PAGE for immunoblotting with the indicated antibodies. Quantitative 
analysis of phospho-STAT3 and total STAT3 levels from four experiments is 
presented (**p<0.01 versus the levels in untreated AV.mycA2AAR-infected cells). 
Basal set at 100. 
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Figure 3.12 Effect of A2AAR expression and sIL-6Rα/IL-6 expression on 
HUVECs viability 
HUVECs were infected with the indicated AVs prior to treatment with or without 
25ng/ml sIL-6 Rα/5ng/ml IL-6 for 3 hrs or 0.1% (w/v) sodium azide for 16 hrs. Cell 
viability was then determined by measurement of MTT reduction. This is one of three 
experiments that produced similar data. 
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Figure 3.13  Effect of MG132 on sIL-6Rα/IL-6-induced STAT1 downregulation 
in A2AAR-expressing HUVECs 
1x105 HUVECs / well were seeded into 6 well plates. 24 hrs after seeding, cells were 
infected with the indicated AVs prior to pre-treatment with or without 6µM MG132 
for 30 min and treatment with 25ng/ml sIL-6 Rα/5ng/ml IL-6 up to 3hrs as indicated. 
The final concentration of vehicle (DMSO) in all wells was 0.1% (V/V). Soluble cell 
extracts equalised for protein content were then fractionated by SDS-PAGE for 
immunoblotting with the indicated antibodies. Quantitative analysis of total STAT1 
levels in A2AAR-expressing cells from three experiments is presented (***p<0.001 
versus STAT1 levels in vehicle-pretreated cells at the given time point). Basal set at 
100. 
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Figure 3.14  Effect of MG132 on sIL-6Rα/IL-6-induced STAT3 downregulation 
in A2AAR-expressing HUVECs 
1x105 HUVECs / well were seeded into 6 well plates. 24 hrs after seeding, cells were 
infected with the indicated AVs prior to pre-treatment with or without 6µM MG132 
for 30 min and treatment with 25ng/ml sIL-6 Rα/5ng/ml IL-6 up to 3 hrs as indicated. 
The final concentration of vehicle (DMSO) in all wells was 0.1% (V/V).  Soluble cell 
extracts equalised for protein content were then fractionated by SDS-PAGE for 
immunoblotting with the indicated antibodies. Quantitative analysis of total STAT3 
levels in A2AAR-expressing cells from three experiments is presented (***p<0.001 
versus STAT3 levels in vehicle-pretreated cells at the given time point). Basal set at 
100. 
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Figure 3.15  Effect of MG132 on IFNα-induced STAT1 downregulation in 
A2AAR-expressing HUVECs 
1x105 HUVECs / well were seeded into 6 well plates. 24 hrs after seeding, cells were 
infected with the indicated AVs prior to pre-treatment with or without 6µM MG132 
for 30 min and treatment with 500 unit/ml IFNα up to 3 hrs as indicated. The final 
concentration of vehicle (DMSO) in all wells was 0.1% (V/V).  Soluble cell extracts 
equalised for protein content were then fractionated by SDS-PAGE for 
immunoblotting with the indicated antibodies. Quantitative analysis of total STAT1 
levels in A2AAR-expressing cells from three experiments is presented (***p<0.001 
versus STAT1 levels in vehicle-pretreated cells at the given time point). Basal set at 
100. 
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Figure 3.16  Effect of MG132 on IFNα-induced STAT3 downregulation in 
A2AAR-expressing HUVECs 
1x105 HUVECs / well were seeded into 6 well plates. 24 hrs after seeding, cells were 
infected with the indicated AVs prior to pre-treatment with or without 6µM MG132 
for 30 min and treatment with 500 unit/ml IFNα up to 3 hrs as indicated. The final 
concentration of vehicle (DMSO) in all wells was 0.1% (V/V).  Soluble cell extracts 
equalised for protein content were then fractionated by SDS-PAGE for 
immunoblotting with the indicated antibodies. Quantitative analysis of total STAT3 
levels in A2AAR-expressing cells from three experiments is presented (***p<0.001 
versus STAT3 levels in vehicle-pretreated cells at the given time point). Basal set at 
100. 
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Figure 3.17 Blocking degradation abolishes the inhibitory effect of the A2AAR on 
STAT1 phosphorylation in response to sIL-6 Rα/IL-6 
1x105 HUVECs / well were seeded into 6 well plates. 24 hrs after seeding, cells were 
infected with the indicated AVs prior to pre-treatment with or without 6µM MG132 
for 30 min and treatment with 25ng/ml sIL-6 Rα/5ng/ml IL-6 up to 3 hrs as indicated. 
The final concentration of vehicle (DMSO) in all wells was 0.1% (V/V).  Soluble cell 
extracts equalised for protein content were then fractionated by SDS-PAGE for 
immunoblotting with the indicated antibodies. Quantitative analysis of phospho-
STAT1 levels from three experiments is presented. Basal set at 100. 
 
 
 
 
 
 
 
 
 
 
 
 
+6µM MG132                                     
30 min pre-incubation 
Mr 
AV.GFP AV.mycA2AAR 
STAT1 
Phospho-STAT1 97 
97 
   Incubation time (hr)                                    
+sIL-6Rα/IL-6 
  0      1      2       3      0    1    2     3 
0.0 0.5 1.0 1.5 2.0 2.5 3.0
0
100
200
300
400
500
AV.GFP
AV.mycA2AAR
sIL-6Rα /IL-6 Exposure Time (hr)
T
y
r7
0
1
 S
T
A
T
1
 p
h
o
s
p
h
o
ry
la
ti
o
n
 (
F
o
ld
s
ti
m
u
la
ti
o
n
 o
v
e
r 
b
a
s
a
l)
 95 
Figure 3.18 Blocking degradation abolishes the inhibitory effect of the A2AAR on 
STAT3 phosphorylation in response to sIL-6 Rα/IL-6 
1x105 HUVECs / well were seeded into 6 well plates. 24 hrs after seeding, cells were 
infected with the indicated AVs prior to pre-treatment with or without 6µM MG132 
for 30 min and treatment with 25ng/ml sIL-6 Rα/5ng/ml IL-6 up to 3 hrs as indicated. 
The final concentration of vehicle (DMSO) in all wells was 0.1% (V/V).  Soluble cell 
extracts equalised for protein content were then fractionated by SDS-PAGE for 
immunoblotting with the indicated antibodies. Quantitative analysis of phospho-
STAT3 levels from three experiments is presented. Basal set at 100. 
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Figure 3.19 Blocking degradation abolishes the inhibitory effect of the A2AAR on 
STAT1 phosphorylation in response to IFNα 
1x105 HUVECs / well were seeded into 6 well plates. 24 hrs after seeding, cells were 
infected with the indicated AVs prior to pre-treatment with or without 6µM MG132 
for 30 min and treatment with 500 unit/ml IFNα up to 3 hrs as indicated. The final 
concentration of vehicle (DMSO) in all wells was 0.1% (V/V).  Soluble cell extracts 
equalised for protein content were then fractionated by SDS-PAGE for 
immunoblotting with the indicated antibodies. Quantitative analysis of phospho-
STAT1 levels from three experiments is presented. Basal set at 100. 
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Figure 3.20 Blocking degradation abolishes the inhibitory effect of the A2AAR on 
STAT3 phosphorylation in response to IFNα 
1x105 HUVECs / well were seeded into 6 well plates. 24 hrs after seeding, cells were 
infected with the indicated AVs prior to pre-treatment with or without 6µM MG132 
for 30 min and treatment with 500 unit/ml IFNα up to 3 hrs as indicated. The final 
concentration of vehicle (DMSO) in all wells was 0.1% (V/V).  Soluble cell extracts 
equalised for protein content were then fractionated by SDS-PAGE for 
immunoblotting with the indicated antibodies. Quantitative analysis of phospho-
STAT3 levels from three experiments is presented. Basal set at 100. 
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3.3   Discussion  
 
Numerous pharmacological studies have identified the A2AAR as a protective anti-
inflammatory G-protein-coupled receptor (Lappas et al.; 2005). Gene dosage studies 
have provided evidence to show that, at least in T-lymphocytes, there is no A2AAR 
reserve (Armstrong et al.; 2001).  Consequently, pathophysiological conditions that 
alter A2AAR expression, such as the onset of hypoxia (Kobayashi and Millhorn; 
1999) and EC exposure to Th1 cytokines (Nguyen et al.; 2003), are likely to alter 
cellular responsiveness to inflammatory stimuli. However, despite unequivocal 
evidence of its potent anti-inflammatory properties across different cell types, only 
the ability of the receptor to suppress NF-қB activation has been offered as an 
explanation for its effects to date (Majumdar and Aggarwal; 2003; Sands et al.; 
2004).   
 
This study has extended these observations by demonstrating that the A2AAR 
overexperession can prime cytokine-activated STATs for degradation by the 
proteasome.  Similar to the effect observed on suppression of  NF-қB in two separate 
cell systems (Sands et al.; 2004), overexpression of the A2AAR in the absence of any 
added agonist was sufficient to prime STATs for degradation (Figure 3.2-3.9). Thus, 
the receptor may be sufficiently active in the absence of agonist to trigger its 
associated signalling pathways. This phenomenon has been observed for both 
endogenous receptors and overexpression studies of GPCRs (Bond and Ijzerman; 
2006; Vischer et al.; 2006). Reversal of the effect of receptor over-expression on 
STAT down-regulation by the A2AAR-selective antagonist ZM241385 (Figure 3.10 
and 3.11) is consistent with this hypothesis. Therefore, “constitutive” activation of the 
A2AAR, whether due to high agonist-independent activity or elevation in locally 
generated adenosine levels, may represent an especially important aspect of its 
function. Moreover, the effect is not restricted to overexpressed A2AARs, since 
exposure of low levels of endogenous A2AAR in HUVECs with ZM241385 also 
potentiates sIL-6Rα/IL-6-stimulated phosphorylation of STAT3 (W.Sands 
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unpublished data).  Endothelial cells are an abundant source of adenosine in vitro, 
partly due to expression of CD39 which converts adenosine triphosphate/adenosine 
diphosphate (ATP/ADP) to adenosine monophosphate (AMP) and CD73 which 
converts AMP to adenosine (Eltzschig et al.; 2004; Zernecke et al.; 2006). Both 
CD39 and CD73 are each strongly induced upon the onset of hypoxia, and CD73 
expression can also be potentiated by IFN-α and adenosine itself via receptor-
mediated elevation of cAMP (Narravula et al.; 2000; Niemela et al.; 2004). Thus, 
control of adenosine accumulation and initiation of protective signalling clearly 
represents an important adaptive mechanism by which hypoxia-mediated damage to 
the endothelium is minimised. The resulting accumulation of adenosine in large blood 
vessels is thought to play an important protective role in vivo by limiting endothelial 
cell activation and subsequent monocyte attachment (Zernecke et al.; 2006).  
 
To begin identifying potential mechanisms by which A2AAR overexpression could 
impact on cytokine signalling, we have been examining the effects of A2AAR on sIL-
6Rα/IL-6 and IFNα signalling in vascular ECs and assessing its functional 
significance. A2AAR overexpression led to the more rapid degradation of STAT1 and 
STAT3 upon sIL-6Rα/IL-6 and IFNα stimulation. To determine whether STATs are 
targeted for degradation by the proteasome, experiments were performed to 
investigate the effect of proteasome inhibitor MG132 on the ability of A2AAR 
overexpression to prime STATs for cytokine-mediated down-regulation. Figure 3.13-
3.16 show that MG132 was sufficient to abolish the effect of A2AAR overexpression 
on priming STATs for down-regulation in response to cytokines. Moreover, results in 
this Chapter show that blocking of proteasomal degradation with MG132 abolished 
A2AAR inhibition of both sIL-6Rα/IL-6 and IFNα-stimulated phosphorylation of 
STATs. Cross-talk between cAMP-mediated signalling pathways and STAT 
activation has been previously reported by Sengupta et al. (1996), and suggests that 
A2AAR-mediated inhibition of STAT is cAMP-dependent. In addition, studies by 
Ivashkiv et al. (1996) have shown that in T cell activation, cAMP can inhibit 
accumulation of  STAT1 protein. The A2AAR is highly expressed within most cells of 
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the immune system, platelets, heart, lung and endothelium (Fredholm et al.; 2001) . 
Classically, the A2AAR signals via the Gs family of G proteins leading to an activation 
of adenylyl cyclase and the generation of cAMP. It is thought to mediate the vast 
majority of its intracellular effects by binding and activating cAMP-dependent 
protein kinase (PKA), which controls the phosphorylation status and activity of 
multiple intracellular substrates (Tasken and Aandahl; 2004). However, another 
family of intracellular cAMP sensors termed Epacs have also been identified (de 
Rooij et al.; 1998). Epac1 and -2 function as cAMP-activated guanine nucleotide 
exchange factors specific for the Rap family of small G proteins and, thus promote 
the accumulation of active GTP-bound Rap1 and -2 (Rooij et al.; 1998; Bos; 2003). 
Interestingly, a role for Epac in EC function was recently revealed by the finding that 
the Epac-mediated activation of Rap1 and the subsequent formation of adherens 
junctions contribute toward the ability of cAMP to enhance endothelial barrier 
function, an important aspect of its anti-inflammatory effects in vascular ECs (Cullere 
et al.; 2005; Fukuhara et al.; 2005). Previous work undertaken in our lab has shown 
that inhibition of STAT phosphorylation and induction of SOCS3 can occur via a 
cAMP/Epac/Rap1 pathway to limit IL-6 receptor signalling (Sands et al.; 2006). In 
addition, new evidence indicates that increased cAMP levels inhibit angiotensin II-
mediated JAK/STAT3 activation by a variety of mechanisms. Interestingly, cAMP-
elevating agents were  shown to inhibit IL-6-induced STAT activation in monocytes 
(Sengupta et al.; 1996). Together, these data establish a link for crosstalk between 
cAMP and JAK/STAT3, although at present, it is not known how cAMP inhibits 
STAT activation. In addition, in this study we showed that inhibition of proteasome 
function was sufficient to block the effect of A2AAR overexpression on STAT 
degradation. This demonstrates that priming of STAT1 and STAT3 for degradation is 
the only mechanism responsible for the down regulation of STATs upon cytokine 
stimulation in our model. 
 
 
 101 
In summary, many different mechanisms have been implicated in downregulating 
STAT1 and STAT3 signalling. However, for many of these the molecular 
mechanisms have not been well characterised. Several cytoplasmic tyrosine 
phosphatases, including tyrosine phosphatases containing a SH2 domain (SHP-1), 
CD45, and protein tyrosine phosphatase 1B, are implicated in the dephosphorylation 
of STAT1 and STAT3. In addition, SOCS are potentially key negative regulatory 
modulators of STAT1 and STAT3 signalling as they bind to Tyr phosphorylated 
cytokine receptors and JAK catalytic sites. Moreover, the protein PIAS3 was found to 
be specific for the inhibition of activated STAT3 (Chung et al.; 1997a). Scaffolding 
proteins such as the STAT3-interacting protein (StIP1), a novel protein consisting of 
12 WD40 repeats, can also inhibit STAT3 signalling by modulating the formation of 
multiprotein complexes that are central in the regulation of signal transduction, 
transcription, and targeted proteolysis. (Collum et al.; 2000) demonstrated that StIP1 
had a high affinity for unphosphorylated JAK and STAT3, and when overexpressed 
blocks STAT3 activation and dimerisation/DNA binding, nuclear translocation, and 
reporter gene transcription following stimulation with IL-6.  
 
Data in this Chapter reveals several important aspects of A2AAR overexpression on 
cytokine and JAK-STAT signalling pathway. These include: 
 
(1) Potentiation of A2AAR function by increasing its overexpression reduces cytokine 
receptor activation of the JAK-STAT pathway by priming Tyr-phosphorylated 
STATs for proteasomal degradation. 
 
 (2) Over-expression of the A2AAR in HUVECs suppresses the ability of IFNα and a 
sIL-6Rα/IL-6 trans-signalling complex to promote Tyr-phosphorylation of STATs 1 
and 3 by targeting cytokine-activated STATs for proteasomal degradation.  
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(3) Pre-incubation with the proteasome inhibitor MG132 was sufficient to abolish the 
effect of A2AAR overexpression on priming both STAT1 and STAT3 for down-
regulation in response to sIL-6Rα/IL-6 and IFNα. 
 
(4) The results show that inhibition of proteasome function was sufficient to block the 
inhibitory effect of the A2AAR overexpression on STAT3 phosphorylation, 
demonstrating that priming of STATs for degradation is the only mechanism 
responsible for the reduced cytokine-stimulated STAT phosphorylation observed in 
A2AAR-overexpressing cells. 
 
(5) The effect of A2AAR overexpression on STAT1 and STAT3 phosphorylation and 
down regulation could be rescued by co-incubation of sIL-6Rα/IL-6 with the A2AAR-
selective antagonist ZM241385. Conversely, co-incubation with the selective agonist 
CGS21680 did not further potentiate the effect of receptor expression to down 
regulate STAT in A2AAR-overexpressing cells.  
 
(6) GFP- and A2AAR-overexpressing HUVECs had similar viabilities that were not 
affected by sIL-6Rα/IL-6 exposure at a 3 hr time point at which STAT degradation 
was detectable only in A2AAR-overexpressing cells. 
 
The results in this chapter have demonstrated that adenovirus-mediated human 
A2AAR gene transfer to vascular ECs in vitro was sufficient to prime Tyr-
phosphorylated STATs for proteasomal degradation upon stimulation of sIL-6Rα/IL-
6 and IFNα. Both this study and others describing agonist-independent signalling 
from the A2AAR have been cell systems in which the recombinant receptor is 
overexpressed (Chen et al.; 2004). Therefore, the physiological significance in vivo of 
any basal activity of endogenous A2AAR expressed at low level is unclear. Gene 
dosage studies have provided evidence to show that, at least in T-lymphocytes, there 
is no A2AAR reserve (Armstrong et al.; 2001).  Consequently, pathophysiological 
conditions that alter A2AAR expression, such as the onset of hypoxia (Kobayashi and 
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Millhorn; 1999) and EC exposure to Th1 cytokines (Nguyen et al.; 2003), are likely 
to alter cellular responsiveness to inflammatory stimuli. The availability of A2AAR- 
deficient mice can now allow assessment of the presence and importance of A2AAR 
expression and function as a potent anti-inflammatory mechanism in vivo. The effect 
of A2AAR overexpression on STAT1 and STAT3 in this study was limited to 
HUVECs in vitro. Differences between endothelial types are well documented such 
as different vascular beds displaying distinct biochemical and immunological 
properties (Sands and Palmer; 2005). Arterial ECs for example are more sensitive to 
eicosanoids and less competent than venous and post capilliary ECs in their ability to 
upregulate adhesion molecule expression such as E-selectin and VCAM-1 (Amberger 
et al.; 1997). 
 
The effect of mechanotrasduction has also not been investgated in this study. 
Normally ECs are exposed to various degrees of pulsatile and shear stresses that vary 
in magnitude in a manner determined by position along the vascular tree and local 
vascular tone. Such forces are well known to affect EC gene expression (Li et al.; 
2005). So, the response in vivo may be different to those of culture system. Viral 
proteins could also change the endothelial function. Although experiments do use 
control virus it cannot rule out the possibility that viral protein somehow contribute to 
the observed effect of A2AAR overexpression. However uninfected cells of very low 
passage (which still contain endogenous low levels of A2AAR) still show inhibition of 
IL-6-mediated STAT phosphorylation when treated with an A2AAR-selective agonist 
CGS21680 (W.Sands unpublished data). 
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Chapter 4 
 
Mechanisms Controlling the Effects of A2AAR Expression on 
Cytokine-Stimulated Degradation of STATs 
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4.1   Introduction 
 
Physiological responses to cytokine stimulation must be regulated appropriately in 
order to prevent over active and damaging inflammatory processes. Several different 
mechanisms by which cytokine signalling is attenuated have been identified. The 
details, however, in determining the functions of specific inhibitors of cytokine 
signalling within particular cytokine signal transduction pathways have often been 
difficult to elucidate. SOCS knockout mice have pointed to the crucial functions of 
specific SOCS proteins in attenuating signalling by specific cytokines (Section 1.6). 
However, for the vast number of cytokines, the picture is complicated and in many 
cases multiple functionally redundant inhibitors are probably responsible for 
attenuating signal transduction. Identifying the roles of negative regulators of 
cytokine signalling in the plethora of signalling networks that are activated in 
response to cytokine is an interesting challenge.  
 
The potent anti-inflammatory effect of the A2AARs have been demonstrated in a 
variety of different cell types (Section 1.5.1.1). One possible reason for this is that 
A2AAR activation can activate common mechanisms that lead to the suppression of 
inflammation. The results in Chapters 3 and 4 suggest that the A2AAR overexpression 
primes cytokine-activated STATs for degradation by the proteasome. The cytokine 
dependence of STAT degradation in A2AAR-overexpressing cells raised the 
possibility that JAK-mediated STAT phosphorylation may responsible for this 
phenomenon. In addition, STATs may be ubiquitylated in A2AAR-overexpressing 
HUVECs following cytokine exposure. Among the key proteins degraded by the Ub-
proteasome system are those involved in the control of inflammation, cell cycle 
regulation and gene expression (Popat et al.; 2006). E3 Ub ligases play a key role in 
governing the cascade of Ub transfer reactions by recognising and catalysing Ub 
conjugation to specific protein substrates (Section 1.7). The E3s, which can be 
generally classified into HECT-type and RING-type families, are involved in the 
regulation of many aspects of the immune system, including the development, 
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activation, and differentiation of lymphocytes, induction of T cell-tolerance antigen 
presentation, immune evasion, and virus budding (Mueller; 2004). In addition to 
proteasome-mediated degradation, E3-promoted ubiquitination affects a wide array of 
biological processes, such as receptor down-regulation, signal transduction, protein 
processing or translocation, protein-protein interaction and gene transcription 
(Passmore and Barford; 2004). Deficiency or mutation of some of  E3s, such as Cbl, 
Cbl-b or Itch, cause abnormal immune responses which can result in autoimmunity, 
malignancy, and inflammation (Bachmaier et al.; 2000; Wohlfert et al.; 2006). 
 
Interestingly, IFN-γ is a key pleiotropic regulatory cytokine (Goldberg et al.; 2002). It 
controls an inducible proteolytic cascade, which consists of PA28 and other inducible 
proteasome subunits, and the activity of aminopeptidases, which lead to increase 
peptide production for MHC I presentation. In addition, IFN-γ also decreases peptide 
destruction by down-regulating the expression of a metalloproteinase, thimet 
oligopeptidase, that actively destroys many antigenic peptides (York et al.; 1999; 
Saveanu et al.; 2005). The UPS plays a significant role in the regulation of both T cell 
receptor (TCR) and co-stimulatory CD28 signalling through the action of ubiquitin 
ligases of the Cbl family (Zhang et al.; 2002a). CD28 co-stimulation results in the 
ubiquitination and degradation of Cbl-β, which eliminates the negative regulators and 
allows the expression of pro-inflammatory cytokines and their receptors. However, 
the most important link between the UPS and inflammation is related to NF-κB. NF-
κB is a master regulator of many inflammatory cytokine genes, and its activation is 
mediated through the UPS. NF-κB is actively inhibited when bound to IκBα. NF-κB 
activation follows the degradation of IκBα, which is dependent on Lys 48-linked 
polyubiquination of IκBα followed by proteasomal degradation. In addition, the 
proteasome has been shown to regulate inflammatory responses by controlling the 
function of macrophages (Qureshi et al.; 2005). It has also been reported that the de-
ubiquitinating enzyme CYLD posatively regulates proximal T cell receptor signalling 
in thymocytes by selectively binding to and deubiquitinating the active form of the 
kinase Lck. Due to defects in T cell development, CYLD-deficient mice had 
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substantially fewer mature CD4+ and CD8+ single-posative thymocytes and 
peripheral T cells (Reiley et al.; 2006). Hence, alterations in the UPS have profound 
effects on immune responses including the regulation of an array of inflammatory 
cytokines. 
 
 Results in Chapter 3 show that the A2AAR overexpression primes cytokine-activated 
STATs for degradation by the proteasome. In addition, pre-incubation with 
proteasome inhibitor MG132 was sufficient to abolish the effect of the A2AAR 
overexpression on priming STAT3 and STAT1 for down-regulation in response to 
cytokines. Because of that, we have investigated the responsibility of JAK for the 
tyrosine phosphorylation of STAT upon cytokine stimulation. In addition, we have 
tested the hypothesis that STAT is ubiquitylated in A2AAR-overexpressing cells 
following cytokine stimulation before degradation by the proteasomal system.  
 
4.2  Results 
 
Phosphorylation is a commonly utilised signal that regulate substrate recognition by 
E3 ubiquitin ligases. For example, IκB kinase (IKK)-stimulated phosphorylation of 
IκBα on Ser32 and 33 is required for its recognition by the F-box component of the 
βTrCP/SCF1 E3 ligase complex (Liu et al.; 2005; Nalepa et al.; 2006). The cytokine 
dependence of STAT degradation in A2AAR-overexpressing cells raised the 
possibility that JAK-mediated STAT phosphorylation was a trigger of this event. 
Thus, several experimental approaches were used to test this hypothesis in more 
detail.  Firstly, the effect of inhibiting JAK activity on STAT degradation in A2AAR-
overexpressing cells was examined. This demonstrated that 0.1 µM of JAK inhibitor 
1 (A potent cell-permeabile and ATP-competitive inhibitor of JAKs. Display spotent 
inhibitory activity against JAK1, JAK2, JAK3 and Tyk2) (Pedranzini et al.; 2006) 
was sufficient to inhibit JAK1 and JAK2 tyr-phosphorylation (Figure 4.1A) and 
STAT1 Tyr-phosphorylation (Figure 4.1B) upon sIL-6Rα/IL-6 stimulation. The same 
concentration of JAK inhibitor was sufficient to abolish the down-regulation of 
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STAT1 and STAT3 upon sIL-6Rα/IL-6 and IFNα stimulation in A2AAR-
overexpressing cells (Figure 4.2-4.5). Secondly, experiments utilised the presence in 
HUVECs of endogenous Ob-Rb leptin receptors. Leptin-bound Ob-Rb selectively 
stimulates JAK-mediated phosphorylation of STAT3 but not STAT1 (Zabeau et al.; 
2003).  Consistent with this observation, exposure of HUVECs to leptin specifically 
promoted the Tyr phosphorylation of STAT3 but not the Tyr phosphorylation of 
STAT1 whereas sIL-6Rα/IL-6, which was used as a positive control, promoted the 
Tyr phosphorylation of both STAT1 and STAT3  (Figure 4.6). In GFP-
overexpressing cells, treatment with leptin produced phosphorylation of STAT3 on 
Tyr705. Overexpression of the A2AAR significantly reduced STAT3 phosphorylation 
at each time point after 15 min (Figure 4.7). Leptin treatment also induced a time-
dependent down-regulation of STAT3 but not STAT1 in A2AAR-overexpressing cells 
after 1hr (Figure 4.8). Cytokine binding to its receptor leads to activation of the 
receptor-associated tyrosine kinase JAKs. JAKs trans-phosphorylate the intracellular 
domain of the receptor, and these phospho-Tyr residues provide docking sites for 
latent cytoplasmic STATs. STATs are recruited to the receptor via their SH2 domain, 
and JAKs phosphorylate STATs on a specific Tyr residue on their cytoplasmic tail. 
Homo- or heterodimerisation of STATs are achieved via reciprocal binding of this 
critical phospho-Tyr of one monomer and SH2 domain of the binding partner (Haan 
et al.; 1999). Following on from our results which show that the A2AAR-
overexpression can prime Tyr-phosphorylated STATs for degradation by the 
proteasome required JAK activity. There are two possible explanations for this 
requirement based on how JAK function. The first one is JAK Tyr-phosphorylated 
STAT.  The second possibility is JAK Tyr-phosphrylation of the receptor. To 
discriminate between the two possibilities HUVECs were co-infected with AVs 
encoding the  A2AAR and either Flag epitope-tagged WT or Tyr705→Phe mutated 
STAT3, since mutation of Tyr705 renders STAT3 resistant to phosphorylation by 
JAKs (Kaptein et al.; 1996). Under conditions in which WT STAT3 underwent 
down-regulation in response to IFNα exposure similar to the effect observed for 
endogenous STATs, the levels of Tyr705→Phe mutated STAT3 were not altered 
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(Figure 4.9). Thus, JAK-mediated phosphorylation of STATs appears to be essential 
for promoting their cytokine-mediated degradation in A2AAR-overexpressing 
HUVECs. Recently, SLIM/Mystique, a ubiquitin E3 ligase for Tyr-phosphorylated 
STATs was identified that promoted the polyubiquitination and degradation of 
phosphorylated STAT1 and STAT4 (Tanaka et al.; 2005). RT-PCR techniques were 
used to test for the presence of SLIM/Mystique mRNA in A2AAR-overexpressing 
HUVECs (Figure 4.10). GAPDH was used as a control for the reverse transcription 
reaction and pcDNAA3/HA-SLIM/Mystique was included as a positive control for 
the SLIM/Mystique PCR reaction. The results showed that SLIM/Mystique was 
undetectable in our system, despite being able to detect the positive control. To 
confirm this lack of SLIM/Mystique mRNA in HUVEC was manifest at the protein 
level, I looked for the presence of SLIM/Mystique protein in HUVECs by western 
blot analysis. HUVECs treated as indicated in the figure legend were solubilised and 
analysed for expression of SLIM/Mystique protein by immunoblotting with anti-
SLIM/Mystique antibody (Figure 4.11). Lysates from HEK293 cells transfected with 
either empty vector or a SLIM/Mystique expression construct were used as negative 
and positive controls respectively for the antibody reactivity (Figure 4.11). Together, 
these results suggest SLIM/Mystique is not expressed at detectable level under 
conditions in which STAT degradation occurs (Figure 4.11). 
 
Cytokine activation of STATs is also negatively regulated by SOCS proteins, which 
can function as E3 ligases. In addition cAMP can induce SOCS3 via activation of 
Epac/Rap1 (Sands et al.; 2006). Thus, A2AAR-overexpression may potentialy up-
regulate SOCS3 expression upon cAMP activation leading to accelerated STAT 
degradation. To further identify the role of A2AAR-overexpression in priming 
cytokine-activated STATs for degradation by the proteasome, the levels of SOCS3 
protein was determined by immunoblotting and probing with an anti-SOCS3 
antibody. The results showed that there is a siginficant difference in SOCS3 
expression between GFP and A2AAR-overexpressing cells upon cytokine stimulation 
at 2 and 3 hrs (Figure 4.12). However, this does not rule out the physiological 
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function of SOCS3 or other SOCS family members in the down-regulation of STAT1 
and STAT3. Proteins targeted for proteasomal degradation are typically tagged on 
one or more Lys residues with Lys48-conjugated polyubiquitin chains (Liu et al.; 
2005; Nalepa et al.; 2006).  These chains are recognised as a degradation signal by 
the 26S proteasome, which then breaks down the target protein into its constituent 
amino acids for use in new protein synthesis and recycles polyubiquitin chains into 
monomers for further rounds of conjugation (Liu et al.; 2005; Nalepa et al.; 2006).  
To assess directly whether STATs were ubiquitylated in A2AAR-overexpressing 
HUVECs following cytokine exposure, STAT3 was immunoprecipitated following 
denaturing cell lysis to remove any STAT-associated proteins and inactivate 
deubiquitylating enzymes (DUBs). Immunoblotting of STAT3 immunoprecipitates 
with anti-ubiquitin antibody revealed that HUVECs treatment with sIL-6Rα/IL-6 only 
resulted in the accumulation of a smear of ubiquitylated STAT3 in A2AAR-
overexpressing cells (Figure 4.13). Thus, the accumulation of ubiquitin-conjugated 
STATs in HUVECs occurred under conditions that also promoted their degradation. 
 
A similar immunoprecipitation approach was attempted for STAT1 but was 
unsuccessful due to its inefficient immunoprecipitation with commercially available 
antibodies.  Instead,  a strategy employing the ability of the UBA domain from 
Saccharomyces cerevisiae protein Dsk2p to specifically isolate ubiquitylated proteins 
from whole cell extracts in vitro was used (Funakoshi et al.; 2002). Using 
recombinant GST-Dsk2pUBA immobilised to glutathione-Sepharose, Tyr701-
phosphorylated STAT1 could only be captured from A2AAR-overexpressing 
HUVECs after treatment with sIL-6Rα/IL-6, i.e. conditions that promoted STAT 
degradation (Figure 4.14). Probing of immunoblots with an anti-ubiquitin antibody 
also confirmed the ability of GST-Dsk2pUBA but not GST alone to specifically 
capture ubiquitylated proteins from soluble HUVECs extract (Figure 4.14). 
 
Ubiquitin is a relatively stable protein in yeast despite its covalent linkage to many 
proteins destined for proteasomal or vacuolar degradation (Swaminathan et al.; 
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1999). This is possible because ubiquitin-protein modification is transient. 
Deubiquitylating enzymes release ubiquitin from polyubiquitin conjugates by 
cleaving the isopeptide bond between the ubiquitins in a chain or at the ubiquitin C 
terminus linked to substrate. The yeast DUB family consists of at least 20 members, 
including 16 in the ubiquitin-specific processing protease (UBP) subfamily (Amerik 
et al.; 2000; Amerik and Hochstrasser; 2004). To further confirm the specificity of 
STAT binding to GST-Dsk2pUBA in vitro, immobilised proteins were incubated 
with or without recombinant human isopeptidase T/UBP5, which selectively removes 
ubiquitin monomers from modified proteins (Lacombe and Gabriel; 2002). Under 
these conditions, incubation of GST-DsK2pUBA-immobilised beads with UBP5 
promoted the release of Tyr701-phosphorylated STAT1 (Figure 4.15). No significant 
release was detectable if the reaction was performed at 4 oC, suggesting that the 
release of STAT1 from GST-Dsk2pUBA required its deubiquitylation by 
enzymatically active UBP5 (Figure 4.15). 
 
To determine the relationship between STAT ubiquitylation and Tyr phosphorylation 
in A2AAR-overexpressing cells, Flag-tagged WT and Tyr705→Phe-mutated STAT3 
were co-expressed in HUVECs with the A2AAR and immunoprecipitated with anti-
Flag antibody-conjugated Sepharose beads following denaturing cell lysis after 
cytokine treatment (Figure 4.16). This demonstrated that under conditions in which 
recombinant WT STAT3 is polyubiquitylated similarly to the endogenous STAT3 in 
response to sIL-6Rα/IL-6, no ubiquitylation of the Tyr705→Phe-mutated STAT3 
could be detected (Figure 4.16). Taken together, these data are consistent with a 
model where by A2AAR-overexpression specifically primes JAK-phosphorylated 
STATs for polyubiquitylation and subsequent degradation by the proteasome.  
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Figure 4.1  Effect of JAK inhibition 1 on sIL-6Rα/IL-6-induced  JAK1, JAK2 
and STAT1 phosphorylation  
 
Panel A: 1x105 HUVECs / well were seeded into 6 well plates. 24 hrs after seeding, 
cells were pre-incubated with or without 0.1 µM JAK inhibitor I for 30 min prior to 
treatment with or without sIL-6Rα/IL-6 for 30 min as indicated. The final 
concentration of vehicle (DMSO) in all wells was 0.1% (V/V).   Soluble cell extracts 
equlised for protein content were then fractionated by SDS-PAGE for 
immunoblotting with anti-phospho-JAK1, anti-phospho-JAK2, anti-JAK1 and anti-
JAK2. 
 
Panel B: 1x105 HUVECs / well were seeded into 6 well plates. 24 hrs after seeding, 
cells were pre-incubated with or without 0.1 µM JAK inhibitor I for 30 min prior to 
treatment with or without sIL-6Rα/IL-6 for 30 min as indicated. The final 
concentration of vehicle (DMSO) in all wells was 0.1% (V/V).  Soluble cell extracts 
equlised for protein content were then fractionated by SDS-PAGE for 
immunoblotting with anti-phospho-STAT1 antibody. 
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Figure 4.2  Effect of JAK inhibition on sIL-6Rα/IL-6-induced STAT1 
phosphorylation and downregulation of STAT1 in A2AAR expressing HUVECs 
 
1x105 HUVECs / well were seeded into 6 well plates. 24 hrs after seeding, cells were 
pre-incubated with or without 0.1 µM JAK inhibitor I for 30 min prior to treatment 
with or without 25ng/ml sIL-6 Rα/5ng/ml IL-6 up to 3 hrs as indicated. The final 
concentration of vehicle (DMSO) in all wells was 0.1% (V/V).  Soluble cell extracts 
equalised for protein content were then fractionated by SDS-PAGE for 
immunoblotting with the indicated antibodies. Quantitative analysis of total STAT1 
levels in A2AAR-expressing cells from three experiments is presented (***p<0.001 
versus STAT1 levels in vehicle-pretreated cells at the given time point). Basal set at 
100. 
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Figure 4. 3 Effect of JAK inhibition on sIL-6Rα/IL-6-induced STAT3 
downregulation in A2AAR expressing HUVECs 
1x105 HUVECs / well were seeded into 6 well plates. 24 hrs after seeding, cells were 
pre-incubated with or without 0.1 µM JAK inhibitor I for 30 min prior to treatment 
with or without 25ng/ml sIL-6 Rα/5ng/ml IL-6 up to 3hr as indicated. The final 
concentration of vehicle (DMSO) in all wells was 0.1% (V/V).  Soluble cell extracts 
equalised for protein content were then fractionated by SDS-PAGE for 
immunoblotting with the indicated antibodies. Quantitative analysis of total STAT3 
levels in A2AAR-expressing cells from three experiments is presented (***p<0.001 
versus STAT3 levels in vehicle-pretreated cells at the given time point). Basal set at 
100. 
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Figure 4.4 Effect of JAK inhibition on IFNα-induced STAT1 downregulation in 
A2AAR expressing HUVECs 
1x105 HUVECs / well were seeded into 6 well plates. 24 hrs after seeding, cells were 
pre-incubated with or without 0.1 µM JAK inhibitor I for 30 min prior to treatment 
with or without 500 unit/ml IFNα up to 3hr as indicated.  The final concentration of 
vehicle (DMSO) in all wells was 0.1% (V/V).  Soluble cell extracts equalised for 
protein content were then fractionated by SDS-PAGE for immunoblotting with the 
indicated antibodies. Quantitative analysis of total STAT1 levels in A2AAR-
expressing cells from three experiments is presented (***p<0.001 versus STAT1 
levels in vehicle-pretreated cells at the given time point). Basal set at 100. 
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Figure 4.5 Effect of JAK inhibition on IFNα-induced STAT3  downregulation in 
A2AAR expressing HUVECs 
1x105 HUVECs / well were seeded into 6 well plates. 24 hrs after seeding, cells were 
pre-incubated with or without 0.1 µM JAK inhibitor I for 30 min prior to treatment 
with or without 500 unit/ml IFNα up to 3hr as indicated. The final concentration of 
vehicle (DMSO) in all wells was 0.1% (V/V).   Soluble cell extracts equalised for 
protein content were then fractionated by SDS-PAGE for immunoblotting with the 
indicated antibodies. Quantitative analysis of total STAT3 levels in A2AAR-
expressing cells from three experiments is presented (***p<0.001 versus STAT3 
levels in vehicle-pretreated cells at the given time point). Basal set at 100. 
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Figure 4.6  Leptin stimulates the specific phosphorylation of  STAT3 but not  
STAT1 
1x105 HUVECs / well were seeded into 6 well plates. 24 hrs after seeding, cells were 
infected with the indicated AVs prior to treatment with or without 25ng/ml sIL-6 
Rα/5ng/ml IL-6 or 100 ng/ml leptin for the indicated times. Soluble cell extracts 
equalised for protein content were then fractionated by SDS-PAGE for 
immunoblotting with the indicated antibodies.  
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Figure 4.7 Effect of A2AAR gene transfer on STAT3 phosphorylation and 
expression in response to leptin 
1x105 HUVECs / well were seeded into 6 well plates. 24 hrs after seeding, cells were 
infected with the indicated AVs prior to treatment with or without 100 ng/ml leptin 
for the indicated times. Soluble cell extracts equalised for protein content were then 
fractionated by SDS-PAGE for immunoblotting with the indicated antibodies. 
Quantitative analysis of phospho-STAT3 and STAT3 levels from three experiments 
is presented (**p<0.005 and *p<0.05 versus corresponding STAT levels in AV.GFP-
infected cells at the given time point). Basal set at 100. 
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Figure 4.8 Effect of A2AAR gene transfer on STAT1 and STAT3 expression in 
response to prolonged exposure to leptin 
1x105 HUVECs / well were seeded into 6 well plates. 24 hrs after seeding, cells were 
infected with the indicated AVs prior to treatment with or without 100 ng/ml leptin 
for the indicated times. Soluble cell extracts equalised for protein content were then 
fractionated by SDS-PAGE for immunoblotting with the indicated antibodies. 
Quantitative analysis of total STAT3 levels in A2AAR-expressing cells from three 
experiments is presented (*p<0.05 versus corresponding STAT levels in AV.GFP-
infected cells at the given time point). Basal set at 100. 
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Figure 4.9 Effect A2AAR gene transfer on WT and Tyr705→Phe mutated 
STAT3 expression levels. 
1x105 HUVECs / well were seeded into 6 well plates. 24 hrs after seeding, cells were 
co-infected with AV myc-A2AAR and either AV. Flag-WT STAT3 or AV.Flag- 
Tyr705→Phe mutated STAT3 prior to treatment with or without 500 unit/ml IFNα 
for 1 hr as indicated. Soluble cell exracts equalised for protein content were then 
fractionated by SDS-PAGE for immunoblotting with the indicated antibodies.  
Quantitative analysis of WT and Tyr705→Phe mutated STAT3 down-regulation in 
A2AAR-expressing cells from three experiments is presented (***P <0.001 versus 
WT). Basal set at 100. 
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Figure 4.10 Effect of A2AAR gene transfer on mRNA levels of the phospho 
STAT-specific E3 Ub ligase SLIM/Mystique in vascular endothelial cells under 
conditions that promote STAT degradation 
1x105 HUVECs / well were seeded into 6 well plates. 24 hrs after seeding, cells were 
infected with the indicated AVs prior to treatment with or without 25ng/ml sIL-6 
Rα/5ng/ml IL-6 for 2hr. Cells were harvested into 0.5 ml of Tri-reagent and RNA 
extracted as described in section 2.3.6. 1µg RNA of each sample was then used to 
generate cDNA as described in 2.3.7. To assess SLIM/Mystique expression 1 µl of 
cDNA was used per reaction. As positive control 50 ng of pcDNAA3/HA- 
SLIM/Mystique plasmid was used.  PCR conditions were given in section 2.3.8. 
DNA was then fractionated by agarose gel. Results are typical of three experiments is 
presented.  
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Figure 4.11  Effect of A2AAR gene transfer on protein expression of the phospho 
STAT-specific E3 Ub ligase SLIM/Mystique in vascular endothelial cells under 
conditions that promote STAT degradation 
1x105 HUVECs / well were seeded into 6 well plates. 24 hrs after seeding, cells were 
infected with the indicated AVs prior to treatment with or without 25ng/ml sIL-6 
Rα/5ng/ml IL-6 for 2hr. Soluble cell extract of HEK293 cells express pcDNAA3/HA-
SLIM/Mystique plasmid used as positive control. Soluble cell extracts equalised for 
protein content were then fractionated by SDS-PAGE for immunoblotting with the 
indicated antibodies.  
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Figure 4.12 Effect of A2AAR gene expression on SOCS3 induction in response to 
sIL-6 Rα/IL-6 
1x105 HUVECs / well were seeded into 6 well plates. 24 hrs after seeding, cells were 
infected with the indicated AVs prior to pre-treatment with MG132 for 30 min and 
treatment with 25ng/ml sIL-6 Rα/5ng/ml IL-6 for up to 3 hrs as indicated. Soluble 
cell extracts equalised for protein content were then fractionated by SDS-PAGE for 
immunoblotting with the indicated antibodies. Quantitative analysis of SOCS3 levels 
from three experiments is presented. Control 100 set at 0 hr of GFP cells. 
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Figure 4.13 A2AAR expression primes STAT3 for cytokine-triggered 
ubiquitylation 
1x105 HUVECs / well were seeded into 6 well plates. 24 hrs after seeding, cells were 
infected with the indicated AVs prior to pre-treatment with or without 6µM MG132 
for 30 min and incubation with 25ng/ml sIL-6 Rα/5ng/ml IL-6 for 1 hr. Samples were 
then denatured by heating in SDS-containing buffer prior to dilution into excess non-
ionic detergent for preparation of clarified extracts and immunoprecipitation of 
STAT3. Immunoprecipitates were fractionated by SDS-PAGE for immunoblotting 
with anti-ubiquitin and STAT3 antibodies.  
 
 
 
 
 
 
 
 
Mr 
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Figure 4.14 A2AAR expression primes STAT1 for cytokine-triggered 
ubiquitylation 
1x105 HUVECs / well were seeded into 6 well plates. 24 hrs after seeding, cells were 
infected with AV.mycA2AAR were pre-treated with  6µM MG132 followed by 
exposure to 25ng/ml sIL-6 Rα/5ng/ml IL-6.Cells were then harvested for preparation 
of protein-equalised soluble fractions and pull-down experiment using 5ug/sample of 
GST (negative control) or GST-Dsk2pUBA. Captured proteins were fractionated by 
SDS-PAGE for immunoblotting with anti-ubiquitin, phospho-STAT1 and total 
STAT1 antibodies. This is one of three experiments that produced similar results.  
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Figure 4.15 Effect of UBP5 on release of STAT1 from GST-Dsk2p 
1x105 HUVECs / well were seeded into 6 well plates. 24 hrs after seeding, cells were 
infected with AV.mycA2AAR were pre-treated with 6µM MG132 followed by 
exposure to 25ng/ml sIL-6Rα/5ng/ml IL-6. Cells were then harvested for preparation 
of protein-equalised soluble fractions and capture of ubiquitylated proteins with GST-
Dsk2pUBA. Following the final wash, beads were resuspended in reaction buffer and 
incubationed with or without UBP5 for 1hr at the indicated temperatures. The 
reaction buffer was then analysed for the presence of Tyr701-phosphorylated and 
total STAT1 by SDS-PAGE and immunoblotting. This is one of three experiments 
that produced similar results.  
 
 
 
 
 
 
 
 
 
.  
 
 
 
 
 
 
 
 
 
 
 
97 
97 
Mr 
 130 
Figure 4.16 A2AAR expression primes Flag-WT but not Tyr705→Phe mutated 
STAT3 for cytokine-triggered ubiquitylation 
1x105 HUVECs / well were seeded into 6 well plates. 24 hrs after seeding, cells were 
co-infected with AV.myc-A2AAR and either AV.Flag-WT STAT3 or AV.Flag-
Tyr705→Phe mutated STAT3 pritotreatment with 6µM MG132 and 25ng/ml sIL-6 
Rα/5ng/ml IL-6 for 1 hr as indicated. Cells were then denatured by heating in SDS-
containing buffer prior to dilution into excess non-ionic detergent for preparation of 
clarified extracts and immunoprecipitation of Flag-STAT3 proteins using M2 
antibody-coupled Sepharose beads. Samples were then fractionated by SDS-PAGE 
prior to immunoblotting with anti-ubiquitin and STAT3 antibodies.  
 
 
Mr 
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4.3  Discussion 
 
JAKs are no longer implicated only in classic cytokine receptor-mediated signalling 
pathways, but are now also known to integrate indirectly into other receptor-mediated 
signal transduction processes. Therefore, an increasing number of therapeutic 
applications exist for biological response modifiers that can modulate JAK/STAT 
activity. Exciting breakthroughs in both physiological and pharmacological methods 
of selective inhibition of cytokine JAK-STAT pathways have recently emerged in the 
form of suppressors of cytokine signalling. The basis of these and other mechanisms 
of negative regulation of JAK activity, including the suppression of JAK expression 
levels caused by tumour- or pathogen-derived agents, the complex interactions of 
JAKs with phosphatases. The possibility of modulating selected JAK/STAT-
mediated cellular signals by inhibiting JAK kinase activity to obtain a posative 
therapeutic outcome is a tantalising prospect, as yet incompletely realised. While 
current data suggest no therapeutic use for JAK1 and TyK2 inhibition, JAK2 
inhibition seems a promising but untested strategy for therapeutic intervention 
(Reiterer and Yen; 2006). More promising, however, are the data indicating a 
possible therapeutic use of JAK inhibition. Results in this Chapter showed that 
degradation of STATs required JAK activity since 1) it was blocked by pre-
incubation with JAK inhibitor 1. 2) STAT1 but not STAT3 was resistant to both 
tyrosine phosphorylation and down-regulation in response to leptin and 3) a 
Tyr705→Phe mutated STAT3 was also resistant to cytokine-triggered degradation, 
suggesting that JAK-mediated phosphorylation of this residue is required to produce 
the effect. The importance of JAK in mediating cytokines signalling has been shown 
in many studies including in vivo studies, where Tyk2 has been shown to be  partially 
necessary for IFN-α/β-induced tyrosine phosphorylation of STAT3 (Karaghiosoff et 
al.; 2000; Shimoda et al.; 2000). The SOCS protein family comprises a group of 
cytokine-inducible genes that were discovered initially to suppress STAT signalling 
by binding to and inhibiting JAKs (Starr and Hilton; 1999; Yasukawa et al.; 1999). 
Some of these proteins are transcriptionally regulated by STATs themselves, 
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suggesting that STATs can negatively regulate their own phosphorylation state. The 
kinase activity of the Tel-JAK2 fusion protein is associated with leukemia and known 
to activate STAT5 (Levy and Gilliland; 2000). SOCS1 has been demonstrated to 
block Tel-JAK2-mediated transformation of hematopoietic cells (Frantsve et al.; 
2001). Recently, a deletion on chromosome 16p that contains SOCS1 has been found 
in 48% of primary hepatocellular carcinomas, raising the possibility that inactivation 
of this gene may participate in hepatocarcinogenesis (Koyama et al.; 1999). It can 
therefore be speculated that negative regulators of STAT signalling might play 
important roles in the control of tumour incidence and/or progression. 
 
Many studies have demonstrated that GPCRs have been shown to be connected to the 
JAK/STAT pathway (Lukashova et al.; 2001). However, the mechanisms involved in 
regulating the activation of this signalling pathway by GPCRs remain limited. In 
addition, little is known about the role of the JAK pathway in the physiological or 
pathophysiological functions of GPCRs. Despite the obvious importance of the 
A2AAR in controlling the expression and function of various transcription factors 
such as p53 (Watson and Irwin; 2006), NF-қB (Chen; 2005) and Smads (Izzi and 
Attisano; 2006), relatively few reports have examined Ub capacity to regulate 
STATs. Our results show that over-expression of the A2AAR in HUVECs led to the 
more rapid degradation of STAT1 and STAT3 in A2AAR overexpressing cells.  
Interestingly, cAMP-elevating agents have been shown to inhibit IL-6-induced STAT 
activation in monocytes (Sengupta et al.; 1996). These data establish a link for 
crosstalk between cAMP-mediated signalling pathway and STAT, and suggest that 
A2AAR mediated inhibition of STAT may possibly be cAMP-dependent. 
 
The ability of V proteins encoded by paramyxoviruses to function as STAT E3 
ubiquitin ligases is a well-established mechanism by which they subvert the 
interferon response (Horvath; 2004a), native cellular mechanisms controlling STAT 
degradation are rather less well defined. The first description of STAT degradation 
centred around the observation that proteasome inhibition produced a more robust 
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accumulation of tyrosine-phosphorylated STAT1 in HeLa cells following exposure to 
IFNγ. This suggests that proteasomal degradation is an important mechanism by 
which STAT1 function is turned off in these cells (Kim and Maniatis; 1996). It was 
been shown that removal of IL-3 from 32D myeloid cells results in a time-dependent 
proteasomal degradation of STAT5 but not STAT1, 2 or 3 (Wang et al.; 2000), 
although nuclear translocation rather than tyrosine phosphorylation seems to be 
required for degradation to occur (Chen et al.; 2006).  Another study has shown that 
the degradation of STAT3 in H4IIE hepatoma cells could be triggered by 
hyperosmotic stress and occurred independently of phosphorylation on Tyr705 
(Schafer et al.; 2005). Taken together, none of these observations are consistent with 
a single unifying mechanism. Thus, while the recent identification of the protein 
“SLIM” as an E3 ubiquitin ligase able to trigger the polyubiquitylation of STAT1 and 
STAT4 is important (Tanaka et al.; 2005), it is unlikely to account for all STAT 
degradation phenomena reported in the literature.  In relation to this issue it is 
important to note that inhibition of proteasome function was sufficient to block the 
inhibitory effect of the A2AAR-overexpression on STAT3 phosphorylation (Figures 
3.17-3.20). This demonstrates that priming of STATs for degradation is the only 
mechanism responsible for the reduced cytokine-stimulated STAT phosphorylation 
observed in A2AAR overexpressing cells (see Chapter 3). Identification of Ub-
conjugation states and nature of chain linkage on STAT3-recognising the states of Ub 
attachment and identification of the E3 ligase(s) responsible for STAT ubiquitylation 
would define new targets on STATs amenable to therapeutic manipulation. However, 
this identification is hampered by the lack of any consensus ubiquitylation sequences 
displayed by E3s (Nalepa et al.; 2006) and assuming the ubiquitylation states are 
conserved, the presence of more than 20 Lys residues common between human 
STATs 1 and 3. However, the results presented in my thesis suggest that there is no 
detectable SLIM message or protein under conditions in which STAT degradation 
occurs (Figure 4.10 and 4.11), suggesting that another E3 is responsible. 
Identification of this new E3 would constitute a major advance towards designing 
strategies for manipulating STAT function. It is becaming increasingly appreciated 
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that SOCS proteins also act by promoting the degradation of specific signalling 
proteins.  Recent work suggests that SOCS box-containing proteins act as adapter 
molecules that recruit activated signalling proteins to the proteasome. The results 
showed that there is a siginficant difference in SOCS3 expression between GFP and 
A2AAR overexpressing cells upon cytokines stimulation at 2 and 3 hrs (Figure 4.12). 
However, this does not rule out the physiological function of SOCS3 or other SOCS 
family members in the down-regulation of STAT1 and STAT3. In addition, we used 
WT and SOCS3 knockout mouse embryonic fibroblasts (MEFs) to test the 
inolvement of SOCS3 in STAT down-regulation. However, these experiments proved 
to be technically difficult as we could not transduce them with the adenovirues at our 
disposal. One study has reported that expression of SOCS1 but not SOCS3 promotes 
the degradation of ubiquitylated JAK2 (Shuai and Liu; 2003) leading to a reduction in 
STAT activation. In addition, STAT1 is known to be regulated by phosphorylation-
dependent polyubiquitination in response to IFN-γ (Kim and Maniatis; 1996). Given 
that SOCS1 can promote the degradation of JAK2, it is also possible that SOCS1 may 
target the degradation of associated STAT1.  
 
In addition, to examine the polyubiquitination of STATs, extracts from A2AAR 
overexpressing cells treated or not treated with proteasome inhibitor MG132 were 
subjected to immunoprecipitation analysis with anti-STAT3 antibody or pull down 
experiments. It is obvious that the amounts of phosphorylated STAT in A2AAR 
expressing cells upon sIL-6Rα/IL-6 stimulation are controlled by the ubiquitin-
dependent proteolysis of STAT1 and STAT3, consistent with the finding that STAT1 
proteins activated by IFN-γ may be negatively regulated by the ubiquitin-proteasome 
pathway (Kim and Maniatis; 1996). These results strongly suggest that STAT1 and 
STAT3 are polyubiquitinated before their degradation by the 26S proteasome. In 
addition, Tyr phosphorylation is required for cytokine-triggered degradation of 
STATs following A2AAR overexpression. However, it is unclear where within the 
cells ubiquitylation and degradation occur, which residues on STATs confer 
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sensitivity to polyubiquitylation, and the nature of the polyubiquitylation chain 
linkage.  
 
Finally, in this study we have demonstrated that the A2AAR overexpression can prime 
cytokine-activated STATs for polyubiquitylation and subsequent degradation by the 
proteasome. It was found that overexpression of the A2AAR in the absence of any 
agonist was sufficient to prime STATs for degradation. It is possible that over the 
course of the experiments, endogenous adenosine released by HUVECs in vitro 
reaches extracellular levels sufficient to cause A2AAR activation. However signalling 
from cytokine receptors is subject to strict negative regulation via several 
mechanisms designed to prevent inappropriately sustained activation of downstream 
responses (Wormald and Hilton; 2004). In most systems activation of STAT is 
transient. This suggests that efficient mechanisms for STAT inactivation must exist. 
At least two possible mechanisms can be envisioned. The first one is 
dephosphorylation of Tyr-phosphorylated STAT. The second mechanism is 
degradation of Tyr-phosphorylated STAT. To determine whether the Tyr-
phosphorylation of STAT1 and STAT3 is involved in ubiquitination and proteasome-
mediated degradation, Flag-tagged WT STAT3 and Tyr705→Phe mutated STAT3 
were used. This demonstrated that under conditions in which recombinant WT 
STAT3 is polyubiquitylated similarly to the endogenous STAT3 in response to sIL-
6Rα/IL-6, no ubiquitylation of the Tyr705→Phe-mutated STAT3 could be detected. 
This result suggested that Tyr-phosphorylation of STAT was crucial for STAT 
ubiquitination and degradation in A2AAR overexpressing cells, since we could not 
observed the same effect in Tyr705→Phe-mutated STAT3 as well in untreated cells 
with cytokines. 
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Phosphorylation is a commonly utilised signal involved in controlling substrate 
recognition by multiple ubiquitin E3 ligases. The cytokine dependence of STAT 
degradation in A2AAR overexpressing cells raised the possibility that JAK-mediated 
STAT phosphorylation was a trigger for this event. Thus, several experimental 
approaches in Chapter 4 were used to test this hypothesis in more detail. 
 
 (1) JAK inhibitor 1 inhibits  Tyr-phosphorylation of JAK1, JAK2 and STAT1. 
  
(2) Degradation required JAK activity since; 
 a) It was blocked by pre-incubation with JAK inhibitor 1. 
 b) STAT1 but not STAT3 was resistant to both tyrosine phosphorylation and 
down-regulation in response to leptin.  
c) A Tyr705→Phe mutated STAT3 was also resistant to cytokine-triggered 
degradation, suggesting that JAK-mediated phosphorylation of this residue is 
required to produce the effect. 
 
(3) To assess directly whether STATs were ubiquitylated in A2AAR overexpressing 
HUVECs following cytokine exposure, STAT3 and Flag-tagged WT STAT3 were 
immunoprecipitated following denaturing cell lysis to remove any STAT-associated 
proteins and inactivate deubiquitylating enzymes. Immunoblotting of STAT3 
immunoprecipitates with anti-ubiquitin antibody revealed that HUVEC treatment 
with sIL-6Rα/IL-6 only resulted in the accumulation of a smear of ubiquitylated 
STAT3 in A2AAR-overexpressing cells. Thus, the accumulation of ubiquitin-
conjugated STATs in HUVECs occurred under conditions that also promoted their 
degradation. 
 
(4) To determine the relationship between STAT ubiquitylation and Tyr 
phosphorylation in A2AAR-overexpressing cells, Flag-tagged WT and Tyr705→Phe 
mutated STAT3 were co-expressed in HUVECs with the A2AAR and 
immunoprecipitated with anti-Flag antibody-conjugated Sepharose beads following 
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denaturing cell lysis after cytokine treatment. These experiments demonstrated that 
under conditions in which recombinant WT STAT3 is polyubiquitylated similarly to 
the endogenous protein in response to sIL-6Rα/IL-6, no ubiquitylation of the 
Tyr705→Phe mutant could be detected. 
 
(5) To date there is only one mammalian E3 ligase known for mediating STAT 
degradation which is SLIM protein. However, our results suggest the involvement of 
another E3 ubiquitin ligase in HUVECs, since we have been unable to detect SLIM 
message or protein in HUVECs under conditions in which STAT degradation occurs. 
The PCR technique has determined by serial dilution of SLIM/Mystique plasmid to 
approximately a few thousand (assuming that 1µg of SLIM plasmid pcDNAA3/HA-
SLIM/Mystique contains 1.5x1011 copies of target DNA).  For the immunoblotting 
experiment the Ab was able to detect the positive control (which was lysates from 
HEK293 cells transfected with SLIM/Mystique cDNA), but the endogenous 
SLIM/Mystique which may be induced in A2AAR overexpressing cells was below the 
detection limit of the Ab. 
 
(6) The results showed that there is a siginficant difference in SOCS3 expression 
between GFP and A2AAR overexpressing cells upon cytokines stimulation at 2 and 3 
hrs (Figure 4.12). However, this does not rule out the physiological function of 
SOCS3 or other SOCS family members in potentially mediating the down-regulation 
of STAT1 and STAT3. 
 
The limitations of approaches in Chapter 4 are the same as in Chapter 3 for the use of 
HUVECs and overexpression of A2AAR (pages 102-103).  
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Chapter 5 
 
Effect of A2AAR Expression on STAT3 Regulated Genes 
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5.1   Introduction 
 
VEGFR-2/Flk-1/KDR is exclusively expressed in endothelial cells and appears to 
play a pivotal role in endothelial cell differentiation and vasculogenesis (Millauer et 
al.; 1993; Quinn et al.; 1993). Many studies have provided evidence for the role of 
VEGFR-2/Flk-1/KDR in tumour vascularisation, growth, and metastasis. For 
example, the manipulation of the cloned receptor to create a “dominant negative” 
mutation is one experimental technique that has helped establish the relevance of Flk-
1 to tumour angiogenesis. The biological relevance of the VEGFR-2/Flk-1/KDR 
receptor/ligand system for tumour-associated angiogenesis in vivo has been 
demonstrated using a retrovirus encoding a dominant-negative Tyr705→Phe mutant 
of the VEGFR-2 ( inhibit kinases), which  prevented the growth of a transplanted 
glioblastoma (Millauer et al.; 1994). Recently, using an anti-sense oligonucleotids 
directed against Flk-1 and Flt-1, it has been shown that VEGF stimulates, endothelial 
cell proliferation, migration, and platelet-activating factor synthesis via VEGFR-2. 
Inhibition of Flt-1 expression failed to affect VEGFs ability to modulate these 
activities (Bernatchez et al.; 1999). These studies have validated targeting of the 
VEGFR-2 signalling pathway for the development of antiangiogenic agents.  
 
The JAK/STAT and PI-3-َK/Akt are two parallel pathways responsible for mediating 
many downstream functions of many receptor and nonreceptor tyrosine kinases, 
including EGFR, Her-2 and c-Src (Liu et al.; 1998; Laughner et al.; 2001; Yu and 
Jove; 2004). gp130, which is frequently activated in a wide range of cancers 
(Hideshima et al.; 2004), also signals through both JAK/STAT and PI-3-َK/Akt 
pathways (Falcone et al.; 1999; Hideshima et al.; 2001). Over-expression and/or 
persistent activation of EGFR/Her-2, Src and IL-6R are known to promote tumour 
growth/survival and to induce VEGF expression and angiogenesis (Laughner et al.; 
2001; Semenza; 2003; Yu and Jove; 2004). As IL-6 activates PI-3-َK/Akt via SHP2 
activation by gp130 this leads to activation of downstream kinases such as Akt 
(Hideshima et al., 2001). Interestingly, it has been shown that blocking STAT3, but 
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not PI-3-َK activity, inhibits VEGF expression in tumour cells with constitutive IL-6 
signalling (Wei et al.; 2003), suggesting that STAT3 continues to activate VEGF 
expression in the absence of PI3K/Akt signalling. 
 
EC dysfunction is characterised by decreased bioavailability of NO, caused in part by 
increased oxidant stress and by decreasing NO synthesis (Cai and Harrison; 2000; 
Fulton et al.; 2001). In the vasculature, NO is normally synthesised by the endothelial 
isoform of eNOS, where it plays a protective role by inhibiting leukocyte trafficking 
and by decreasing platelet adhesion and aggregation (Fleming and Busse; 1999; 
Stuehr; 1999; Dudzinski et al.; 2006). NO production by endothelial cells is regulated 
by changes in eNOS enzyme activity and gene expression. The expression of eNOS 
can be regulated by biophysical stimuli (such as shear stress or hypoxia), growth 
factors (such as TGF-β1, FGF, VEGF, or PDGF), hormones (such as estrogens, 
insulin, angiotensin II, or endothelin 1) (Li et al.; 2002), or NO itself (Dudzinski et 
al.; 2006) and IL-6 (Saura et al.; 2006). 
 
The results in Chapters 3 and 4 suggest that A2AAR overexpression primes JAK-
phosphorylated STATs for polyubiquitylation and subsequent degradation by the 
proteasome. For the down-regulation of STAT proteins observed in A2AAR-
overexpressing cells to be considered functionally significant, the ability of cytokines 
to promote the accumulation of STAT-regulated target gene products should be 
compromised. In the course of our studies, we identified the vascular endothelial 
growth factor (VEGF) receptor VEGFR-2 and eNOS as proteins in HUVECs whose 
levels are controlled by STAT3. Since multiple studies have shown that elevated 
levels of STAT3 phosphorylation are associated with increased expression of 
potential downstream targets of STAT3, such as VEGF  (Turkson; 2004) and down 
regulation of eNOS in ECs (Saura et al.; 2006). Inhibition of constitutively active 
STAT3 signalling pathways may inhibit inflammation and tumour cell growth in 
vitro and in vivo as well as provide a novel means for therapeutic intervention in 
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human diseases. In this Chapter we investigate the effect of A2AAR overexpression 
on the physiologically relevant genes regulated by STAT3 in HUVECs. 
 
5.2  Results 
 
The STATs function as downstream effectors of cytokine and growth factor receptor 
signalling. Compared with normal cells and tissues, constitutively activated STATs 
have been detected in a wide variety of human cancer cell lines and inflamed tissue. 
STATs are activated by tyrosine phosphorylation, which is normally a transient and 
tightly regulated process (Heinrich et al.; 2003). The down-regulation of STAT 
proteins observed in A2AAR-overexpressing cells would be predicted to modify the 
ability of cytokines to promote STAT-induced target gene expression. VEGFR-2 is a 
protein in ECs whose levels are positively controlled by STAT3. Incubation of 
HUVECs with sIL-6Rα/IL-6 for 4 hr increased VEGFR-2 (Figure 5.1). The cytokine 
dependence of STAT degradation in A2AAR-overexpressing cells (see Chapter 3) 
raised the possibility that JAK-mediated STAT phosphorylation was a trigger for this 
event. JAK inhibition experiments demonstrated that 0.1 µM of JAK inhibitor 1 was 
sufficient to inhibit Tyr-phosphorylation of JAKs and STATs upon sIL-6Rα/IL-6 
stimulation. In this Chapter I wanted to test the effect of JAK inhibition on VEGFR-2 
expression when HUVECs were stimulated with sIL-6Rα/IL-6. My results show that, 
expression of VEGFR-2 upon sIL-6Rα/IL-6 stimulation was blocked by JAK 
inhibitor 1 pre-treatment (Figure 5.2). Furthermore, in Chapter 4 we demonstrated 
that JAK-mediated phosphorylation of STATs was the critical step triggering down-
regulation when HUVECs were co-infected with AVs encoding the A2AAR and either 
Flag epitope-tagged WT or Tyr705→Phe mutated STAT3, since mutation of Tyr705 
renders STAT3 resistant to phosphorylation by JAK (Kaptein et al.; 1996). In this 
Chapter expression of VEGFR-2 was abolished by overexpression of a dominant-
negative Tyr705→Phe STAT3 mutant and produced by overexpression of WT 
STAT3 (Figure 5.3). The results show that A2AAR overexpression has two effects on 
VEGFR-2 expression. The first effect was incubation of A2AAR-overexpressing cells 
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with sIL-6Rα/IL-6 for 4 hr triggered a 91±6% down regulation of VEGFR-2 
compared to levels in untreated controls (Figure 5.4). The second effect was that 
over-expression of the A2AAR alone increased VEGFR-2 expression (Figur 5.4), 
although this phenomenon appears to be STAT-independent since receptor expression 
alone produces no detectable changes in STAT phosphorylation (see Chapter 3). The 
data are consistent with the hypothesis that A2AAR overexpression can prime 
cytokine-activated STATs for degradation by the proteasome. Also, A2AAR-
overexpression was able to down regulate VEGFR-2 expression. This may occur via 
inhibition of STAT3 regulation of VEGF expression.  
  
NO produced by endothelial cells plays a crucial role for regulation of many 
biological functions such as vasodilatation, host defense, tissue respiration, and 
substrate utilisation (Moncada et al.; 1991; Trochu et al.; 2000). Many studies have 
show that IL-6 can decrease eNOS expression in ECs. It has been shown that IL-6 
treatment of human aortic endothelial cells (HAEC) decreases steady-State levels of 
human eNOS mRNA and protein and this decrease in eNOS expression is caused in 
part by IL-6 inhibition of transactivation of the human eNOS promoter (Saura et al.; 
2006). cAMP signal transduction is a novel pivotal mechanism for regulation of 
endothelial NO production and may play a crucial role in the control of 
cardiovascular function. For example, many studies have shown that heart failure is 
associated with a depressed systemic and cardiac endothelial NO production, and 
defective endothelial NO formation has been recognised as an important mechanism 
contributing to the progressive deterioration of this disease (Katz et al.; 1993; Mohri 
et al.; 1997; Zhang et al.; 1999b). To investigate if over-expression of the A2AAR 
could regulate eNOS expression, several experimental approaches were used. The 
data shown in Figure 5.5 shows that levels of eNOS were reduced by transient 
overexpression of WT STAT3. In contrast, eNOS levels were up-regulated by over-
expression of a dominant-negative Tyr705→Phe mutated STAT3. From Figure 5.6 it 
can be seen that there is no significant change in eNOS expression when the cells are 
incubated with sIL-6Rα/IL-6. However incubation of A2AAR-overexpressing cells 
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with sIL-6Rα/IL-6 for 2hr marginally up-regulates eNOS expression compared to 
controls (Figure 5.7). These results suggest that STAT3 negatively regulates eNOS 
expression upon sIL-6Rα/IL-6 in A2AAR-overexpressing cells.  
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Figure 5.1 Effect of sIL-6Rα/IL-6 on VEGFR2 expression 
1x105 HUVECs / well were seeded into 6 well plates. 24 hrs after seeding, cells were 
serum starving for 4 hrs prior to treatment with or without 25ng/ml sIL-6 Rα/5ng/ml 
IL-6 for the indicated times. Soluble cell extracts equalised for protein content were 
then fractionated by SDS-PAGE for immunoblotting with the indicated antibodie. 
Quantitative analysis of VEGFR2 levels from three experiments is presented (***P 
<0.001 versus the response observed in control cells). Basal set at 100. 
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Figure 5.2 Effect of JAK inhibition 1 on sIL-6Rα/IL-6-induced VEGFR2 
expression in HUVECs 
1x105 HUVECs / well were seeded into 6 well plates. 24 hrs after seeding, cells were 
then serum starving for 4 hrs prior to pre-incubation with or without 0.1 uM JAK 
inhibitor I for 30 min then treatment with or without 25ng/ml sIL-6 Rα/5ng/ml IL-6 
for 30 min as indicated.  Soluble cell extracts equalised for protein content were then 
fractionated by SDS-PAGE for immunoblotting with anti-VEGFR2 antibody. (**P 
<0.005 and ***P <0.001 versus the response observed in control cells). Basal set at 
100. 
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Figure 5.3 Effect of WT and Tyr705→Phe mutated STAT3 expression on 
VEGFR2 expression in HUVECs 
1x105 HUVECs / well were seeded into 6 well plates. 24 hrs after seeding, cells were 
co-infected with AV. Flag-WT STAT3 or AV.Flag-Tyr705→Phe mutated STAT3 
prior to treatment with or without 25ng/ml sIL-6 Rα/5ng/ml IL-6 for 1 hr as 
indicated. Soluble cell exracts equalised for protein content were then fractionated by 
SDS-PAGE for immunoblotting with the indicated antibodies (***P <0.001 versus 
the response observed in mutant STAT3). Basal set at 100. 
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Figure 5.4 Effect of A2AAR gene transfer on VEGFR2 expression in response to 
sIL-6Rα/IL-6 
1x105 HUVECs / well were seeded into 6 well plates. 24 hrs after seeding, cells were 
infected with the indicated AVs prior to  serum starving for 4hr and treatment with or 
without 25ng/ml sIL-6 Rα/5ng/ml IL-6 for the indicated times. Soluble cell extracts 
equalised for protein content were then fractionated by SDS-PAGE for 
immunoblotting with the indicated antibodies. Quantitative analysis of VEGFR2 
down-regulation in A2AAR-expressing cells from three experiments is presented 
(***P <0.001 versus the response observed in AV.GFP infected cells) Basal set at 2 
hrs.  
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Figure 5.5 Effect of WT and Tyr705→Phe mutated STAT3 expression on eNOS 
expression 
1x105 HUVECs / well were seeded into 6 well plates. 24 hrs after seeding, cells were 
co-infected with AV. Flag-WT STAT3 or AV.Flag-Tyr705→Phe mutated STAT3 
prior to treatment with or without 25ng/ml sIL-6 Rα/5ng/ml IL-6 for 1 hr as 
indicated. Soluble cell exracts equalised for protein content were then fractionated by 
SDS-PAGE for immunoblotting with the indicated antibodies (***P <0.001 and *P 
<0.05 versus the response observed in WT STAT3). Basal set at 100.  
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Figure 5.6 Effect of sIL-6Rα/IL-6 on eNOS expression 
1x105 HUVECs / well were seeded into 6 well plates. 24 hrs after seeding, cells were 
serum starving for 4 hrs prior to treatment with or without 25ng/ml sIL-6 Rα/5ng/ml 
IL-6 for the indicated times. Soluble cell extracts equalised for protein content were 
then fractionated by SDS-PAGE for immunoblotting with the indicated antibodies. 
Basal set at 100. 
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Figure 5.7 Effect of A2AAR gene transfer on eNOS expression in response to sIL-
6Rα/IL-6 
1x105 HUVECs / well were seeded into 6 well plates. 24 hrs after seeding, cells were 
infected with the indicated AVs prior to  serum starving for 4hr and treatment with or 
without 25ng/ml sIL-6 Rα/5ng/ml IL-6 for the indicated times. Soluble cell extracts 
equalised for protein content were then fractionated by SDS-PAGE for 
immunoblotting with the indicated antibodies. (**P <0.005 versus the response 
observed in AV.GFP infected cells).  Basal set at 100.  
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5.3  Discussion 
 
VEGF is up-regulated by multiple stimuli, including hypoxia (Levy et al.; 1995b; 
Levy et al.; 1995a), growth factors (Nauck et al.; 1997), and cytokines (Li et al.; 
1995; Ryuto et al.; 1996). Conversely, few agents have been shown to reduce VEGF 
expression as described presently for A2AAR agonists. Glucocorticoids inhibit the up-
regulation of VEGF induced by stimuli such as serum, platelet-derived growth factor, 
phorbol esters, and platelet-activating factor in different cell types (Finkenzeller et 
al.; 1995; Heiss et al.; 1996; Nauck et al.; 1997).  
 
 VEGFR2 is one of the major regulators of vasculogenesis and angiogenesis. The 
detailed analysis of the role of VEGFR2-mediated signal transduction suggested that 
the inhibition of VEGFR pathway would provide a powerful antiangiogenic signal 
that could be highly useful in inhibiting pathogenic angiogenesis To date, several 
small molecule VEGFR2 kinase (KDR) inhibitors have been tested in animal cancer 
models and resultant changes in tumor vasculature have been described. Strong anti-
angiogenic responses are induced by SU5416 (a potent  inhibitor of VEGFR protein 
kinases) (Vajkoczy et al.; 1999; Laird et al.; 2000). While the mechanism by which 
A2AAR activation results in VEGFR2 down-regulation has begun to be explored, our 
results show that A2AAR overexpression down-regulated VEGFR-2 under the same 
conditions that promoted STAT degradation after cytokine stimulation (see Chapter 
3). In A2AAR-overexpressing cells, the ability of the A2AAR to stimulate down 
regulation of VEGFR-2 after 4hr of sIL-6Rα/IL-6 stimulation was significant 
compared with control cells. The expression of VEGFR-2 upon sIL-6Rα/IL-6 was 
inhibited by JAK inhibitor 1, abolished by over-expression of Tyr705→Phe mutated 
STAT3 and induced by overexpression of WT STAT3. Several studies have reported 
that VEGF-induced proliferation is mediated by the interaction of VEGF with 
VEGFR2 in both breast cancer cells and in endothelial cells (Mercurio et al.; 2004; 
Liang and Hyder; 2005). However, the role of A2AAR in VEGFR2 regulation may be 
complex. In addition VEGFR2 is exclusively expressed in endothelial cells and 
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appears to play a pivotal role in endothelial cell differentiation and vasculogenesis 
(Millauer et al.; 1993; Quinn et al.; 1993). It has also been demonstrated that 
VEGFR-2 signals through STAT3 (Bartoli et al.; 2003). Blocking STAT3 in 
endothelial cells inhibit their migration and vessel formation (Yahata et al.; 2003). 
Interestingly, a relationship between tumour STAT3 activity and STAT3 signalling 
has been recently described (Wang et al.; 2004). Our results in Chapter 3 
demonstrated that the human A2AAR overexpression was able to confer an ability of 
sIL-6Rα/IL-6 to trigger a time-dependent reduction in the levels of STAT proteins 
that was due entirely to proteasomal degradation. In terms of functional 
consequences, the results of this Chapter show that the degradation was associated 
with an attenuation of sIL-6Rα/IL-6-stimulated STAT3-dependent up-regulation of 
VEGFR2. Blocking STAT3 signalling in either tumour or dendritic cells abrogates 
tumour-induced inhibition of dendritic cell maturation (Wang et al.; 2004). Thus, 
STAT3 plays a central role in propagating oncogenic signals from tumour cells to 
effector cells involved in tumour angiogenesis and immune evasion. It is a well 
established fact that blocking STAT3 signalling in tumour cells inhibits  tumour cell 
proliferation and induces apoptosis (Darnell; 2002; Yu and Jove; 2004). In diverse 
human cancers displaying dependence on persistently activated STAT3 for 
survival/proliferation (Darnell; 2002; Yu and Jove; 2004), targeting STAT3 is 
expected to evoke potent anti-tumour effects through direct tumour cell death, anti-
tumour immune responses and anti-angiogenesis.  PC12 cells, which express A2A and 
A2BARs (Arslan et al.; 1999), have been employed to study AR signal transduction 
and physiological activity. It has been shown previously that activation of the A2AAR 
in PC12 cells results in a substantial reduction of VEGF, which is observed at both 
the mRNA and protein levels. Furthermore, this down-regulation of VEGF mRNA 
occurs because of an inhibition of VEGF gene transcription (Olah and Roudabush; 
2000). The nonselective AR agonist, 5-(N-ethylcarboxamido) adenosine, was also 
reported to down-regulate VEGF expression in PC12 cells (Kobayashi and Millhorn; 
1999). Other cell types have been shown to respond to AR agonists with either 
increases or decreases in VEGF expression (Grant et al.; 1999; Wakai et al.; 2001; 
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Feoktistov et al.; 2002). This differential regulation may exist because of the subtype 
specificity of various AR ligands, and because of cell-specific variations in the signal 
transduction cascade to which a distinct AR subtype may be linked. Stimulation of 
the A2AAR in PC12 cells substantially reduces VEGF mRNA expression and VEGF 
protein secretion. Regulation of VEGF secretion by the A2AAR, or perhaps other G 
protein-coupled receptors, on selected targets may represent a means to positively or 
negatively regulate angiogenesis for therapeutic benefit. In this study A2AAR was 
able to down-regulate the VEGFR-2 under the same conditions promoted STAT 
degradation after cytokines stimulation.  
 
It has been demonstrated that adenosine enhances IL-1-induced NO production 
through activation of  A2AAR (Ikeda et al.; 1997a; Ikeda et al.; 1997b; Dubey et al.; 
1998). In addition, activation of the A2AAR can increase NO production in porcine 
coronary endothelial cells (Olanrewaju and Mustafa; 2000) and in HUVECs (Wyatt et 
al.; 2002). In this study, we have demonstrated that A2AAR overexpression increases 
eNOS induction in A2AAR overexpressing cells. This increase in eNOS induction is 
consistent with our results in Chapter 3 which show that overexpression of the 
A2AAR triggers the down-regulation of STAT after treatment with sIL-6Rα/IL-6 for 
3hr. In addition our results show that Tyr705→Phe-mutated STAT3 enhances eNOS 
expression, while overexpression of WT STAT3 reduces eNOS expression. Different 
studies have found that inflammatory mediators decrease eNOS expression (Marsden 
et al.; 1992; Weiss et al.; 1994; Tai et al.; 2004). Furthermore, TNF-α can decrease 
eNOS expression by inhibiting eNOS promoter transactivation and also by 
destabilising eNOS mRNA (Yoshizumi et al.; 1993; Alonso et al.; 1997; Searles; 
2006). CRP, an effector of the acute phase response, decreases eNOS expression by 
destabilising its mRNA (Venugopal et al.; 2002; Verma et al.; 2002). IL-6, a major 
trigger of the APR, has been shown to decrease eNOS expression.  Recent studies 
point to IL-6 as a marker of cardiovascular disease as well as systemic inflammation 
(Tracy et al.; 1997; Libby; 2001; Ridker et al.; 2001). IL-6 plasma levels are elevated 
in myocardial infarction, unstable angina, and atherosclerosis. Chronic inflammation 
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may trigger synthesis of IL-6, which activates STAT3. STAT3 in turn drives 
transcription of acute phase response reactants, such as CRP that contribute to the 
development and progression of atherosclerosis (Verma et al.; 2005; Paffen and 
DeMaat; 2006). Accumulating evidence demonstrates that the A2AAR increases the 
production of NO by human and porcine arterial endothelial cells, which in turn leads 
to vasodilation (Lin et al.; 2007). 
 
Our results show that incubation of A2AAR-overexpressing cells with sIL-6Rα/IL-6 
for 2 hr up-regulates eNOS expression compared with control cells. This result is 
consistent with finding that adenosine-induced NO production is blocked by the 
potent eNOS inhibitor l-NIO (Jiang et al.; 2002; Benamar et al.; 2003) but not by the 
selective iNOS inhibitor l-NIL (Connor et al.; 1995), suggesting eNOS but not iNOS 
is responsible for the effect of adenosine on NO production. The importance of eNOS 
in NO production by adenosine is further supported by the observation that adenosine 
enhances phosphorylation of eNOS at its activation sate (Ser 1177) (Albrecht et al.; 
2003; Zhang and Hintze; 2006). Moreover, adenosine significantly increased eNOS, 
but not iNOS, activity (Albrecht et al.; 2003). It has been suggested that a large 
amount of NO produced by iNOS is toxic, whereas eNOS is a protective enzyme 
(Albrecht et al.; 2003). Therefore, it is highly likely that adenosine-induced NO 
generation through eNOS can result in cardioprotection, which may explain the 
cardioprotective effect of adenosine. Multiple lines of evidence have suggested that 
the A2AAR is critical for adenosine-mediated protection against ischaemia-
reperfusion injury. A2AAR-mediated inhibition of tissue ischaemia-reperfusion injury 
has been documented in various organ systems, including liver, lung, kidney, and 
heart (Okusa et al.; 1999; Harada et al.; 2000). However, the precise mechanisms 
responsible for A2AAR-mediated tissue protection remain unknown. The A2AAR is 
widely distributed and mediates a variety of physiological responses in mammals. 
A2AARs couple to Gs proteins and activate adenylyl cyclase, leading to an increase in 
cellular cAMP levels (Dobson and Fenton; 1997; Sullivan et al.; 2001). The 
mechanisms of protection mediated by A2AAR activation may include inhibition of 
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leukocyte-mediated inflammatory response, chemokine production and vasodilation 
(Shryock et al.; 1998; Lew and Kao; 1999). A recent study has also shown that 
cAMP induces eNOS activation and increases endothelial NO production from 
isolated canine and porcine coronary microvessels (Kudej et al.; 2000; Zhang et al.; 
2002b). In cultured endothelial cells, both PKA and PKB have been reported to have 
effects on eNOS phosphorylation and activation (Dimmeler et al.; 1999; Fulton et al.; 
1999; Michell et al.; 2001; Boo et al.; 2002). These observations may suggest that 
expression of A2AARs elevate cAMP which induce eNOS expression as our results 
would suggest A2AAR-expressing cells up-regulates eNOS expression (Figure 5.4). 
Thus the data suggest there are two possible mechanisms; the first one is cAMP via 
ERK directly up-regulate eNOS. The second mechanism is cAMP up-regulates eNOS 
expression via down-regulation of STAT3. In summary the results suggest that 
STAT3 regulates eNOS expression upon sIL-6Rα/IL-6, since A2AAR overexpression 
which primes cytokine-activated STATs for degradation by the proteasome, was 
sufficient to up-regulate eNOS expression. 
 
Data in Chapter 5 reveals several important aspects. These include: 
 
(1) Incubation of HUVECs with sIL-6Rα/IL-6 for 4 hr increased VEGFR-2 protein 
levels. 
 
(2) Expression of VEGFR-2 upon sIL-6Rα/IL-6 stimulation was blocked by JAK 
inhibitor 1 pre-treatment. 
 
 (3) Expression of VEGFR-2 was abolished by over-expression of a dominant-
negative Tyr705→Phe STAT3 mutant and induced by overexpression of WT STAT3.  
 
(4) The results show that A2AAR overexpression has two effects on VEGFR-2 
expression. The first effect was incubation of A2AAR overexpressing cells with sIL-
6Rα/IL-6 for 4 hr triggered a 91±6% down regulation of VEGFR-2 compared to 
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levels in untreated controls. The second effect was that over-expression of the A2AAR 
alone increased VEGFR-2 expression.  
 
 (5) The result shows that levels of eNOS were reduced by transient overexpression 
of WT STAT3. In contrast, eNOS levels were up-regulated by overexpression of a 
dominant-negative Tyr705→Phe mutated STAT3. 
 
(6)  There is no significant change in eNOS expression when the cells are incubated 
with sIL-6Rα/IL-6. 
 
 (7) Incubation of A2AAR-overexpressing cells with sIL-6Rα/IL-6 for 2 hr marginally 
up-regulates eNOS expression compared to controls. 
 
In the course of my studies, I have identified the vascular endothelial growth factor 
(VEGF) receptor VEGFR2 and eNOS as proteins in ECs whose levels are controlled 
by STAT3.  The interaction between the eNOS promoter and STAT3 has been 
studied by Marta Saura et al. (2006). They first studied the effects of IL-6 upon the 
human eNOS 5′-flanking region extending 1600 bp upstream from the transcriptional 
start site. Then, they transfected HAEC with an eNOS promoter luciferase construct 
(eNOS-Luc). While Control cells were also co-transfected with plasmid constitutively 
expressing Renilla luciferase. Then, human eNOS promoter transactivation was 
measured as firefly luciferase activity normalised to Renilla luciferase activity. Their 
data show that STAT3 upon IL-6 activation inhibits eNOS promoter activity in 
endothelial cells in a dose-dependent manner. While any interaction between STAT3 
and the VEGFR2 promoter has yet to be identified, several experiments could be used 
to address this issue. One approach is chromatin immunoprecipitation (ChIP) analysis 
which could be applied to assess cytokine-inducible STAT3 recruitment to the 
VEGFR2 promoter. To perform this experiment, cells have to be stimulated with and 
without IL-6 and then fixed. Then DNA has to be sheared to fragment sizes of 
roughly 500 bp. STAT3 is then immunoprecipitated and DNA fragments analysed by 
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PCR.  Primers would be designed to amplify a target sequence of no greater then 200 
bp that incorporates any putative STAT3 binding sites in the VEGFR2 promoter. 
Secondly, reporter gene assays could be employed to confirm IL-6-inducible STAT3 
activation of VEGFR2 promoter. This could be done by cloning the VEGFR2 
promoter upstream of a luciferase ORF in a mammalian expression vector such as 
pLuc (Chiou et al.; 2000). If cytokine activation of luciferase expression is observed, 
the STAT sites in the promoter could be mutated and used to compare their ability to 
induce luciferase following IL-6 stimulation. Additionally, the effect of the dominant-
negative Tyr705→Phe STAT3 mutant following IL-6 stimulation could also be 
assessed as further evidence for a role of STAT3.  
 
The limitations of approaches in this Chapter are the same as in Chapter 3 and 4 for 
the use of HUVECs and overexpression of A2AAR (pages 102-103).  
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Chapter 6 
Final Discussion 
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The pro and anti-inflammatory mediators are both meant to be beneficial to the 
organism. During the initial appearance of pro- and anti-inflammatory mediators in 
the circulation, the beneficial effects usually outweigh their harmful effects. However, 
when the balance between these two opposing forces is lost, the mediators become 
harmful. Sequelae of inappropriate or prolonged inflammation contribute to the 
pathogenesis of many diseases including atherosclerosis (D'Cruz; 1998; Sands and 
Palmer; 2005), rheumatoid arthritis (Karouzakis et al.; 2006) sepsis, (D'Cruz; 1998; 
Kinlay et al.; 2001; Greaves and Channon; 2002; Gueler et al.; 2004), heart disease 
(Kinlay et al.; 2001), and cancer (Howe; 2007). Fundamental to the inflammatory 
response is the interaction between ECs and leukocytes. This interaction triggers 
further downstream signalling events leading to cytokine, chemokine and growth 
factor release, surface expression of adhesion molecules and expression of other pro-
inflammatory proteins.  
 
In this investigation, I have demonstrated that the A2AAR overexpression can prime 
cytokine-activated STATs for polyubiquitylation and subsequent degradation by the 
proteasome (Figure 3.2-3.9).  Similar to the effect observed on suppression of  NF-қB 
in two separate cell systems (Sands et al.; 2004), expression of the A2AAR in the 
absence of any agonist was sufficient to prime STATs for degradation. Pre-incubation 
with the proteasome inhibitor MG132 was sufficient to abolish the effect of the 
A2AAR overexpression on priming both STAT1 and STAT3 for down-regulation in 
response to both cytokines sIL-6Rα/IL-6 and IFNα. Our data reveals several 
important aspects of A2AAR overexpression on JAK-STAT upon cytokine 
stimulation. These include: (1) Potentiation of A2AAR function by increasing its 
expression reduces cytokine receptor activation of the JAK-STAT pathway by 
priming Tyr-phosphorylated STAT for proteasomal degradation. (2) Over-expression 
of the A2AAR in HUVECs suppressed the ability of IFNα and a sIL-6Rα/IL-6 trans-
signalling complex to promote Tyr-phosphorylation of STATs 1 and 3 by targeting 
cytokine-activated STATs for proteasomal degradation. (3) Immunoprecipitation and 
pull-down experiments revealed that endogenous and recombinant WT STAT3 were 
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ubiquitylated following cytokine treatment of A2AAR overexpressing cells while no 
detectable ubiquitylation of Tyr705→Phe-mutated STAT3 was observed. 
Degradation required JAK-mediated phosphorylation of STATs as deduced from 
three lines of evidence. First, the effect was abolished by a concentration of JAK 
inhibitor 1 that abolished Tyr-phosphorylation of STAT1 and STAT3. Second, 
STAT3 but not STAT1 was targeted for degradation following exposure of A2AAR- 
overexpressing cells to leptin, reflecting the ability of leptin to specifically promote 
the Tyr-phosphorylation of STAT3. Third, a Tyr705→Phe mutated STAT3 was 
resistant to both JAK-mediated phosphorylation and cytokine-triggered degradation 
in A2AAR overexpressing cells.  
 
The multiple signalling employed by the A2AAR to inhibit STAT activity raise an 
important question. How does the A2AAR affect STAT activity by different 
mechanism? One possibility is that A2AAR overexpression leads to the activation of 
multiple distinct signalling molecules, which then affect the STAT pathway by 
independent mechanism. One key feature of the A2AAR is the long C-terminal tail, 
which plays a role in regulating the high level of constitutive activity of the receptor 
(Klinger et al.; 2002). In addition it is shown to be involved in the formation of 
heterodimers with the dopamine D2 receptors within the rat striatum (Canals et al.; 
2003), although it is not required for the formation of A2AAR homodimers (Canals et 
al.; 2004). Therefore its precise role in the formation of oligomers is still unclear. In 
order to understand the molecular events by which STAT degradation occurs, it 
would an important step to identify which A2AAR-activated signalling pathways are 
responsible. A2AAR activation has been reported to activate at least two primary 
signalling cascades in vascular ECs. The first one is the cAMP-adenylyl cyclase 
(Linden; 2001), causing an elevated levels of intracellular cAMP. cAMP causes the 
activation of cAMP-dependent protein kinase (PKA) and “exchange protein activated 
by cAMP” (Epac). Epac functions as a guanine nucleotide exchange factor for the 
Rap family of small G-proteins (Bos; 2003; Tasken and Aandahl; 2004). The second 
pathway is extracellular signal-regulated kinase (ERK). cAMP-independent 
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activation of ERK through the activation of A2AAR (Sexl et al.; 1997) is thought to 
be required for receptor-mediated generation of nitric oxide, which subsequently 
activates soluble guanylyl cyclase (Wyatt et al.; 2002). The resulting accumulation of 
cyclic GMP (cGMP) activates cGMP-dependent protein kinase. A range of selective 
inhibitors and activators of relevant intracellular signalling pathways would be 
needed to be tested for their ability to either block or mimic A2AAR-mediated priming 
of STAT degradation. For example, a contribution of Epac could be tested by 
determining the extent to which Epac-selective activator 8-pCPT-2′-O-me-cAMP 
(Kooistra et al.; 2005) can prime STATs for cytokine-triggered degradation, and 
whether its depletion by siRNA abolished the A2AAR’s effect. 
 
To date, only one mammalian E3 Ub ligase (termed “SLIM” or “Mystique”) has been 
demonstrated to target Tyr-phosphorylated STATs for polyubiquitylation (Tanaka et 
al.; 2005). However, the results presented here suggest that there is no involvement of 
SLIM under conditions in which STAT degradation occurs, suggesting that another 
E3 is responsible. Identification of this new E3 would constitute a major advance 
towards designing strategies for manipulating STAT function, and is therefore a key 
objective. There are several technically distinct strategies that could be used to 
identify the E3 ligase. First strategy is the STAT3 proteomics.  The most straight 
forward method for identifying the protein responsible would be to purify STAT-
associated proteins in cytokine-stimulated A2AAR-overexpressing cells via a two-step 
tandem affinity purification (TAP) procedure (see Chapter 7). Similar approaches 
have already been used to demonstrate that KLHL12 function as the substrate 
recognition component of the E3 complex responsible for degradation of Dsh 
proteins (Angers et al.; 2006).  The second strategy is using E3 Ub ligase siRNA 
library screening (see Chapter 7). This approach is particulary suited to HUVECs 
since our lab and others  have been able to achieve almost complete target gene 
knockdown following siRNA transfection into these cells (Huang et al.; 2005; 
Kooistra et al.; 2005). 
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The A2AAR displays two desirable features that would make it suitable to act as a 
brake of the inflammatory response. One important feature is the level of constitutive 
activity displayed by the receptor, an activity which is associated with the C-terminal 
of the receptor, since its removal can inhibit the level of constitutive activity (Klinger 
et al.; 2002). The constitutive activity of the receptor would allow the receptor to 
mediate its anti-inflammatory effects even in the absence of agonist as described in 
this thesis. The constitutive activity of the receptor suggests that regulation of A2AAR 
expression would be critical in the inhibition of inflammatory responses. Studies in 
A2AAR-/- cells showed that there was no significant compensatory increase in the 
expression of any of the other ARs, suggesting that the anti-inflammatory events 
triggered by A2AAR expression are specific for this receptor (Lukashev et al.; 2003). 
In addition, demonstration of the absence of receptor reserve in murine T-cells 
suggests that A2AAR expression needs to be tightly regulated (Armstrong et al.; 
2001). The regulation of A2AAR expression is supported by the reported alterations in  
expression in response to Th1 cytokines in Ecs is likely to alter cellular 
responsiveness to inflammatory stimuli (Nguyen et al.; 2003). Moreover, in mature 
plasmacytoid dendritic cells, the A2AAR becomes up-regulated in response to CpG 
oligodeoxynucleotide activation of TLR-9, leading to a decrease in IL-6, IL-12 and 
IFNα production (Schnurr et al.; 2005). Therefore, there are precedents for the 
regulation of A2AAR expression by different inflammatory stimuli resulting in the 
inhibition of inflammatory responses. 
 
 A2AAR overexpression leads to the accelerated degradation of Tyr-phpsphorylated 
STATs. The JAK-STAT signalling cascade plays an important role in the activation 
of several different inflammatory genes including eNOS and VEGF. Targeting STAT 
proteins for therapeutic intervention in cancer remains to be fully explored. In 
addition to the development of tyrosine kinase inhibitors, antisense STAT 
oligonucleotides, it will be important to consider alternative strategies for targeting of 
constitutive STAT signalling (Seidel et al.; 2000; Turkson and Jove; 2000). Such 
strategies could potentially include: (1) development of receptor-ligand interaction 
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antagonists, such as cytokine antagonists and receptor-neutralising antibodies; (2) 
inhibition of STAT activating tyrosine kinases; (3) activation of STAT-specific 
phosphatases; (4) targeting of STAT-regulated genes involved in malignant 
progression; and (5) development of small molecule inhibitors that interfere with 
STAT dimerisation and/or DNA binding. With regard to the latter, recent progress 
has been made in design of short peptides that effectively block STAT3 dimerisation 
and DNA-binding activity both in vitro and in vivo (Turkson et al.; 2001). 
Importantly, these peptides inhibit cell transformation mediated by activated STAT3 
and provide the basis for development of peptidomimetics with drug-like features. 
For drug development, molecular assays that are designed to specifically measure 
activated STAT3 DNA-binding or gene-regulatory activities can be applied for drug 
refinement through structure-activity relationship studies. In the clinical setting, 
immunohistochemical assays for detection of activated phosphotyrosine-forms of 
STAT3 and STAT5 can provide convenient molecular markers for monitoring the 
efficacy of inhibitors of STAT signalling in biopsies from cancer patients. Gene 
expression profiling by microarray technology is expected to reveal a molecular 
signature of STAT-regulated genes that may have diagnostic as well as prognostic 
applications (Turkson and Jove; 2000; Nikitakis et al.; 2004).  
 
 STAT activation is negatively regulated by SOCS proteins. Our results do not rule 
out the physiological involvement of SOCS3 in down-regulation of STAT in A2AAR-
overexpressing cells. Thus, A2AAR overexpression may up-regulate other SOCS 
expression such as SOCS1 leading to accelerated STAT1 and STAT3 degradation. 
SOCS proteins were originally identified as cytokine-inducible SH2-domains-
containing proteins (CIS). They are known to inhibit STAT activation by at least two 
distinct mechanisms that differ between family members:  SOCS1 inhibits activation 
of JAK by directly binding to JAK, while SOCS3 inhibits the action of JAK only 
when bind to receptors such as gp130 (Section 1.3). Expression of SOCS1 but not 
SOCS3 promotes the degradation of ubiquitinylated JAK2 leading to the reduction of 
STAT activation (Shuai and Liu; 2003). Moreover, STAT1 is known to be regulated 
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by phosphorylation-dependent ubiquitination in response to IFNγ (Kim and Maniatis; 
1996). SOCS proteins typically consist of a phosphotyrosine-binding SH2 domain, a 
C-terminal SOCS-box involved in proteasome recruitment and a pre-SH2 domain that 
only in the case of SOCS1 and SOCS3 contains a JAK-blocking KIR domain. 
Association of SOCS proteins with their target substrates is believed to occur solely 
via their SH2 domain. Given that SOCS can promote the degradation of JAK, it is 
also possible that SOCS can target the degradation of associated STAT proteins. 
Therefore A2AAR overexpression may negatively regulate STAT1 and STAT3 
protein levels by increasing the levels of SOCS expression.  However, results in 
Chapter 4 suggest there is a significant difference in SOCS3 expression between GFP 
and A2AAR overexpressing cells upon cytokines stimulation at 2 and 3 hrs (Figure 
4.12). However, this does not rule out the physiological function of SOCS3 or other 
SOCS family members in the down-regulation of STATs. To further identify the 
precise role for A2AAR-mediated anti-inflammatory effects, immuoblotting using 
anti-SOCS antibodies or employing SOCS-/- cells could be used to determine the 
effect of the A2AAR on SOCS expression. In addition, it would be interesting to 
determine if this represents a common mechanism of action.  For example, STAT 
activation is also stimulated by other cytokines like IL-11, which utilises a common 
gp130 receptor component. Similar analysis of STAT1 and STAT3 activation and 
SOCS expression could be used to determine if A2AAR is important in this way. 
Another important topic for future studies is to define the mechanisms of crosstalk 
between JAKs and other pathways. For instance, the receptor Notch has been 
reported to promote STAT3 activation, and the Notch effectors Hes1 and Hes5 have 
been found to associate directly with JAK2 and STAT3 (Kamakura et al.; 2004). 
Evidence for cooperation between the JAK/STAT and Notch pathways has also been 
provided by work in Drosophila (Josten et al.; 2004) and genetic screens in 
Drosophila have identified additional potential modifiers of the JAK/STAT pathway 
(Bach et al.; 2003). JAKs have also been reported to be activated by a variety of 
structurally diverse receptors beyond the cytokine receptors. Examples include 
receptor tyrosine kinases, and G-protein-coupled receptors (such as chemokine 
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receptors). Hyperactivation of STAT1 and STAT3 due to either inactivation of SOCS 
promoters by methylation (Niwa et al.; 2005) or mutationally activated JAK/other 
STAT-phosphorylating tyrosine kinases has been observed in breast cancer cell lines 
as well as prostate, ovarian, pancreatic and hepatocellular carcinomas (Verma et al.; 
2003).  Importantly, in many of these cases, blockade of STAT activation triggers 
apoptosis of the affected cells (Verma et al.; 2003; Yu and Jove; 2004). Thus, 
manipulation of the A2AAR signalling system might provide one strategy with which 
to arrest tumour growth resulting from inappropriate activation of STATs. In 
addition, VEGF is up-regulated by multiple stimuli, including hypoxia (Levy et al.; 
1995b), growth factors (Nauck et al.; 1997), and cytokines (Li et al.; 1995; Ryuto et 
al.; 1996).  
 
 Since Tyr-phosphorylation is clearly the critical step in targeting STATs for 
degradation in A2AAR overexpressing cells, it is extremely important to clarify 
whether it functions simply as a classical phosphodegron, or whether the nuclear 
translocation that occurs as a result of phosphorylation is also important for localising 
the phosphorylated STAT dimer with the relevant E3 ubiquitin ligase. This may be 
tested by comparing the extent to which the A2AAR overexpression primes STATs 
for cytokine-triggered polyubiquitylation and degradation in cytosolic and nuclear 
fraction (see Chapter 7).  
 
In conclusion, the identification in this study of a previously unappreciated 
mechanism by which a GPCR can negatively control STAT function by targeting 
tyrosine-phosphorylated STATs for degradation has significant implications for 
diseases associated with altered regulation of the JAK-STAT pathway in vascular 
endothelium. It also suggests that potentiation of A2AAR overexpression function 
might prove a particularly useful strategy with which to down-regulate pro-
inflammatory responses in vascular endothelium by virtue of its capacity to inhibit 
both the JAK-STAT and NF-қB signalling pathways utilised by distinct pro-
inflammatory stimuli. 
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Chapter 7 
Future Experimental Approaches 
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The centeral hypothesis of the future work is that the over-expression of the A2AAR 
primes STATs for cytokine-triggered polyubiquitylation and protesomal degradation, 
and that this is achieved by increasing the activity and/or expression of an E3 Ub 
ligase that specifically targets Tyr-phosphorylated STATs. I also hypothesise that this 
previously unappreciated process is an important mechanism by which the 
inflammatory response could be suppressed by this receptor. Processes regulating 
protein turnover by the UPS are attractive targets for therapeutic intervention but are 
currently underexploited (Nalepa et al.; 2006). Thus, while the machinery controlling 
STAT degradation in ECs has tremendous potential for the generation of novel anti-
inflammatory therapeutics for treatment of CVDs, fully exploiting this opportunity 
would require a detailed understanding of the molecular mechanisms responsible. To 
achieve this, future work would be aimed at : 
 
1) Characterising in detail and defining the subcellular localisation of the STATs 
ubiquitylation and degradation events. 
2) Identification the A2AAR-regulated E3 Ub ligase responsible. 
3) Identification of Ub-conjugation sites and the nature of any chain linkage on 
STAT3. 
4) Identification of the A2AAR-activated signalling pathway(s) responsible for 
priming STATs for degradation. 
 
Proposal experimental procedures: 
 
1) Characterisation and localisation of STAT polyubiquitylation and 
degradation 
 
 Having demonstrating that Tyr-phosphorylation is required for cytokine-triggered 
degradation of STATs following A2AAR overexpression, it is unclear where 
ubiquitylation and degradation occur. These questions could be answered as follows:- 
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1.1) Are STATs degraded in the nucleus?  
 
Tyr-phosphorylation is followed by the α-importin-mediated translocation of STAT 
dimer into the nucleus (Norman and Shiekhattar; 2006). This would be tested by 
comparing the extent to which the A2AAR overexpression primes STATs for 
cytokine-triggered polyubiquitylation and degradation in cytosolic and nuclear 
fractions. Based on these findings, several experimental approaches such as siRNA-
mediated knockdown of importin-α (Which play important role in translocation of 
STATs from cytosol to the nucleus) could be use to test the important of nucleus 
loclisation in STAT degradation. Moreover, nuclear import of STAT1 has been 
shown to be mediated by importin-α 5/NPI-1, one of the importin- α family members. 
Here, we attempt to determine whether the stimulation-induced nuclear import of 
STAT3 is mediated by importin-α similar to the import of STAT1. The domain 
structure of importin-α could be divided into an N-terminal region (the importin-β 
binding domain), a central region (classical NLS binding domain), and a short C-
terminal region. It is well known that the N-terminal domain of importin-α is essential 
for importin-β binding, and that the deletion of this domain causes a loss of import 
activity. In the case of STAT1, N-terminal deletion mutants of importin-α 5/NPI-1 
lack the importin-β binding domain and cannot bind to importin-β, inhibiting the 
nuclear import of STAT1 (Sekimoto et al.; 1997; McBride et al.; 2002). Therefore, 
we could examine the issue of whether the N-terminal deletion mutant of importin-α 
5/NPI-1 inhibits the nuclear import of STAT3 and its degradation in A2AAR-
overexpressing cells. 
 
During the process of IL-6-mediated transcriptional activation of STAT3, STAT3 
proteins translocate into the nucleus and are subsequently exported from the nucleus 
in a chromosomal region maintenance 1 (CRM1)-dependent manner (Bhattacharya 
and Schindler; 2003). Use of nuclear export inhibitor leptomycin B (to inhibit STAT 
nuclear export) and expression of STAT3 mutants in which nuclear localisation or 
export sequences are disrupted) could be used to determine whether Tyr-
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phosphorylation alone is sufficient for STAT ubiquitylation and degradation, or if 
nuclear localisation is also critical. If degradation occurs in the nucleus, it would be 
expected that blocking export will cause nuclear accumulation of Ub STAT. 
 
2) Identification of the E3 ligase for STAT ubiquitylation 
 
To date only one E3 ligase termed “SLIM or Mystique” has been demonstrated to 
target Tyr-phosphorylated STATs for polyubiquitylation (Tanaka et al.; 2005). 
However I have been unable to detect SLIM message or protein under conditions 
resulting in STAT degradation suggesting that another E3 is responsible. 
Identification of this new E3 would constitue a major advance towards designing 
strategies for manipulating STAT function. Two different strategies are proposed:- 
 
A) Tandem affinity purification (TAP) of STAT-associated E3 ligase 
The most straightforward strategy for identifying the protein responsible would be to 
purify STAT-associated protein in cytokine-stimulated A2AAR-overexpressing cells 
via two-step tandem affinity purification (TAP) procedure. Similar approaches have 
already been used to demonstrate that KLHL12 function as the substrate recognition 
component of the E3 complex responsible for degredation of Dsh proteins (Angers et 
al.; 2006). To identify the A2AAR-regulated STAT E3, a TAP construct would be 
generated comprising streptavidin-(Streptag) and Ni2+  chelate-(His6) binding affinity 
tags placed in tandem at the C-terminus of STAT3 (Tagwerker et al.; 2006). The C-
terminus is being chosen as others have demonstrated that even the addition of large 
fluorescent protein tags at this terminus does not compromise STAT3 function 
(Pranada et al.; 2004). The rationale for using these tags is that they allow two-step 
purification under denaturing conditions, which is essential to inactivate 
deubiquitylating enzymes that would otherwise remove polyUb chains and the 
associated E3 during purification  (Tagwerker et al.; 2006). A recombinant AV would 
be generated to ensure efficient expression of the TAP-tagged STAT3 in HUVECs to 
the same level as endogenous STAT3. After confirming functional expression, it 
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would be co-expressed with the A2AAR and purified by sequential Ni2+ chelate- and 
streptavidin-affinity chromatography steps following treatment with cytokine and 
MG132 to promote accumulation of ubiquitylated STATs. To prevent dissociation 
recruited E3s following denaturing cell lysis, cellular protein would be cross-linked 
by treatment with formaldehyde prior to lysis. STAT-associated proteins from the 
final streptavidin-affinity step would be eluted and digested with trypsin for analysis 
of the resulting peptides by tryptic peptide mass fingerprinting using matrix-assisted 
laser desorption/ionisation-time of flight (MALDI/TOF) (Bito et al.; 2003) and/or 
peptide separation by nano-liquid chromatography and analysis by tandem mass 
spectrometry (LC-MS/MS) (Xu and Peng; 2006). Result would be used to interrogate 
EBI and NCBI human databases using publicly available MASCOT search 
algorithms. GFP-expressing HUVECs would be used as a negative control. 
 
B) E3 Ub ligase siRNA library screening  
Libraries of validated siRNAs specific for more than 200 human E3 Ub ligases are 
now available commercially from Dharmacon and Ambion. These provide a rapid 
means with which to screen a range of structurally diverse E3s based on whether 
knockdown blocks sIL-6Rα/IL-6-mediated degradation of STATs in A2AAR 
overexpressing HUVECs compared with non-targeting siRNA-treated control cells. 
This approach is particularly suited to HUVECs since our lab (Sands et al.; 2006) and 
others (Huang et al.; 2005; Kooistra et al.; 2005) have been able to achieve almost 
complete target gene knockdown following siRNA transfection into these cells. We 
would initially start by screening large numbers of group by dividing the library into 
manageable groups of 50 then screen them to identify the effective group. After that 
we could further subdivided any putative group over several rounds of screening to 
isolate the E3 ligase activity which responsible for STATs ubiquitination. To confirm 
that it functions as a bona fide Ub E3 ligase on phospho-STAT3, those that are 
identified from our screen will be expressed, purified and used in vitro Ub E3 ligase 
assays using phospho-STAT3 as a substrate. 
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3) Identification of Ub-conjugation sites  and nature of chain linkage on STAT3 
 
Identifying the sites of Ub attachment would define new targets on STAT amenable 
to therapeutic manipulation. However identification is hampered by the lack of any 
consensus ubiquitylation sequences displayed by E3s (Nalepa et al.; 2006) and 
(assuming the ubiquitylation sites are conserved) the presence of more than 20 
common Lys between STATs 1 and 3. Thus, Ub attachment sites should ideally be 
determined directly. To achieve this, adenoviruses (AV) would be used to co-express 
Flag-Tagged-WT STAT3 with the A2AAR prior to treatment with cytokine and 
proteasome inhibitor MG132 to promote accumulation of ubiquitylated STAT3 (as 
described in Chapter 2). Flag-STAT3 could then be affinity purified using anti-flag 
antibody M2-Sepharose columns and eluted with Flag peptide. Following SDS-
PAGE and Colloidal Blue staining, bands corresponding to ubiquitylated Flag-
STAT3 would be excised and destained prior to in gel digestion with trypsin and 
peptide extraction. Conjugated ubiquitins are digested by trypsin to either a Gly-Gly 
remnant that adds a mass of 114.043 Da to the affected Lys residue on the tagged 
protein or a longer Leu-Arg-Gly-Gly remnant due to miscleavage (Xu and Peng; 
2006). Moreover, the ubiquitinated Lys residue on STAT3 will be resistant to trypsin 
cleavage. Following peptide separation by nano-liquid chromatography and analysis 
by tandem mass spectrometry (LC-MS/MS), these modifications are detectable as 
distinctive mass spectrometry (MS/MS) spectra that can be matched to specific Lys 
residues on STAT3 using search algorithms (Xu and Peng; 2006). A similar approach 
has been successfully employed to isolate and identify proteins conjugated to 
NEDD8, a molecule related to Ub (Norman and Shiekhattar; 2006). Its success 
depends largely on the ability to sufficient purify enough of ubiquitylated STAT3 for 
mass spectrometry.  
 
To determine the nature of Ub chain linkage, HA-tagged Ub molecules in which all 
Lys residues (Ub contains seven Lys residues Lys6, Lys11, Lys27, Lys29, Lys33, 
Lys48 and Lys63) could be individually mutated to Arg, co-expressed with the 
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A2AAR and tested for their ability to form Ub chains by probing anti-STAT3 
immunoprecipitates with anti-HA antibody. Attenuated incorporation of mutated Ub 
where different Lys residues are mutated to Arg versus WT would identify the Lys 
residues involved in chain formation. A similar approach, using a mutated Ub in 
which all seven Lys residues are mutated to Arg, would help determine whether 
STAT3 is polyubiquitylated or multimonoubiquitylated. This is because the mutated 
Ub cannot support chain elongation. 
 
4) Identification of the A2AAR-activated signalling pathway(s) responsible for 
priming STAT degradation 
 
Having identified the molecular events by which STAT degradation occurs, it would 
be important to identify which A2AAR-activated signalling pathways are responsible.   
A2AAR activation has been reported to activate at least two primary signalling 
cascades in vascular endothelial cells. One leads to Adenylyl cyclase activation which 
results in the elevation of intracellular cyclic AMP (cAMP) levels, leading to the 
activation of cAMP-dependent protein kinase (PKA) and exchange protein activated 
by cAMP (Epac), which functions as a guanine nucleotide exchange factor for the 
Rap family of small G-proteins (Tasken and Aandahl; 2004).  Another pathway is the  
Extracellular signal-regulated kinase (ERK). cAMP-independent activation of ERK 
by the A2AAR (Sexl et al.; 1997) is thought to be required for receptor-mediated 
generation of nitric oxide, which subsequently activates soluble guanylyl cyclase 
(Wyatt et al.; 2002).The resulting accumulation of cyclic GMP (cGMP) activates 
cGMP-dependent protein kinase. 
 
A range of selective inhibitors and activitors of relevant interacellular signalling 
pathways will need to be tested for their ability to either block or mimic A2AAR-
overexpression-mediated priming of STAT degradation. Fore example, a contribution 
of Epac can be tested by determining the extent to which Epac-selective activitior 8-
pCPT-2′-O-Me-cAMP (Kooistra et al.; 2005) can prime STATs for cytokine-
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triggered degradation, and whether its depletion by siRNA abolishes the A2AAR’s 
effect. Our Lab has successful applied such approaches to identify a previously 
unkown Epac1-regulated anti-inflammatory signalling pathway in vascular Ecs 
(Sands et al.; 2006). To determine whether cAMP or ERK pathways may stimulate 
by the A2AAR involve in STATs degradation in A2AAR-overexpression cells, a 
broader range of inhibitors and activators for cAMP and ERK will initially be 
screened for their ability to block STAT degradation prior to performing more 
discriminating siRNA-mediated knockdown experiments to assess any potential role 
of candidate intermediate proteins downstream of the A2AAR. Such as the effect of 
PKA could be inhibited by PKA inhibitors Rp-8-CPT-cAMPS (Park et al.; 2007) or  
H-89 (Kaneto et al.; 2007). In addition, we could activate PKA by PKA-specific 
activator N(6)-benzoyladenosine 3',5-cyclic monophosphate (N(6)Bz-cAMP) (Kwan 
et al.; 2007) or by the adenylyl cyclase activator forskolin (FSK) (Keller et al.; 2007). 
On the other hand, the involvement of ERK in STAT degradation in A2AAR-
overexpressing HUVECs could be test by using MEK  inhibitor (U0126) (Ciccarelli 
et al.; 2005).  The effect of Raf /MEK/ERK pathway activation could be investigated 
by expressing a Raf-ER fusion protein in A2AAR-overexpressing cells and activating 
the ER by selective ER activator 4-hydroxytamoxifen. This will specifically activate 
the ERK pathway and will provide some insight its role as a possible STAT 
degradation signal in A2AAR overexpressing cells. 
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